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SUMMARY: 
This study describes: 
1. The preparation of a biologically active methanol extract from 
S.tuberculatiformis. 
2. The demonstration of biological activity for both the crude 
S.tuberculatiformis extract and Compound A. 
3. The effects of the crude S.tuberculatiformis extract and Compound A 
on nuclear translocation of the androgen and estrogens receptors in 
three different prostate cancer cell-lines. 
4. Cell viability assays demonstrating the potency (IC50) for Compound A 
and the crude S.tuberculatiformis extract between the three prostate 
cancer cell-lines. 
5. Caspase assays to demonstrate apoptosis for the crude 
S.tuberculatiformis extract and Compound A in prostate cancer cell-
lines. 
Stellenbosch University  https://scholar.sun.ac.za
iii 
 
OPSOMMING: 
Hierdie studie beskryf: 
1. Die bereiding van 'n biologies-aktiewe kru metanolekstrak uit 
S.tuberculatiformis. 
2. Die bepaling van die biologiese aktiwiteit vir beide die kru metanolekstrak uit 
S.tuberculatiformis en verbinding A. 
3. Die effek van die kru S.tuberculatiformis ekstrak en verbindingA op die 
translokasie van die glukokortikoïed- en androgeenreseptore in drie 
verskillende prostaatkanker sel-lyne. 
4. Sellewensvatbaarheidstoetse (IC50) met drie prostaatkankersellyne om die 
toksisiteit van die kru metanolekstrak uit S.tuberculatiformis en verbinding A te 
bepaal. 
5. Kaspasetoetse in prostaatkanker sel-lyne om die apoptotiese effek van die 
kru metanolekstrak uit S.tuberculatiformis en verbinding A te demonstreer 
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CHAPTER 1 
INTRODUCTION 
This chapter presents a summary of the socioeconomic and medical significance 
of prostate cancer and the role of steroid receptors in prostate tumorigenesis as well 
as the motivation for Salsola tuberculatiformis Bostchantzev extract and Compound 
A as the basis in the development of potential treatment. This leads to the 
formulation of the aims and objectives of the study in relation to this issue in the 
global and South African settings.  An overview of the structure of the thesis is 
included. 
1.1 BACKGROUND 
Cancer represents a growing social and economic burden in both developed and 
developing countries. In 2012 global cancer statistics estimated 14.1 million new 
cases and 8.2 million deaths [1,2]. Developing countries comprise ±82% of the world’s 
population and despite this they only account for 57% of cases and 65% of cancer 
deaths. This is due to several factors including population demographics and 
acquisition bias. However, the burden of cancer will continue to shift to less 
developed countries due to growth and ageing of the population and increasing 
prevalence of known risk factors [2]. In South Africa, more than 100 000 people are 
diagnosed with cancer every year with only 60% surviving the diagnosis (CANSA, 
2010).  
The incidence of prostate cancer is on the rise globally in almost all countries, 
with prostate cancer being predicted to be the most common cancer in men in fifteen 
years [1,2]. Currently, the non-localised disease is without any curative therapy [3]. In 
2012, more than 1.1 million cases of prostate cancer (PCa) were recorded 
accounting for ±8 % of all new cases of cancer worldwide (15 % of all cancers in 
men) [4].  
The most effective treatment for disseminated prostate cancer is hormone 
therapy, in particular chemical castration through androgen ablation therapy [5]. This 
therapy is effective because most prostate cancers are dependent on androgens at 
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initial diagnosis. The androgen receptor (AR) acts as an oncogene promoting 
carcinoma development. Thus the endocrine therapy of prostate cancer aims to 
reduce serum androgens and inhibit the AR [6,7]. The likelihood of recovery is highest 
if treated early but prostate cancer can persist and continue to grow slowly following 
initial therapy and there is a significant probability (approximately 20-30%) of it 
reoccurring within the first 5 years following treatment [Prostate Cancer Foundation, 
2014]. These re-occurrences are accompanied by functional changes in which the 
AR activates genomic and non-genomic signalling pathways that can be activated in 
low androgen ligand environments and lead to a resistance to hormone 
manipulations. Treatment subsequently becomes palliative. This progression is 
known as castration resistant prostate cancer (CRPC). Despite this loss of sensitivity 
to Androgen Ablation Therapy (AAT), the AR continues to be expressed throughout 
prostate cancer progression and AR-negative prostate cancer cells do not have a 
significant growth or survival advantage [6].  
Glucocorticoid receptor (GR) mediated pathways play an opposing role in 
prostate tumorigenesis and result in tumour suppression. Glucocorticoids are 
therefore a part of the standard treatment for prostate cancer [6]. The AR and GR are 
closely related transcription factors (TF) that belong to a superfamily of nuclear 
hormone receptors. Once these receptors bind to their cognate steroid ligands, the 
AR and GR dissociate from their cytoplasmic chaperone proteins, form homodimers 
and translocate to the nucleus where they bind to palindromic hormone response 
elements (HRE) to activate gene expression. This is known as transactivation [7]. In 
addition to the genomic, DNA-binding transactivation there is a negative regulation of 
gene expression, referred to as transrepression that does not require DNA-binding 
but is mediated through cross-talk with other TFs [5–7]. The GR also activates other 
mechanisms for indirect gene repression by blocking mitogen-activated protein 
kinases [6]. The GR transrepression of other TFs, including NFκB and AP-1, are 
critical for the anti-inflammatory activity of glucocorticoids and this mechanism was 
recently shown to be vital for its tumor suppressor effects [6]. The AR has also been 
shown to interact and modulate some TFs, including NFκBβ and AP-1[7],  although 
the mechanisms have yet to be fully elucidated. Thus the opposing roles of the AR 
and GR in prostate cancer suggest that a dual steroid receptor modulator that 
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inhibits androgen and glucocorticoid transactivation while enhancing GR 
transrepression would be the ideal treatment [7].  
The steroid modulation of the African shrub known as Salsola tuberculatiformis 
Botschantzev, locally known as Gannabos, was first postulated when Basson et al. 
identified it as the agent responsible for the “Grootlamsiekte” syndrome that occurs 
in Karakul sheep. The syndrome is characterised by a prolonged gestation period 
resulting in fetal post-maturity rendering the lamb’s coat overgrown and economically 
worthless [8,9]. Basson et al. also described additional biological effects of this plant 
such as its ability to inhibit the estrus cycle in rats and its use as a contraceptive by 
Bushmen [8,9]. These finding initiated investigations into the active components of the 
plant. It was discovered that the active contraceptive properties could be extracted 
with methanol and Swart et al. developed a bioassay based on the terminal enzyme 
in adrenal corticosteroidogenesis, cytochrome P450-dependent 11β-hydroxylase, 
being inhibited by the active component. The isolated active fractions were, however, 
extremely labile and only partial structures of the active components could be 
obtained. These structures indicated the presence of synephrine and a highly 
reactive aziridine and this information led to the synthesis of a more stable analogue, 
2-(4-acetoxyphenyl) 2-chloro-N-methylethylammonium-chloride or Compound A 
(CpdA) [8]. It was shown that this synthetic compound mimicked the properties of its 
natural counterpart and, in addition, was stabilised by steroid-binding globulins in 
plasma thus enhancing its biological activity in vivo [8]. Further investigation of the 
properties of CpdA by Yemelyanov et al. revealed that CpdA acted as a dual steroid 
receptor modulator that interacted with the GR, the AR and multiple TFs, including 
NFκB and AP-1, resulting in translocation but inhibiting transactivation of GR and AR 
while simultaneously enhancing transrepression of the GR. They also showed that, 
due to opposing roles of these receptors in PCa, CpdA initiated apoptosis in various 
PCa cell-lines with differing steroid receptor status [7]. 
Since CpdA is a synthetic chemical and based upon the partial structures 
identified in the active S.tuberculatiformis fraction, it may be argued that the original 
extracts may demonstrate additional or alternative therapeutic activity. Elements 
characteristic of the active S.tuberculatiformis compound(s) that potentially possess 
alternate, enhanced or complimentary benefits in PCa prevention or treatment or 
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other medical research may have been lost in CpdA being synthesized as the lead 
compound. 
1.2 AIMS 
This study set out to determine if the biological properties of CpdA, in which the 
compound acts as a dual steroid receptor modulator could be reproduced using the 
original S.tuberculatiformis crude extract. The study was carried out with the 
following aims:  
1. To extract the active components from S.tuberculatiformis with 
methanol and determine the biological activity in both the crude 
extract of S.tuberculatiformis and CpdA  
2. To demonstrate that the S.tuberculatiformis extract interacts with 
the androgen and glucocorticoid receptors resulting in nuclear 
translocation.  
3. To determine the potency of the S.tuberculatiformis crude 
extract and CpdA in PCa cell models which express the relevant 
steroid receptors. 
4. To demonstrate that the cell-death caused by the 
S.tuberculatiformis crude extract in PCa is due to apoptosis. 
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1.3 THESIS OVERVIEW 
In the current study, the burden of cancer, with specific reference to PCa 
prevalence, incidence and epidemiology, is discussed in Chapter Two. It further 
describes the anatomy and physiology of the normal prostate and the role of steroid 
signaling in prostatic maintenance and development. The manipulation of these 
mechanisms in prostate cancer development and progression, with specific 
emphasis on apoptotic pathways is also discussed. The mechanisms of action of 
nuclear hormone receptors are described in depth with specific reference to the AR 
and GR and their roles in prostate cancer development and treatment. These are 
discussed with reference to the current literature and accepted knowledge base for 
S.tuberculatiformis and CpdA, highlighting the therapeutic potential for these agents 
and the need for further research. 
Chapter Three presents the methodology used in this study with particular 
emphasis on the framework of the techniques as these were unfamiliar methods 
within our group which were acquired and subsequently established as novel 
protocols in our laboratory. This included immunofluorescence to demonstrate 
receptor nuclear translocation in PCa cell models in the presence of CpdA and 
S.tuberculatiformis. In addition, cell viability and caspase assays were optimised to 
demonstrate the potency and apoptotic effects of S.tuberculatiformis and CpdA, 
respectively. The methanol extraction and determination of the biological activity by 
cytochrome P450-dependent 11β-hydroxylase difference spectral assay are also 
presented together with techniques applied in assays using PCa cell models 
expressing steroid receptors. 
In Chapter Four the results of these investigations are presented together with 
statistical analyses. In the final chapter these results are discussed critically in the 
context of the current body of information, with reference to the direction of future 
studies and research, indicating the potential of S.tuberculatiformis as a novel 
therapeutic agent for PCa, capitalising on the selective steroid modulation 
demonstrated in this and other studies.   
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CHAPTER 2 
LITERATURE REVIEW:  
PROSTATE CANCER, SALSOLA TUBERCULATIFORMIS 
AND COMPOUND A 
This chapter presents an overview of carcinogenesis with specific emphasis on 
mechanisms for the initiation and progression of PCa as well as the role of steroids 
and steroid receptors in health and disease. Additionally pathways for apoptosis are 
presented, highlighting therapeutic targets for treatment interventions in PCa 
focusing on selective steroid receptor modulation. This information is then applied to 
the present state of knowledge on the mechanisms of action of the novel PCa 
chemotherapeutic agents CpdA and S.tuberculatiformis crude extract as a 
background to this study. 
2.1 PROSTATE CANCER 
Cancer is thought to be one of the oldest diseases in existence with the earliest 
evidence of it being recorded ± 1600 B.C [10]. Cancer refers to a group of diseases 
characterised by the formation of abnormal cells that grow and spread 
uncontrollably. This results in the invasion of other organs within the body, a process 
known as metastasis, and is the major cause of death from cancer [4]. Cancer 
development has been divided into three phases: initiation, promotion and 
progression (Figure 2.1). Initiation involves the formation of abnormal cells through 
the malfunction of, or damage to, genes that control cell growth, division and 
apoptosis. Promotion is associated with the uncontrolled growth of abnormal cells 
resulting in tumour formation within an organ. Progression refers to the metastasis of 
the tumour and patient survival is significantly reduced at this stage.  
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Figure 2.1 Illustration of the progression of PCa from normal epithelium to metastasis. The 
three stages (initiation, promotion and progression) of cancer development are shown along with the 
clinical evolution of a PCa tumour. Adapted from Abate-Shen & Shen (2000) [11]. 
Since its discovery and consequential investigation there have been great strides 
in understanding and treating this disease. However, the developed therapies are 
relatively inadequate and cancer is still a leading cause of death today. Cancer may 
be treated with surgery, radiation, immunotherapy, hormones and chemotherapy 
[4,12]. All these therapeutic strategies are invasive and associated with significant 
side-effects. A specific combination of therapies is chosen depending on the 
characteristics and site of the cancer at diagnosis. The best treatment option for 
metastatic cancer is chemotherapy as it is a drug treatment that targets cell growth 
and proliferation. These powerful drugs circulate in the bloodstream and target the 
cells that are actively growing. Since cancer cells divide faster than normal cells they 
are more susceptible but damage to healthy cells is unavoidable. Owing to toxicity 
,which is often severe, there are extensive drug-related side-effects and this 
treatment is therefore used sparingly or in conjunction with other targeted treatments 
[12]. Chemotherapy is thus primarily used to remove recurrent or metastatic cancer 
and as a palliative therapy.  New therapies need to be developed to prevent or 
improve the treatment of cancers prior to metastasis thus improving therapeutic 
approaches and disease related mortality and morbidity. 
2.1.1 EPIDEMIOLOGY 
PCa is the second most common cancer, as well as one of the leading causes of 
cancer-related deaths, in men worldwide (World Cancer Research Fund 
International, 2012). Global statistics for PCa incidence and mortality are significantly 
varied due to availability of resources, access to diagnostic facilities and erratic or 
incomplete records. Despite this, trends have become apparent. The incidence rate 
Stellenbosch University  https://scholar.sun.ac.za
8 
 
is lowest in Asia and highest in the USA with the current lifetime risk of PCa within 
the USA estimated to be 1 in 6 with a risk of death between 8% and 26%, depending 
on the staging and degree of differentiation of the tumour at diagnosis [13,14]. This 
disparity indicates that lifestyle and genetics could have an influence on PCa 
development and progression. This observation is further supported by the variation 
found between African-American men (AAM) and Caucasian-American men (CAM). 
The incidence rate in AAM is 1.6-1.9 times higher than in CAM with a resulting 
mortality rate that is 2-3 times higher in AAM [15–20]. AAM were also younger at 
diagnosis, had higher grade and stage tumours as well as the worst prognosis, all of 
which could be attributed to a greater biological aggressiveness [19,21]. Overall, a 
weak but consistent trend between higher circulating testosterone (T) and/or 
estrogens (E) and high-risk ethnic/racial groups has been observed by several 
studies. Ross et al found higher T, free T, and estrone in 50 healthy young AAM 
when compared with 50 young CAM but later ascertained that serum T levels in 
Japanese men were not lower than those of the United States whites and blacks 
[22,23]. De Jong et al. found 71% higher circulating total T levels in Caucasian-Dutch 
men than in Japanese men. These studies, as well as others, reveal an association 
between increased risk and increased ratio of T to 5α-dihydrotestosterone (DHT) [24]. 
This association is endorsed by the human prostate’s dependency on androgens for 
normal maintenance. Thus it is logical to presume that prostate malignancies 
develop under abnormal androgenic stimulation and that an increased ratio would be 
easier to manipulate. This theory is further supported by the fact that eunuchs do not 
develop PCa and a higher incidence of PCa is observed in men who used 
androgens as anabolic agents or therapeutics [1,25]. PCa therefore seems to arise 
from the hormonal environment of the ageing human male, which is characterised by 
a steady decline in circulating androgens and a reduced production of DHT in the 
prostatic epithelium, but the onset/progression is heavily influenced by lifestyle and 
genetics. 
In South Africa, the initial incidence of PCa was low with more Caucasian-
Africans presenting with PCa than Black-Africans. However, owing to possible 
under-diagnosis/reporting, poor access to screening facilities and lack of an up-to-
date cancer registry Heyns et al. conducted a study to compare the presenting 
features and management of PCa among different racial groups in the Western 
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Cape [26]. They found that during the period of 1995 to 2005 black men in Western 
Cape Province presented with higher grade and stage PCa and higher serum PSA 
levels than white or coloured men. Black men also received potentially curative 
treatment less often and had a significantly shorter duration of follow-up than white 
or coloured men, possibly owing to earlier deaths from PCa. This demonstrated that 
in regions where screening is not readily available, and men with PCa present 
because of cancer-related symptoms, the disease is locally advanced or metastatic 
in most cases and is therefore incurable. Although this study was strongly influenced 
by ascertainment bias and socioeconomic factors there remains a strong suggestion 
that men of black ancestry have a biological predisposition to this disease. This trend 
could account for PCa being the leading cause of cancer deaths among South 
African men resulting in South Africa being amongst the countries with the highest 
PCa mortality rates with 1 in every 23 South African men being diagnosed in their 
lifetimes having a ±60% chance of surviving the diagnosis (CANSA, 2011)., In South 
Africa PCa thus remains a very relevant threat in health-care and awareness, 
education and treatment development need to be further investigated. In order to 
better identify therapeutic targets in PCa it is important to understand the integrated 
mechanisms for signalling in prostate development and maintenance in health and 
disease.   
2.1.2 HEALTHY PROSTATE 
The prostate is not essential for life but plays a pivotal role in male reproduction. 
It forms part of the male accessory sex glands which also include the seminal 
vesicles and bulbourtethral glands [27]. The secretion from each of these glands is 
added to the testicular fluid and constitutes a substantial part of the semen. In 1861 
Sir Henry Thomson stated that the word ‘prostate’ originated as an anatomical term 
that refers to this organ “standing before or anterior to the bladder and vesiculae 
seminales in the supine position of the subject” [28]. The prostate is often described 
as resembling a walnut in size and appearance. It is comprised primarily of exocrine 
glandular tissue enclosed by a capsule, consisting of connective and fibrous tissue, 
and is located at the base of the bladder surrounding the urethra and in front of the 
rectum [29,30]. The seminal vesicle duct and vas deferens merge above the prostate 
to form the ejaculatory ducts which transverse the prostate and empty into the 
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urethra at the verumontanum (a 70° degree turn in the urethra). Below this site 
excretory ducts from the prostate enter the urethra and contribute prostatic 
secretions to the seminal fluid during ejaculation [27,29]. 
The uniform structure of the prostate can be divided into four distinct regions that 
differ structurally and functionally. These regions or zones are known as the 
transition zone, central zone, peripheral zone and anterior fibromuscular stroma 
(Figure 2.2) [31]. The transition zone surrounds the urethra between the bladder neck 
and verumontanum and encompasses ± 5-10% of the prostate. It is comprised of  
mostly glandular tissue (± 75%) and, combined with advancing age and altered 
hormonal activity, is where benign prostatic hyperplasia (BPH), a non-cancerous 
prostate condition, primarily originates [31]. BPH causes a dramatic enlargement of 
the transition zone and results in lower urinary tract symptoms (Prostate Cancer 
Foundation, 2016). The central zone contains the ejaculatory ducts and is located 
between the transition and peripheral zones. It accounts for ± 20% of the prostate 
and possesses the least amount of glandular tissue (± 20%) [31]. ]. The peripheral 
zone is the largest, incorporating ± 70% of the prostrate, the majority of which is 
comprised of glandular tissue (±70%). This zone is made up of the peripheral 
sections of the prostate gland and is closest to the rectum [31]. Approximately 75% of 
PCa arises within this zone. The anterior fibromuscular stroma comprises ± 5% of 
the prostate and is devoid of glandular components but is instead composed of 
smooth muscle and fibrous tissue [31]. There is no clearly defined anatomical capsule 
that surrounds the prostate –instead, the smooth muscle of this zone gradually 
extends into fibrous tissue that subsequently ends in loose connective and adipose 
tissue. 
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Figure 2.2 McNeal’s zonal anatomy of the prostate gland. (a) Transaxial and (b) sagittal 
sections. AFS anterior fibromuscular stroma; CZ central zone; ED ejaculatory duct; TZ transition zone; 
PZ peripheral zone. (Mayo Foundation for Medical Education and Research, with permission. All 
rights reserved) [31] 
The principle function of the prostate is to produce and excrete a fluid that makes 
up ± 20% of the seminal fluid during ejaculation. The prostatic secretions are a milky 
white alkaline mixture of simple sugars, proteins, enzymes and minerals [32]. While 
this secretion is not essential for fertilisation it enhances the in vivo health and fertility 
of the sperm. The simple sugars provide a source of energy for the sperm. The 
slightly alkaline pH neutralises the acidic environment of the vagina while specific 
enzymes break down proteins in an effort to free the sperm cells from the viscous 
semen after ejaculation [32]. Other components such as spermine and prostaglandins 
aid sperm mobility and uterus stimulation, respectively, in order to assist in sperm 
transport [32]. Specific proteins coat the sperm and prevent premature activation of 
factors required for egg penetration while antiagglutinin factors prevent sperm from 
clumping together. The prostate gland also acts as a valve preventing urine flow 
during ejaculation as well as using its smooth muscle to expel semen from the body 
[29,32] . 
Therefore, the prostate is a complex tubulo-alveolar gland composed of an 
epithelial parenchyma embedded within a stromal tissue matrix [30]. It consists of 
three main cell types: epithelium-basal cells, secretory luminal or glandular cells and 
neuroendocrine cells (Figure 2.3A) [30]. The epithelium-basal cells are 
undifferentiated cells that lack secretory activity and rest upon the basement 
membrane. These cells express low/undetectable levels of the AR and, as a result, 
are independent of androgens for their growth and survival [33,34]. Alternately the 
oestrogen receptor (ER), progesterone receptor (PR) and GR are expressed by the 
epithelium-basal cells [33,34]. The secretory luminal cells constitute the exocrine 
compartment and is the major cell type in the epithelium. These cells are terminally 
differentiated and are dependent on androgens for their survival.  These cells are 
also responsible for the secretion of prostate specific antigen (PSA) and prostatic 
acid phosphatase (PAP) into the glandular lumen and it is within these cells that the 
majority of PCa arises [33]. The neuroendocrine cells are a small number of post-
mitotic, terminally differentiated, androgen-insensitive cells that are dispersed among 
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the secretory epithelium [35]. The stroma of the prostate is comprised of 
myofibroblasts, fibroblasts and smooth muscle cells. It expresses the AR and the ER 
as well as the 5α-reductase isozymes and supplies essential nutrients and growth 
factors that are responsible for the direction of epithelial cell development, 
maintenance and differentiation. The interactions between the stroma and epithelial 
cells are pivotal for normal prostate functions, growth and survival [30].           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Overview of the prostate histology and endocrinology. A. The histological structure of 
the prostate identifying the four cell types; luminal, basal, neuroendocrine and stromal cells. 
Reproduced from Abate-Shen C & Shen MM (2016) [380]. B. Enlarged section (red outline) of the 
prostate illustrating the endocrinology. T, testosterone; SHBG, sex hormone binding globulin; A, 
albumin; DHT, 5α-dihydrotestosterone; P, prolactin;  E, estradiol; 3αD, 3α,17β-androstenediol ; 3βD, 
3β,17β-androstenediol ; 5αR1/2, 5α-reductase Type1/2; 3α-HOR, 3α-hydroxysteroid oxido-reductase; 
3β-HOR, 3β-hydroxysteroid oxido-reductase; 3β-HD2, Type II 3β-hydroxysteroid dehydrogenase; AR, 
androgen receptor; ERα/β, oestrogen receptor α/β . Adapted from How CKM & Habib FK (2010) [36] 
B 
aA 
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Endocrine stimulation is an essential requirement for prostate development, 
maintenance and function. Both normal and aberrant prostate cellular function is 
governed mainly by androgens although other hormones still have a synergistic or 
antagonistic influence (Figure 2.3B). In 1941, Huggins and Hodges first 
demonstrated the reduction in prostatic size post castration [25]. The main circulating 
androgen in men is T, mainly produced by the Leydig cells in the testes, although the 
adrenal gland also contributes (± 5%) to T production [32]. The release of androgens 
is controlled through the gonadotrophin luteinizing hormone (LH) and luteinizing 
hormone releasing factor (LHRF) within the hypothalamic pituitary gonadal axis 
through feedback mechanisms. Once in circulation most of the T is bound to serum 
proteins, mainly sex hormone binding globulin (SHBG) and albumin, resulting in only 
an estimated 2-3% of the T existing in the bioavailable free form [37]. This is important 
for regulating the amount of free T available for uptake in target tissues. Free T 
diffuses into the prostate where the majority (90%) of it is irreversibly converted by 
the enzyme 5α-reductase to a more potent intracellular androgen, 5α-
dihydrotestosterone (DHT) [38,39]. There are two isoforms of 5α-reductase, Type 1 
and 2, with type 1 being present in most tissues while type 2 is the predominant 
isoenzyme in the prostate [40,41]. The 5α-reduction occurs predominately in the 
stroma after which DHT is transported into the epithelium [39,42]. However, the 
epithelium can also produce some DHT (±10%) but only in the basal cells [39]. Both 
DHT and T bind to the AR which is responsible for cell proliferation, migration and 
inflammatory responses [43]. It is by regulating the effect of the androgens and the AR 
that the prostate maintains its function and development. 
Although androgens are the primary hormone for the prostate, other hormones 
also exhibit important regulatory effects (Figure 2.3B).  The pituitary hormone, 
prolactin, enhances the uptake of androgens into the prostatic epithelium allowing for 
easier movement of testosterone and DHT into the basal and luminal cells [44–48]. 
Estrogen (E) also influences prostatic function although the levels of ER in the 
prostate are relatively low [49,50]. E is produced when the enzyme aromatase 
irreversibly converts DHT into estradiol [51,52]. E appears to function in a synergistic 
fashion with androgens although they have opposing effects on the different cell 
types within the prostate [50,53–55]. The major target of E in the prostate is the stromal 
compartment where it stimulates cell growth [50,55,56]. However, E causes the 
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epithelium to undergo apoptosis resulting in a regression of this compartment. Thus, 
the prostate is influenced by a variety of sex steroids and hormones but androgens 
are essential for normal prostate development, maintenance and function. The 
different cellular compartments of the prostate also have a synergistic relationship 
allowing for important interactions to occur. It is when these hormones and 
relationships undergo alterations that abnormal prostate function can occur resulting 
in various diseases such as BPH or PCa.         
2.1.2 PCA DEVELOPMENT 
Initially, most PCas are androgen dependent. This means that the androgens, 
T and DHT, are required for growth and survival of PCa cells [25]. ]. In 1966 Huggins 
won the Nobel Prize for his work on hormonal treatment of PCa [57]. As a result, 
androgen ablation has become the cornerstone therapy in clinical approaches to the 
treatment of  PCa [25,57]. If PCa is localised, the treatment of choice is prostatectomy 
and/or irradiation but if the PCa is unconfined then hormone deprivation is the front 
line treatment. Hormone deprivation can be accomplished by surgical (orchiectomy) 
or medical (LH-releasing hormone agonists, anti-androgens) castration and it is this 
treatment that is known as androgen ablation therapy (AAT). Despite this treatment 
most tumours eventually become refractory to AAT within 5 years leading to 
castration resistant PCa (CRPC) which is characterised by progression and 
metastasis, primarily in bone and lymph nodes, and patient survival is significantly 
reduced. The treatment of CRPC is limited and palliative with little to no increase in 
patient survival  [48,58–62].  
There are several pathways by which CRPC can develop. Chen et al. highlighted the 
critical role that the AR plays in the development of CRPC by demonstrating that the 
AR gene is consistently up-regulated during tumour progression in different 
experimental models of CRPC [62]. The mechanisms of CRPC development can be 
broadly divided into those pathways involving the AR and those that bypass the AR 
(Figure 2.4). These pathways are not mutually exclusive and often overlap in CRPC 
but they provide insights into the mechanisms by which cancer cells subvert normal 
growth control and escape attempts of treatment. They also provide possible 
treatment targets for the development of new therapeutic strategies. 
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During androgen-dependent progression, PCa cells depend primarily on the AR for 
growth and survival. When the AR is inactive, it is bound to heat-shock proteins in 
the cytoplasm of prostate cells. DHT binds to the AR, dissociating it from these heat-
shock proteins. The DHT-AR complex translocates into the nucleus, dimerizes, and 
binds to the androgen-response elements (ARE), thereby activating genes involved 
in cell growth. During androgen-independent progression, PCa relies on various 
cellular pathways, some involving the AR and others bypassing it. Illustrated in 
Figure 2.4 are the 7 most documented mechanisms by which PCa progresses to 
CRPC. These pathways include the dysregulation of the AR caused by a mutation 
that would allow the AR to be activated by various ligands (3) or by deregulated 
growth factors and cytokines that can also activate the AR, usually with the aid of AR 
co-activators (5). The AR may also be amplified and therefore may be activated even 
by reduced DHT levels (2). Pathways that bypass the AR include the loss of PTEN 
which reverses the inhibition of the phosphatidylinositol 3-kinase (PI3-K)–Akt 
pathway, permitting activated Akt to phosphorylate the pro-apoptotic protein, Bad. 
This activation results in the release of the anti-apoptotic protein, Bcl-2, which 
eventually leads to cell survival (6). In addition, androgen-independent cells may 
over-express Bcl-2. PCa cells may furthermore also develop neuroendocrine-like 
behaviour and secrete neuropeptides that induce the growth of adjacent cells thus 
promoting the survival of the surrounding tumour (1). Through these mechanisms 
PCa may survive therapeutic interventions by manipulating AR-mediated cell survival 
[63,64].  
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 Four distinct pathways have been proven to result in CRPC: the hypersensitivity, 
promiscuous receptor, outlaw and co-factor pathways [reviewed in 64].  
Hypersensitivity refers to the ability of PCa cells to develop enabling cells to 
utilise very low concentrations of androgens to maintain growth. Normal total 
testosterone levels in adulthood are between 240-950 ng/dL. Post castration T 
decreases more than 90% to 20-50 ng/dL [62,63,65,66]. In CRPC even these low levels 
may be sufficient for androgen stimulation. Consequently these cells are not 
androgen-independent but rather castration resistant and androgen sensitive. This 
hypersensitivity can be achieved through several mechanisms. One such 
mechanism is the increased expression of the AR which allows enhanced ligand 
binding. This mechanism is supported by multiple studies that have shown increased 
expression of the AR in CRPC [62,67–72]. This increase is likely associated with AR 
gene amplification as a result of mutations and/or selective environmental pressure. 
Another mechanism is increased sensitivity of the AR to androgens. Gregory et al. 
demonstrated that recurrent PCa showed increased sensitivity to the growth 
promoting effects of DHT [65].  The concentration of DHT required for androgen-
independent cells to exhibit growth was 104-fold lower than that required for the 
androgen-sensitive LNCaP cells. A third method of hypersensitivity is observed when 
PCa cells increase their intracellular production of androgens by increasing the 5α-
reductase activity within the PCa cell which in turn increases the rate of T conversion 
to DHT [72–74]. 
 The promiscuous pathway is characterised by mutations in the AR that 
broaden the specificity of the AR to include non-androgenic steroids and anti-
androgens that are naturally present within the circulation [75–81]. These mutations are 
often clustered within the ligand-binding domain.   
The outlaw pathway refers to receptor mutations which allow non-steroid 
molecules to bind and activate the AR as ligands as well as downstream signalling of 
the AR by ligand-independent mechanisms [64,74,82,83]. For example dysregulated 
growth factors (including insulin-like growth factor, keratinocyte growth factor, 
epidermal growth factor and cytokines) that activate the AR and/or AR-dependent 
genes through dysregulated signal transduction pathways (over-expression of the 
receptor tyrosine kinase HER-2/neu) [84–86]. This results in proliferation of the PCa 
cells independent of androgen control. The activation of outlaw pathways highlights 
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the importance of tumour-microenvironment interactions in the development of 
CRPC, just as Paget identified that a “fertile soil” was necessary for the successful 
growth of cancer metastases [87–89].  
The AR is influenced by a large and varied number of co-activators and co-
repressors that are involved in the regulation of AR-dependent transcription [90]. 
These function as signalling intermediates between the AR and transcriptional 
machinery. In the co-factor pathway there are changes in the balance between co-
activators and co-repressors that are involved in AR driven transcription which, in 
turn, influences AR activation [74,91–94]. An increase in co-activator proteins of the AR 
has been shown in CRPC resulting in the enhancement of the receptor reactivity to 
alternate ligands (outlaw and promiscuous pathways) and sensitised the receptor to 
stimulation by ligands present at low levels (hypersensitivity pathway) as well as 
allowing ligand independent activation [91,95–99]. These findings highlight the fact that 
the progression to CRPC involves multiple mechanisms. Furthermore, these 
pathways emphasise that the progression of PCa to CRPC is not necessarily 
androgen resistance but rather androgen manipulation offering a plausible 
mechanism as to the manner in which the androgen blockade in CRPC often 
remains therapeutically useful. 
Pathways which bypass the AR include apoptotic modulation and 
neuroendocrine differentiation. The stem cell model of PCa offers an additional 
attractive postulate for AR independent modulation. Bypass pathways avoid the AR 
completely and PCa cells subsequently develop the ability to survive independent of 
AR activation. This survival is achieved either through modulation of apoptosis and 
dysregulation of apoptotic genes or through neuroendocrine differentiation of the 
PCa cells. Apoptotic modulation is the best known bypass mechanism as CRPC 
cells regularly up-regulate anti-apoptotic molecules, such as Akt and Bcl-2 [100–103]. 
When the tumour suppressor gene, phosphatase and tensin homologue (PTEN), is 
inactivated its inhibitory effect on Akt is lifted. The Akt pathway inactivates various 
pro-apoptotic proteins but one of its primary targets is the anti-apoptotic protein, Bcl-
2 which frees it from the bound inhibitor Bad, resulting in cell survival and loss of 
PTEN [64]. ]. Over-expression of Bcl-2 is common in a number of cancers including 
CRPC. In the neuroendocrine differentiation mechanism PCa cells take on 
neuroendocrine characteristics favouring secretion of neuropeptides which increased 
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growth and proliferation [64]. 
The stem cell model of PCa postulates that not all cells within the tumour are 
tumorigenic but only a small subset of cells which are the PCa stem cells [101,104]. 
These cells are not affected by androgen depletion but differentiate into androgen-
dependent and androgen-independent cells [104]. In the presence of AAT the 
androgen-independent cells develop a survival advantage in the heterogenic 
phenotype which is observed clinically and leads to CRPC [60].  
PCa and its subsequent development to CRPC is a complicated, multi-step 
progression. The above mechanisms are by no means the only possibility for 
alternative signalling but by beginning to understand the survival mechanisms 
activated in PCa, new treatment targets can be identified. It is clear, however, that 
steroid hormone receptors play a pivotal role in regulating PCa and remain a primary 
therapeutic target. 
2.1.2.1 PCa and Apoptosis 
In 1972, Kerr et al. coined the term apoptosis as “a general mechanism of 
controlled cell deletion, which is complimentary to mitosis in the regulation of animal 
populations” [105].  Apoptosis, or programmed cell death, is fundamental in normal 
physiology, maintaining healthy cell populations and controlling excessive 
proliferation through elimination of old, mutated, damaged or infected cells. The 
signal transduction pathways of apoptosis ultimately all lead to the activation of the 
caspase cascade pathway. Caspases are a family of intracellular cysteine 
proteinases that affect cell death through a cascade of proteolytic cleavages which 
degrade cellular targets leading to apoptosis. The caspase cascade pathway is 
controlled by a balance between pro-and anti-apoptotic signalling.  Activation of pro-
proliferative pathways and inhibition of pro-apoptotic pathways allows uncontrolled 
cellular growth which is a hallmark of cancer. As a result apoptosis and apoptotic 
signal transduction pathways have become one of the main targets for novel PCa 
therapy strategies [105–108]. The direct apoptotic signalling pathways can be divided 
into extrinsic and intrinsic pathways although other signalling pathways also have a 
strong influence on regulation [109–111].  
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The intrinsic pathway (Figure 2.5) is activated by cell death signals that are 
generated from the interior of the cell by biological or metabolic disturbances that 
trigger multiple apoptotic mechanisms [109]. These death signals are mediated by the 
Bcl-2 family which is a group of highly conserved proteins that serve either as anti-
apoptotic or pro-apoptotic molecules [112]. The anti-apoptotic and the pro-apoptotic 
proteins form a complex network that regulate cell fate and determine the 
susceptibility of cells to death signals.  
In a normal cell the pro-apoptotic molecules, such as Bax and Bak, are 
antagonized by anti-apoptotic proteins such as Bcl-2. Initiation of the death signal 
within the cell can be triggered by a variety of incidents including anticancer drugs, 
DNA damaging agents, kinase inhibitors, hypoxia, growth factor withdrawal, and UV 
or ionizing radiation. In response to these and other triggers, the pro-apoptotic 
molecules are activated by transcriptional up-regulation (Bax, Noxa), subcellular 
relocalisation (Bim, Bmf), dephosphorylation (Bad), or proteolysis (Bid). These 
activated pro-apoptotic molecules inactivate anti-apoptotic molecules and 
subsequently Bax and Bak insert into the mitochondrial membrane. This insertion 
causes increased permeability of the outer mitochondrial membrane and enables the 
release of mitochondrial factors such as cytochrome c. In the cytoplasm, cytochrome 
c and the adaptor protein Apaf-1 form a complex that activates caspase-9, which in 
turn triggers the caspase cascade pathway resulting in apoptosis [113,114]. Activation 
of the caspase cascade pathway can be blocked by inhibitors of apoptosis proteins 
(IAPs) which are up-regulated in response to survival signals [109–112].  
In most cancers, including PCa, Bcl-2 expression is high and, it is expressed 
in 70% of androgen-independent tumours in PCa [100,115]. Thus, it appears the 
expression levels of Bcl-2 correlate to the progression of PCa and that over-
expression of Bcl-2 may enable PCa cells to survive in an androgen-deprived 
environment. Bcl-2 also increases the resistance of PCa cells to radio- and 
chemotherapy [116–120]. Even less is known about Bcl-xL, another anti-apoptotic 
protein, in PCa progression; however, there is emerging evidence that, in many 
aspects, it behaves in a manner similar to Bcl-2 [121,122]. ]. Pro-apoptotic Bcl-2 family 
members are also important in regulating apoptosis in PCa. More than 80% of PC-3 
cells over-expressing Bax and Bak undergo apoptosis [123,124]. Additionally, over 
expression of Bax in AR-positive, but not in AR-negative PCa cells, induces 
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apoptosis which is lost when AR is knocked down indicating AR is required for the 
signalling mechanism [125].  These experiments suggest a role for the pro-apoptotic 
members of the Bcl-2 family in regulating apoptosis in PCa. Currently, studies 
suggest a significant role for IAPs in regulating apoptosis in PCa cells with 
implications in both cancer progression and carcinogenesis. High expression of IAP, 
including cIAP1, cIAP2, and XIAP, and Survivin has been linked to bad clinical 
prognosis for cancer patients [126–129]. Survivin expression increases during PCa 
progression −from normal prostate through primary low-grade to high-grade PCa 
with the highest expression in lymph node metastases [127–129]. There is also 
evidence for a role of IAPs, other than Survivin, in regulating cell death in PCa [130]. 
These studies thus all support the role of IAPs in PCa progression to CRPC. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Extrinsic and intrinsic apoptotic pathways. The extrinsic pathway is initiated by the 
binding of the TNF family members to their corresponding TNF receptors triggering their trimerization 
and activation. The intrinsic pathway is initiated by signals generated inside the cell that alter the 
balance between the pro- and anti-apoptotic members of the Bcl-2 family. The two pathways are 
interlinked and their cross-talk is mediated by Caspase-8 and -6..Reproduced from Lorenzo PI, 
Arnoldussen YJ & Saatcioglu S. (2007)[131]. 
The extrinsic pathway (Figure 2.5) is stimulated by extracellular stress signals 
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that are sensed and propagated via cell surface receptors referred to as death 
receptors. These death receptors include the Fas/CD95/Apo-1 receptor which binds 
the Fas ligand (FasL, Apo-1L or CD95L), the tumour necrosis factor-related 
apoptosis-inducing ligand receptor (TRAIL-R) that interacts with tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL), which possesses potent anti-
tumour activity, and the tumour necrosis factor receptor (TNF-R) which exists as two 
different functional receptors, TNF-R1 and TNF-R2, that both bind tumour necrosis 
factor (TNF) [111]. TNF is a multi-functional cytokine involved in apoptosis, cell 
survival, inflammation, and immunity. These receptors belong to the TNF receptor 
(TNF-R) family and their combined functions include the ability to trigger proliferation, 
survival, differentiation, or cell death depending on the cell type and kind of signal 
[111]. The TNF-R family is activated by structurally related ligands that belong to the 
TNF family and upon binding of the ligand the receptors undergo trimerization and 
recruit adaptor proteins, such as FADD and TRADD. These adaptor proteins bind to 
an intracellular region on the receptor known as the death domain (DD). This 
interaction is essential for the efficient recruitment of procaspase-8, thus forming the 
death inducing signalling complex (DISC). Several procaspase-8 molecules must 
aggregate in order for autocatalytic activation to occur. Once activated the 
procaspase-8 molecule initiates the caspase cascade pathway [109,110,113]. 
In cancer cells, death receptors are often down-regulated or altogether absent 
[132]. TNF-R signalling can be inhibited by proteins that associate with their 
cytoplasmic domain. One such common protein is FLICE inhibitory protein (FLIP) 
which is often highly expressed in many cancers [133]. Androgens can induce the 
expression of c-FLIP, which has a cluster of 4 AREs within its promoter region, 
thereby protecting the cell from apoptosis [134]. Several studies indicate that the 
different TNF-R pathways can be manipulated in a variety of ways in order to induce 
cell survival.  
In PCa Fas and FasL are elevated initially but rapidly decrease or become 
lost through mutations desensitising the cells to Fas-mediated apoptosis [135–140].  
Chopra et al. compared TNF-dependent apoptosis in PCa cell lines and determined 
that the androgen-sensitive LNCaP cells were sensitive to TNF-mediated apoptosis, 
while the androgen-independent PC-3 and normal prostate cells were resistant 
[141,142]. This suggests that the resistance to TNF-R mediated apoptosis is a factor in 
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the development of CRPC. Apart from inducing apoptosis TNF can also promote cell 
survival as shown in PCa cells in vitro. TNF can activate NFκB-dependent pro-
survival pathways, resulting in an increase of Bcl-2, through a mechanism that 
involves the activation of PI3K/AKT (Figure 2.6) [143,144]. In addition, PCa patients 
experiencing a relapse after AAT have increased serum TNF levels compared to 
untreated patients or patients in remission and this increase in TNF levels correlates 
with a higher mortality rate [145]. Conversely, TRAIL possesses potent anti-tumour 
activity as well as the ability to primarily kill cancer cells while having no effect on 
normal cells [132]. However, certain PCa cell models are resistant to TRAIL induced 
apoptosis and studies have revealed a link to the involvement of AKT signalling 
[146,147].   
Cross talk between the extrinsic and intrinsic apoptotic pathways (Figure 2.5) 
may amplify the apoptotic response and is mediated by a pro-apoptotic Bcl-2 family 
member known as Bid. Caspase-8, which is up-regulated through the extrinsic 
pathway, mediates cleavage of Bid and this increases its activity and results in 
translocation to the mitochondria, where it acts together with the pro-apoptotic 
proteins, Bax and Bak, to induce cytochrome c release, activating the intrinsic 
pathway [109,110]. In addition, a mitochondria-mediated amplification of caspase-8 
activity through caspase-6 has also been described [148].  
2.1.2.1.1 Additional Signal-Transduction Pathways: 
As mentioned above, other signal transduction pathways can indirectly 
influence the apoptotic pathways. There are four well-defined signalling-transduction 
pathways that have an effect on cell survival. They are the p53, mitogen-activated 
protein kinases (MAPKs), AKT/PTEN/mTOR and NFκB pathways. All these 
pathways have been shown to be dysregulated in cancer to promote cancer cell 
survival.  
1. p53: 
p53 is one of the most studied tumour-suppressor proteins and has the ability 
to signal through a variety of growth inhibitory pathways including induction of cell 
cycle arrest, senescence, differentiation and apoptosis. This broad range of activity 
establishes p53 as a key regulator of cell growth which is substantiated by the loss 
or alterations of its function observed in most human cancers [reviewed in 149–151].  
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At rest p53 is maintained at low levels by continuous ubiquitination and 
subsequent degradation.  The activation of p53 is achieved by the inhibition of its 
degradation, which results in its accumulation in the nucleus where it activates the 
transcription of many different target genes [152]. p53-dependent transcription is a 
highly regulated event influenced by a range of post-translational covalent 
modifications of p53 [reviewed in 149,153]. A large number of p53 transcriptional targets are 
involved in apoptosis but the BH-3 domain protein PUMA seems to be the most 
critical one in this regard [154,155]. p53 also has transcription-independent pro-
apoptotic properties through interaction with members of the Bcl-2 family (Figure 2.5 
and 2.6) [156].  
p53 mutations are present in most cancers. In PCa, the reported frequency of 
mutations in p53 is highly variable. Overall, it appears that clinically early stage 
confined tumours have few or no mutations in p53, whereas the metastatic and 
CRPC harbour a high frequency of mutations [157–160]. An indication that p53 is more 
important for the progression than for the initiation of PCa [158,161].   Androgens have 
been shown to negatively influence p53 expression [162,163].  In agreement with these 
findings, androgen deprivation caused an increase in p53 in the xenograft model 
CWR22, which correlated with a decrease in cellular proliferation [164]. Conversely, 
p53 can affect androgen signalling as physiological levels of p53 are necessary and 
have a protective effect on AR but overexpression of p53 blocks androgen signalling 
[165,166]. These findings indicate that androgen-dependent growth of PCa depends on 
a balance between AR and p53 and if disrupted it may result in PCa progression [166]. 
One of the major regulators of p53 is the ubiquitin E3 ligase MDM2 that 
targets p53 for proteasomal degradation. In normal cells, MDM2 is weakly 
expressed, allowing p53 activation after injury or DNA damage. However, in human 
cancers, including PCa, elevated expression of MDM2 has been observed that is 
associated with poor prognosis [167–169]. Interestingly, MDM2 is a target of AKT, one 
of the main pro-survival pathways activated in PCa progression. AKT-induced 
phosphorylation of MDM2 promotes its stabilization, decreasing the levels of p53 and 
consequently inhibits apoptosis [169].  
 
One of the first p53 target genes which were identified was p21_Waf1/Cip1 (a 
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cyclin-dependent kinase inhibitor).  Deletion of p21 eliminates the ability of p53 to 
induce G1 cell cycle arrest in many cell systems [150]. In addition to p53, p21 can be 
regulated by different factors, among them androgens [170]. Consistent with this, in a 
variety of cancers, p21 expression does not correlate with p53 status [158]. In PCa, 
clinical studies suggest that increased p21 expression levels are a negative 
prognostic factor as p21 over-expression may correlate with resistance to radiation 
therapy for local recurrence after radical prostatectomy and with the development of 
CRPC  [158,171,172]. 
2. AKT/PTEN/mTOR 
The PI3K/AKT signal-transduction pathway (Figure 2.6) has an important role 
in carcinogenesis due to its ability to both induce cell proliferation and inhibit 
apoptosis [173,174]. The AKT serine/threonine kinase family [also called protein kinase 
B (PKB)] has three highly conserved members, AKT1, AKT2, and AKT3. Activation 
of AKT requires the anchoring of the protein to the membrane and its 
phosphorylation at two different sites. In this process, two different kinases are 
involved, PDK1 and mTOR-Rictor complex [175]. Fully active AKT dissociates from 
the plasma membrane and targets substrates located in the cytoplasm and nucleus 
resulting in cell survival and proliferation [176]. 
Studies in PCa cell lines reveal that AKT activity contributes to PCa 
progression by dramatically accelerating prostate tumour growth [177].  AKT activity 
increases with increasing malignancy and correlates with the aggressiveness of the 
tumour [178–180]. The main negative regulator of AKT activation, the dual-specificity 
phosphatase PTEN (also called MMAC1), was initially identified as a mutation hot 
spot in cancers [74]. The overexpression of PTEN inhibits phosphorylation and 
activation of AKT by blocking its anchoring to the membrane [181,182]. ]. In recent years 
it has become clear that the loss of PTEN and subsequent activation of AKT is a 
critical event in PCa progression and in highly correlated with advanced PCa stage 
[183].  
Cells lacking PTEN or harbouring constitutively active AKT present high levels 
of mTOR activity which results in increased cell growth [183]. Silencing mTOR in PC-3 
cells induces cell cycle arrest and apoptosis [184].  
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The AKT pathway has many other downstream substrates −among them IKK 
kinase, an activator of the NFΚB pathway [185,186]. The inhibition of AKT in PCa cell 
lines activates the apoptotic process through inactivation of NFΚB signalling [187,188]. 
Apart from the pro-proliferative effects of AKT through mTOR or NFΚB activation, 
this pathway also has anti-apoptotic effects through phosphorylation and inactivation 
of other pro-apoptotic proteins, such as Caspase-9, BAD, and FOXO transcription 
factors [169,179,189] 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 AKT/PTEN/mTOR pathways. The phosphorylation of the phosphatidylinositol 
phosphate PIP2 to PIP3 by phosphatidylinositol 3-kinase (PI3K) results in the phosphorylation and 
activation of AKT. Fully active AKT inhibits apoptosis through phosphorylation and inhibition of 
different pro-apoptotic proteins such as BAD, Par-4, Caspase-9, or by activating MDM2-dependent 
p53 degradation. Dephosphorylation of PIP3 by PTEN inhibits AKT recruitment to the membrane, 
thus blocking its activation. PIP2, phosphatidylinositol phosphate PtdIns(4,5)P2; PIP3, 
PtdIns(3,4,5)P3; PDK1, phosphoinositide dependent protein kinase 1; mTOR, mammalian target of 
rapamycin; TSC1, tuberous sclerosis complex 1; TSC2 tuberin; MDM2, mouse double minute 2; Par-
4, prostate apoptosis response-4 protein; NFκB, nuclear factor κB; PTEN, phosphatase with tensin 
homology, which is deleted on chromosome 10. Reproduced from Lorenzo PI, Arnoldussen YJ & 
Saatcioglu S. (2007) [131]. 
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3. Mitogen-activated Protein Kinases (MAPKs) 
MAPKs are important mediators of signal transduction. They play a key role in 
the regulation of many cellular processes, including apoptosis [190]. The MAPKs are 
serine/threonine kinases that are phosphorylated and activated by stimuli such as 
cytokines, growth factors, and environmental stress as a result of a cascade of three 
protein kinases acting in series. MAPK is activated by a MAPK kinase (MAPKK), 
which in turn is activated by a MAPKK kinase (MAPKKK) (Figure 2.7) [190]. The three 
best studied MAPK pathways result in the activation of the extracellular signal-
regulated kinases (ERKs), c-Jun N-terminal kinases/stress-activated protein kinases 
(JNKs/SAPKs), and p38 MAPKs [191]. The ERK pathway is mainly involved in growth, 
differentiation, and development, while JNK and p38 MAPK pathways are involved 
mainly in inflammation, apoptosis, growth, and differentiation [192]. All three of the 
pathways appear to be involved in PCa proliferation but the JNK pathway seems to 
be involved in apoptosis as well. 
In PCa the effect of activated ERK is hypothesised to either reduce apoptosis 
or to induce cell proliferation. Staining for active ERK in epithelial cells increases 
progressively from normal prostate tissue to BPH to PCa [193,194]. While loss of 
activation of ERK has been observed in late-stage CRPC and metastatic disease, 
elevated levels of active ERK in high-grade and advanced stages of prostate 
tumours have been linked to increased cell proliferation that directly translates to 
poor prognosis [195,196].  
The p38 MAPK signalling pathway and its possible role in PCa is at present 
not clear. However, overexpression of p38 MAPK has been found in BPH and PCa, 
and correlates with enhanced cell proliferation [197]. 
 The biological effect of JNK signalling in cells, including PCa cells, is 
determined by the cell type and the size and duration of the stimulus [162]. 
Discrepancies in JNK activation and function have been observed in PCa studies 
[198–200]. Different studies have correlated apoptosis in PCa cell models to JNK 
activation. In PC-3 and DU145 cells, JNK is strongly activated and linked to cell 
death under stressful stimuli including cytotoxic drugs [198,199]. An interaction between 
JNK and AR pathways has been reported in PCa cells with a negative cross talk 
occurring between the AR and activator protein-1 (AP-1), a downstream target of 
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JNK, resulting in suppression of JNK-mediated apoptosis. 
 
 
 
 
 
 
 
 
 
Figure 2.7 Mitogen-activated protein kinase (MAPK) pathways. The activation of the three 
main MAPK signaling pathways ultimately results in the activation of the extracellular signal regulated 
kinases (ERK), p38 MAPKs, and c-Jun N terminal kinase/stress-activated kinases (JNK/SAPK). 
Activated MAPKs exert their action through the phosphorylation of different effectors both in the 
cytoplasm and in the nucleus. Tpl2, tumor progression locus 2; DLK, dual leucine zipper kinase; 
TAK1, TGF-β1-associated kinase 1; ASK, apoptosis signal- regulating kinase; MLK, mixed lineage 
kinase; MEKK, MAPK/ERK kinase; MEK, MAPK/ERK kinase; MKK, MAPK kinase. Reproduced from 
Lorenzo PI, Arnoldussen YJ & Saatcioglu S. (2007) [131]. 
 
4. NFκB 
NFκB is a cell survival factor and can be activated by a wide variety of stimuli.  
Under normal conditions, NFκB is required for normal development as well as 
immune and inflammatory responses to infection, and cellular stress and injury 
[201,202]. The NFΚB family comprises five members, namely, NFκB1 (p105-p50), 
NFκB2 (p100-p52), c-Rel, Rel A, and Rel B [reviewed in203]. In a resting state, NFΚB 
dimers are bound to specific inhibitors of NFκB (IBs) in the cytoplasm. In response to 
a variety of stimuli, the activation of the IB kinase (IKK) complex causes IB 
phosphorylation, which leads to nuclear translocation of NFκB dimers that regulate 
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transcription of target genes (Figure 2.8).  Once in the nucleus, the NFΚB dimers are 
subjected to further regulation through phosphorylation and/or acetylation [203]. 
Interestingly, NFκB can activate the expression of its own inhibitor IB, thereby 
providing a negative feedback loop on NFκB activation.  
Since NFκB is involved in the regulation of apoptosis, cell proliferation, 
differentiation, and tumorigenesis it is not surprising to find that NFΚB dependent 
gene expression is dysfunctional in various diseases, including cancer, which 
suggests that NFκB inhibitors could be used as therapeutic agents [203–206]. However, 
due to the large variety of NFκB effects in the normal physiology, NFκB inhibitors 
would be expected to have significant side effects including immuno-suppression 
which would limit the therapeutic application [205]. 
There is growing evidence that NFκB proteins play a role in the initiation 
and/or progression of PCa [reviewed in 204]. There is a correlation between NFκB 
activation and the grade of PCa [180,204,207]. Supporting this possible role of NFκB 
activation in PCa progression, in vitro studies using the PC-3 cell line demonstrated 
that increased NFκB activity contributed directly to cancer cell invasion [208,209]. 
Additionally NFκB activation protected PCa cells from apoptosis as well as 
contributed to PCa cell survival after AAT [204]. Blockade of NFκB activity is therefore 
associated with tumour suppression [210,211]. Surprisingly, several reports indicate a 
proapoptotic role for NFκB in the LNCaP cell model. NFκB activation is required for 
2-methoxyestradiol-mediated p53 induction and apoptosis [211]. It is not clear if this 
proapoptotic role of NFκB is due to the androgen dependence of these cells or to the 
low basal levels of NFκB activity. It is also possible that it depends on other cellular 
changes such as PTEN or p53 status [204]. 
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Figure 2.8 NFκB pathways. Under non-stimulated conditions, NFκB dimers are sequestered in 
the cytoplasm through their assembly with the specific inhibitory factor IκBα. Once activated, NFκB 
regulates the transcription of diverse anti-apoptotic and cell cycle regulatory genes that lead to 
apoptosis evasion and cell proliferation. Reproduced from Lorenzo PI, Arnoldussen YJ & Saatcioglu 
S. (2007) [280]. 
 
In summary, a number of signalling pathways are affected during prostate 
carcinogenesis. These mechanisms allow the PCa to evade the normal cell control 
mechanisms, ultimately leading to apoptosis-resistance and advanced CRPC. The 
AR and GR play important roles in this signalling. 
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2.1.3 NUCLEAR HORMONE RECEPTOR SIGNALLING PATHWAY 
 The GR and AR are closely related transcription factors (TF) from a family of 
nuclear hormone receptors. They are also known as NR3C1 and  NR3C4 (nuclear 
receptor subfamily, group C, members 1 and 4) respectively [212–214]. Nuclear 
receptors have the same general structure (Figure 2.9) in that they are made up of 
modular proteins divided into five functional domains: a variable amino-terminal 
regulatory domain (NTD), a DNA-binding domain (DBD), a ligand-binding domain 
(LBD) and a small hinge region (H) containing a nuclear localisation signal and 
important sites for phosphorylation, acetylation and degradation [86,215–220]. In the NTD 
and H regions there are significant differences between the nuclear receptors 
allowing for variations in homeostatic control and signalling. In contrast, the 
sequences of the DBD and LBD regions are highly conserved resulting in 
considerable functional specificity [218]. In addition to these domains, nuclear 
receptors possess two transcriptional activation domains: activation function 1 (AF-1) 
located in the NTD and activation function 2 (AF-2) located in the LBD. AF-1 works in 
a ligand-independent manner and is responsible for optimal transcriptional activity 
and ligand binding. AF-2 works in a ligand-dependent manner and allows for the 
binding of cofactors important for inducing transcriptional activity  [221–223].   
 
 
 
 
 
 
Figure 2.9 Structure of the nuclear family receptors. A) Schematic representation of the general 
structure and functional domains of nuclear receptors. Reproduced from Africander, 2010[221]. B) 
Individual nuclear receptor structures and there domain similarity. Activation function 1; AF-1, 
activation function 2; AF-2; NTD, N-terminal regulatory domain; DBD, DNA-binding domain; LBD, 
ligand-binding domain; H, hinge region. Reproduced from Li & Al-Azzawi, (2009) [217].  
B 
A 
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In the absence of ligands nuclear receptors are bound to heat shock proteins 
(HSPs) and other chaperone proteins which keep the receptor in the cytoplasm in a 
resting, unbound, state. The LBD allows high affinity binding of the ligand to the 
receptor which when bound generates a conformational change within the receptor 
that results in dissociation of the HSPs and chaperone proteins. This activation of the 
receptor is regulated by the interaction of co-regulators and receptor co-regulator 
phosphorylation in response to growth factors. Phosphorylation sensitises the 
receptors response to low levels of ligands and recruits nuclear co-activators 
required for chromatin remodelling [224,225]. It is the NTD receptor region that mediates 
the majority of transcriptional activity and is the most active co-regulator interaction 
surface [226,227].These interactions result in receptor translocation from the cytoplasm 
to the nucleus and homodimer formation. Various models of homodimerisation have 
been described but the most well characterised interaction is the DBD-mediated 
dimerisation which is essential for receptor-DNA complex formation and regulation of 
transcription [228]. Additional receptor interactions have been reported to result from 
intra- or inter- molecular interactions between the amino and carboxyl termini of the 
receptor, known as the N/C interactions [228–230]. Studies show that N/C interaction is 
dependent on the AF-2 domain and that it facilitates ligand retention by the nuclear 
receptors [231,232]. It is only following these events that the receptor homodimer can 
bind to hormone-response elements (HREs) located in the promotor regions of target 
genes and actively engage essential co-factors as well as assemble the 
transcriptional machinery required to regulate the expression of the target genes 
[225,233,234].  
Two zinc finger motifs are contained in the cysteine-rich DBD along with a short 
C-terminal extension that forms part of the hinge [235,236]. These zinc fingers are 
responsible for the recognition and stabilisation of the hormone receptor-DNA 
complex. The first zinc finger assists the binding of the receptor in the major groove 
of DNA by recognising specific base pairs within the HRE [237].  Many genes contain 
HREs in their promotors that are not specific to a singular nuclear hormone receptor 
due to the highly conserved DBDs that recognise virtually identical DNA sequences. 
For example all nuclear hormone receptors, with the exception of the ER, bind to the 
three-nucleotide-spaced repeated palindromic binding motif TGTTCT [213]. The 
conserved amino acids in the second zinc finger mediate dimerization of the 
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receptors and stabilise the receptor-DNA complex [236,238,239]. Once the receptor 
homodimer has bound to the HRE transcription occurs. However, transcriptional 
activity is also dependent on an array of co-regulators and co-regulator complexes 
that are recruited upon receptor binding [225].  These co-regulators are often 
chromatin remodelling complexes, since they contain histone acetyltransferase 
(HAT) or deacetylase activity, which loosen or tighten, respectively, the chromatin 
structure and assist the binding of transcriptional machinery to the DNA. This 
stimulates (co-activator) or represses (co-repressor) gene expression [43]. Nuclear 
hormone receptors play a pivotal role in regulating gene expression and thereby 
determining cellular mechanisms and functions as evidenced by the AR and GR 
activity in PCa.     
   
 
 
 
 
 
 
 
Figure 2.10 Nuclear receptor mechanism of action.  Steroid receptors are synthesized in 
inactive forms that are associated with HSP complexes in the cytoplasm and/or nucleus. Hormone 
binding causes dissociation of steroid receptors from HSP complexes and the receptors to undergo 
dimerisation where upon they translocate into the nucleus. Various co-regulators and transcriptional 
machinery are then recruited so the homodimer can bind to specific response elements in target 
genes initiating transcription. 
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2.1.3.1 AR and PCa 
Androgens, mediated by the AR, are the main hormonal regulators in the 
prostate. The AR activates genes responsible for maintaining the balance between 
cell proliferation, apoptosis and cell differentiation [65,72,240].  As previously described 
in 2.1.3, the AR is expressed, to some degree, in nearly all primary PCa and plays a 
critical role in the progression of PCa [241–243]. It is through manipulation of the AR 
pathway that most PCa circumvents the normal mechanisms of proliferation 
regulation, leading to uncontrolled growth, and bypassing apoptosis. Various studies, 
in both humans and animal models, suggest a relationship between the cellular AR 
expression and the level of malignancy and subsequent disease progression in both 
primary and metastatic PCa [244,245]. Huggins and Hodges provided the first in vivo 
evidence that targeting androgen/AR signalling via AAT could suppress PCa growth 
and progression [25]. Hence the AR remains a natural target for the development of 
current and future treatments for PCa. 
AR and cell proliferation 
Since early studies demonstrating the benefits of AAT in PCa, the AR has 
been a target to reduce tumour growth. However, it has been established that the AR 
plays differential roles in cell proliferation. Multiple studies have demonstrated that 
the AR can act as a stimulator to promote PCa cell growth as well as a suppressor 
[246–249]. This contrasting AR function is dependent on the different PCa cell types and 
tumour microenvironments. There are stem/progenitor cells and 3 types of epithelial 
cells in the normal prostate: (1) luminal cells, (2) intermediate cells and (3) basal 
cells. PCa can develop from any of these cells and so is often a mix of cells in 
various stages of differentiation which results in differing cellular mechanisms [250,251].  
Bonkhoff et al. established that AAT resulted in the majority of the luminal epithelial 
cells being eliminated and that it had little effect on the basal cells. Therefore, AAT 
may only affect specific cell types which may partially explain why AAT would 
eventually fail [252]. These observations have led to numerous studies of the different 
PCa cell types and the effect that the AR has on them. It has been shown that the 
AR promotes PCa growth when derived from luminal and stromal cells but 
suppresses the PCa growth when derived from stem, basal and intermediate cells 
(as summarised in Table) [248,253–261].   
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Table 2.1 Summary of the sensitivity of androgens on the different PCa types. The 
androgen/AR signal exhibits different roles in prostate cancer progress and can either suppress or 
promote PCa growth depending on the PCa cell type.  
 
AR and Apoptosis: 
In addition to affecting cell proliferation, the AR also modulates apoptotic 
pathways allowing for PCa survival.  In the normal prostate, tissue homeostasis is 
maintained through controlled cell death which is a natural barrier against the 
development of cancer [106,262]. Importantly, studies have indicated that the AR has 
an essential influence on PCa cell death via distinct apoptotic mechanisms with 
accumulating evidence suggests that targeting androgens and AR-mediated cell 
death signalling could alter PCa progression [163,201,202,263–266].  The AR appears to 
modulate apoptosis in both positive and negative ways and can either promote or 
suppress apoptosis (Figure 2.11) through the adjustment of the different apoptotic 
signalling pathways determined again by the tumour microenvironment [267–270]. 
AR negative roles in PCa cell apoptosis (Anti-Apoptotic): 
There are many mechanisms by which AR protects cells from apoptosis. 
Protection is executed through the manipulation and deregulation of the AR which is 
one of the regulators for the apoptotic pathways, as previously described. It is 
through these mechanisms that PCa progresses to CRPC and they have therefore 
become targets for the development of alternate and novel therapeutic strategies. 
One of the most important contributors to AR cell preservation is the cyclin-
dependent kinase inhibitor p21 (WAF1, CIP1, SDI1, or CAP20) that protects against 
Cell Types Marker 
AR roles in 
growth 
Cell 
amount 
after AAT 
Reference 
Stem/Progenitor 
cells 
CD133, CK5+, CK8-, AR- 
Suppressor Increase 
Lee et al. (2012) [258]  
Basal cells CK5+, CK8-, AR- Niu et al. (2008) [247] 
Litvinov et al. (2004) [256] 
Litvinov et al. (2006) [257] 
Intermediate 
cells 
CK5+, CK8+, AR- 
Luminal cells CK5-, CK8+, AR+ 
Promoter Decrease 
Niu et al. (2008) [247] 
Eder et al. (2000) [253] 
Haag et al. (2005) [254] 
Liao et al. (2005) [255] 
Stromal cells 
(Smooth muscle 
cells, 
fibroblasts) 
A-SMA, Vimentin, 
Calponin 
Niu et al. (2008) [247] 
Halin et al. (2007) [259] 
Gleave et al. (1991) [260]  
Lai et al. (2012) [258] 
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p53-mediated apoptosis [271]. An apoptosis-resistant phenotype may arise from over 
expression of p21 which induces cell cycle arrest [272]. Lu et al. showed that AR, by 
stimulating p21 mRNA and protein levels, acted as an inhibitor of apoptosis and 
thereby promoted PCa LNCaP cell growth [170]. They also found that androgens 
could enhance the p21 gene expression at the transcriptional level through a 
functional ARE located at À200bp of the p21 gene proximal to the promoter region 
which led to the inhibition of apoptosis. Another possible mechanism whereby 
apoptosis is suppressed is through direct down regulation of the p53 by the AR [163].  
Rokhlin et al. found that the AR promotes cell survival through inhibition of p53 
expression and caspase-2 activation which suppresses the TNF-R family. They also 
showed that this suppression could subsequently be enhanced by p53 knockdown 
[163]. Other studies have shown that androgens can block apoptosis induced by Fas 
activation and TNFα [273]. Additionally, Kadowaki et al. found that AR-positive LNCaP 
cells were resistant to TRAIL-induced apoptosis, while the AR-negative PC-3 cells 
were sensitive, supporting an AR protection mechanism [274]. 
 Sun et al. showed the AR functioned as an anti-apoptotic element in LNCaP cells 
by activating PI3K and AKT1/AKT2 [275,276 The AR also suppressed apoptosis by 
inhibiting the pro-apoptotic molecule Bad, the Bcl-2-associated death protein. 
Apoptosis is inhibited when the AR activates MAPK and increases the 
phosphorylation of ERK-1 and ERK-2 which inactivate Bad [277,278].  
The AR also protects PCa cells from apoptosis in an androgen-independent 
manner. Diallo et al. found that AR-negative PC-3 cells were more sensitive to the 
anti-cancer drug effect via inducing caspase-dependent apoptosis than PC-3 cells 
stably transfected with AR in the absence of androgen [279]. Other studies showed 
that the down-regulation of AR induced PCa apoptotic death upon addition of a 
proteasome inhibitor and the chemotherapeutic agent, docetaxel [267,280]. Liao et al. 
showed that apoptotic death in PCa cells was achieved by knockdown of AR via 
siRNA [255]. They also found both cisplatin and the proteasome inhibitor induced 
caspase-3 associated cell death in AR-negative PC-3 cells while non-caspase-3 
associated cell death was observed in AR-positive PC-3_AR and LNCaP cells. In 
addition, they found that co-treatment with Bortezomib and the AR antagonist 
Casodex caused significant decrease in AR expression and led to increased 
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caspase-3 activity in LNCaP and PC-3_AR cells, suggesting AR might suppress 
caspase-3 expression [267]. 
AR positive roles in PCa cell apoptosis (Pro-Apoptotic) 
In contrast to the dominant role of AR in cell proliferation, positive roles promoting 
apoptosis have been described (Figure 2.11) [125,268,281]. Godfrey et al reported that in 
androgen-independent PCa cells, the AR could promote stress-induced cell death 
independent of its transcription activity [268]. Similar results supporting this finding 
were reported in 2012 by Lin et al. [281]. They demonstrated that DNA damage and 
AR proteasomal degradation were induced by UV. Up-regulation of PIRH2 and p53 
as well as down-regulation of p21 resulted from AR degradation of the N-terminal 
domain resulting in apoptotic cell death.  This suggested that AR could promote a 
response to radiotherapy through the PIRH2-p53-p21 axis.  However, other studies 
have reported conflicting results, showing that AR could protect PCa from irradiation-
induced apoptosis [273].  
In addition to intracellular AR functions in apoptosis, it has been suggested that 
membrane AR can induce apoptosis in PCa cells as well [282,283].  One study showed 
that membrane AR activation resulted in down-regulation of PI-3K/Akt/NFκB activity 
which induced apoptotic responses via Bad, FasL and caspase-3 in PCa [283]. Other 
studies demonstrated that truncated PolyQ expression of AR gene promoted 
apoptosis through up-regulation of Bax and JNK suggesting that the anti-death/pro-
death function of AR is mediated by transcriptional regulation of apoptosis 
associated genes [281,284,285]. 
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Figure 2.11 Major roles of AR in apoptosis is as a suppressor. In contrast to the main 
negative roles of AR in apoptosis, under specific circumstances (exposing to UV for example), AR 
may induce apoptosis. Reproduced from Wen et al. (2014) [286]. 
Since both positive and negative roles of AR in PCa cell apoptosis have been 
reported, it is still arguable when and under what circumstances AR selectively plays 
its roles. It is known that AR function is regulated by multiple signalling pathways and 
depending on different AR associated protein complexes, determined by cell micro-
environments and cell type’s −the AR may induce or suppress cell apoptosis. The 
anti-apoptosis and pro-survival function of AR is mediated mainly by transcriptional 
regulation of its target genes.  In contrast, the pro-apoptosis function of AR is mainly 
transcription-independent, or mediated by membrane AR.  
Challenges to current AAT 
PCa progression is not dependent entirely on any single pathway and none of the 
mechanisms described contribute to PCa growth and metastasis equally.  Apoptosis 
plays a dominant role in controlling the PCa proliferation and survival. This dual AR 
function of apoptosis and proliferation may offer a plausible explanation, in part, as to 
why ATT is ineffective in CRPC. Thus the AR is one of the most important 
mechanisms that regulate cell death induction while at the same time promoting 
resistance.  
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2.1.3.2 The GR and PCa 
Glucocorticoids are involved in extensive cellular modulation and are major 
regulators of growth, energy production, metabolic processes, immune and 
cardiovascular function and reproduction as well as playing an important role in 
activating mechanisms that aid in the recovery from stress and maintain 
homeostasis. These effects are carried out through both positive and negative gene 
manipulations mediated through the GR.  
There are two subsets of GR; GRα and GRβ. GRα is the receptor that binds 
glucocorticoids while GRβ does not. GRβ has inherent GRα-independent 
transcriptional activity and exerts a dominantly negative effect on GRα-mediated 
transcription [287,288]. The GRα utilises several mechanisms to manipulate cellular 
responses, the most prominent of which is through nuclear signalling where it acts as 
a TF that binds to glucocorticoid response elements (GREs) in the promotor regions 
of target genes and results in stimulation or suppression of the transcription of these 
genes, known as transactivation or transrepression, respectively (Figure 2.12). 
Transrepression also occurs when GRα- activated monomers interact with other TFs 
such as Activator Protein-1 (AP-1), nuclear factor-kB (NFκB), CRE-binding protein 
(CREB), signal transducer and activator of transcription 5 (STAT5), which, via 
protein–protein interactions, interfere with the transcription activity of these TFs and 
down-regulate their target genes. GR-mediated transactivation may be inhibited by 
inflammatory mediators such as TNF-α and growth signals such as Insulin-like 
Growth Factor-1 (IGF-1) which activates the transcription factors AP-1 and NFκB [289–
291].  The activated GRα monomer can also interact with many other co-activators 
(p160, p300/CREB binding protein (CPB) and p300/CPB-associated factor (P/CAF)) 
and co-repressors. The GRα is governed by post-translational modifications of the 
receptor such as ubiquitination, sumoylation, acetylation and phosphorylation which 
determine whether the GR is down- or up-regulated [292–295]. Many of these control 
mechanisms are altered in autoimmune diseases and cancer.  In the context of 
cancer, glucocorticoids are a standard treatment in many cancers as they exhibit an 
effect on the regulation of inflammation and apoptosis. Recent developments of GR-
specific ligands, suggest that novel selective GR modulators (SGRMs) can trigger 
the expression of only a desirable subset of genes, enhancing their therapeutic 
effects while decreasing their side-effects and offering an attractive target for drug 
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development [296]. 
Figure 2.12 GR signal transduction pathway. Glucocorticoids, such as cortisol, diffuse into the 
cell where ligand binding induces molecular rearrangement of the GR complex and nuclear 
translocation resulting in mechanisms that either activate (transactivation) or inhibit (transrepression) 
of transcription. Reproduced from Labeur M & Holsboer F (2010) [11]. 
Despite the wide use of glucocorticoids as the treatment of PCa, it is only 
recently that the changes of GR expression during prostate tumorigenesis and its 
role in PCa have begun to be understood. In 2007, Yemelyanov et al. showed that 
GR signalling in early stage PCa exhibited anti-tumour effects on proliferation, 
differentiation and transformation in PCa cell models expressing the GR [6]. However 
loss of GR expression occurs in PCa progression and the GR is decreased or absent 
in 70--85% of PCa when compared to the normal prostate or BPH [6]. This early 
change in GR levels mirrors the changes in ERβ expression, another PCa inhibitor, 
reported by Fixemer et al. yet other steroid hormone receptor expression, such as 
AR and PR, remain constant [297]. Thus the GR can act as an anti-tumour agent in 
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early PCa when the GR is still expressed, favouring the use of glucocorticoids as 
treatment in the early stages of tumour development. The mechanism utilised by the 
GR to affect its anti-cancer effects appear to be exerted through transrepression 
which in most cases is mediated by direct interaction of the GR with other TFs or by 
crosstalk between the GR and other signalling pathways [214,290,298–300]. One of the 
most important interactions in this regard is with the MAPK signalling pathway. This 
pathway plays a vital role in the proliferation and survival of PCa [301,302]. Yemelyanov 
et al. found that activation of GR signalling blocked the activity of four major MAPKs: 
p38, JNK/SAPK, Mek1/2 and Erk1/2 [6]. This blockade appeared to involve increased 
expression of MKP1, a primary glucocorticoid-responsive gene, as well as an 
additional level of MAPK regulation via the post-transcriptional decrease of MAPK 
total protein levels [298,303]. It was further shown that numerous TFs had down-
regulated activity upon GR activation many of which are recognised MAPK targets, 
indicating that this could be a consequence of the GR-mediated MAPK blockade [6].  
Although this shows that the GR can be used as an anti-cancer agent it is 
applicable primarily to early-stage disease and an evaluation of the GR expression 
and glucocorticoid treatment in CRPC and PCa metastatic lesions still requires 
investigation. 
Yano et al. demonstrated that the effects of glucocorticoid-activated GR in 
CRPC resulted in suppression of two major angiogenic factors, VEGF and IL-8 [304]. 
These two angiogenesis-related TFs mediate gene expressions that correlate with 
tumour metastasis and poor prognosis in PCa [305–308]. These results provide 
evidence that the therapeutic effect of glucocorticoids in CRPC can be directly 
attributed to the inhibition of angiogenesis by a reduction in both VEGF and IL-8. A 
recent study, supporting this, showed that dexamethasone (DEX) could directly 
suppress the in vitro growth of DU145 and PC-3, both of which express GRs [296].  
The clinical use of glucocorticoids as an angiogenesis inhibitor in combination with 
anticancer agents, such as docetaxel, may enhance their therapeutic effect on 
CRPC. 
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GR as a regulator of the AR pathway 
Glucocorticoid treatment is mainly used to help patients manage pain and 
adverse side-effects of chemotherapy [309,310]. However, glucocorticoids have also 
been shown to act as a ligand for the mutated AR and alter IL-6 signalling resulting 
in the promotion of PCa cell proliferation [79,311Additionally, the AR and GR bind to 
similar HRE domains and this has led to a degree of overlap. It has been determined 
that approximately half of the AR binding site overlaps with that of the GR in PCa 
cells expressing both receptors and this has revealed that the AR and GR are 
capable of binding to the same DNA sites [312–314]. Gene expression schemes of Dex-
induced GR and DHT-induced AR are highly overlapping and the shared AR- and 
GR-binding events are associated with genes regulated by both androgens and 
glucocorticoids [313]. This led Sahu et al. to suggest that the AR and GR occupied by 
their cognate ligands are capable of using the same cis-elements to regulate 
transcription and that glucocorticoid-activated GR can take over the regulation of AR 
target genes [313]. 
Studies have furthermore demonstrated that activation of GR signalling can 
maintain an active AR under androgen deprived conditions in PCa. This is despite 
the previous reports on the tumour suppressive activities of the GR in PCa cells. GR 
should, therefore, be considered as a partial agonist/antagonist for the AR, in that 
liganded GR is an anti-AR in the presence of androgens but an AR agonist in the 
absence of androgen. [312,313,315,316]. The apparent interplay between AR and GR 
signalling is of potential clinical importance as about 30% of PCa cells express GR 
with increased GR protein expression detected in PCa after androgen-deprivation 
therapies and in CRPC tissue [7,317].  Unlike the AR, GR function is indispensable for 
life, which presents an inherent challenge in the establishment of GR signalling 
blockades aimed at treating or investigating CRPC and emphasises the need for 
selective blockades [318].  
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Figure 2.13 Interplay of AR and GR pathways in prostate cancer cells. Dex, dexamethasone; 
anti-androgen (e.g., enzalutamide).Reproduced from Phihlajamaa et al. (2015) [319]. 
Side-effects of GR treatment: 
The effects of glucocorticoid treatment can be summarised as anti-
inflammatory/immuno-suppressive, metabolic, and toxic. Glucocorticoids are 
associated with multiple side-effects that develop in different organs and tissues 
during chronic treatment. The list of undesirable effects includes changes in glucose 
and fat metabolism, Cushing's syndrome, diabetes, glaucoma, osteoporosis, muscle 
and skin atrophy, decreased wound healing, changes in mood and cognition, growth 
retardation and infertility. Many of these effects are severe and sometimes 
irreversible. In cancer treatment the anti-inflammatory and immuno-suppressive 
effects are desired while the metabolic and toxic effects are associated with adverse 
side-effects [320]. The anti-inflammatory proteins are produced through the induction 
of the GR and the resulting transactivation of their target genes. On the contrary, the 
majority of the pro-inflammatory genes that encode cytokines, chemokines, and 
adhesion molecules, are regulated by the transcription factors NFκB and AP-1 
[Reviewed in 321]. In these cases, the GR exerts its anti-inflammatory effects by 
interacting as a monomer with the subunits of respective TFs, inhibiting their activity 
and repressing the expression of the respective pro-inflammatory proteins. Based on 
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the large number of genes that are regulated in this manner, it has been 
hypothesised that the transrepression mechanism is sufficient to achieve anti-
inflammatory effects [322–324]. 
 Moreover, a number of side effects seem to be mediated predominantly via 
the transactivation mechanism [325–327]. Therefore, the identification of novel selective 
GR ligands, which cause a receptor conformation that prefers a GR-protein 
interaction, and not a GR-DNA binding-dependent mechanism, would be of 
therapeutic benefit. Such partial agonists may have widely similar anti-inflammatory 
effects and, while they should clearly induce fewer side effects as the DNA-
independent GR mechanism alone, are sufficient for anti-inflammatory actions. 
Another side effect often neglected in studies is the so-called acquired resistance. 
Although most patients suffering from chronic inflammatory diseases have a good 
response to GC treatment at the start of therapy, a subpopulation of patients will 
over time inevitably become unresponsive to GC treatments. This may be ascribed 
to a physiological feedback mechanism −a homologous down-regulation of GR 
whereby glucocorticoids inhibit their own receptor levels. Thus, for optimal 
therapeutic value, the novel selective GR ligands should not only inhibit 
transactivation and up-regulate transrepression but also not trigger the regulatory 
feedback mechanism. 
Differential targeting of the AR and GR in PCa 
Given that AR and GR play opposing roles in PCa tumorigenesis, Yemelyanov et 
al. proposed that dual steroid receptor modulators that act as anti-androgens and 
simultaneously promote transrepression by the GR would make an ideal therapy for 
PCa [7]. They confirmed the differential modulatory effect using several PCa cell lines 
with different AR/GR status including a modified LNCaP cell line that expressed both 
receptors. They found that differential targeting of the AR and GR induces 
endoplasmic reticulum stress (ERS) and apoptosis in multiple PCa cell lines. 
Surprisingly, the PCa cells had a high expression of nuclear AR and GR following 
androgen ablation or chemotherapy. This was an unexpected result, as GR 
expression is strongly decreased in primary PCa in non-treated patients [6,328]. ]. 
However, since both AR and GR are widely expressed in treated human PCa this 
only strengthened the hypothesis of the proposed PCa treatment strategy by 
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differential targeting of the AR and GR. A number of compounds have been found to 
have a dual regulatory effect on the AR and GR in PCa.  Among these is 2-(4-
acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride (Compound A) which is 
a synthetic analogue of a hydroxyphenyl aziridine precursor found in the African 
shrub Salsola tuberculatiformis Botsch which is the subject of this study [8,43]. 
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2.2 SALSOLA TUBERCULATIFORMIS BOSTCHANTZEV 
 The African shrub known as Salsola tuberculatiformis Botschantzev, locally 
known as Gannabos (Figure 2.14), is a plant that belongs to the family 
Chenopodiaceae which grows in the arid areas of South Africa, Namibia and Angola 
[329]. It belongs to the genus Salsola of which 69 different species are found in 
Southern Africa. Salsola tuberculatiformis Botsch occurs in a wide range of dry 
habitats and brackish soil and is extremely drought resistant. This plant genus has 
long been associated with medicinal qualities as documented by Ploss et al. in 1906 
who reported the use of aqueous extracts from Salsola species as a contraceptive in 
Algeria [8,330].  
 
 
 
 
 
 
Figure 2.14 Images of the African shrub, S.tuberculatiformis. Reproduced from Swart et al. 
(2003) [8]. 
  Later, this same plant was revealed as the responsible agent for 
“Grootlamsiekte” or “Laat Lammetjie” syndrome that occurs in Karakul sheep which 
are farmed for the Swakara or Karakul pelt industry [9]. This syndrome is 
characterised by a prolonged gestation period of ± 213 days (normal gestation, 149 
days) that results in foetal post-maturity rendering the lamb’s coat overgrown and 
economically worthless [331De Lange et al. established that this prolonged gestation 
was due to the ingestion of S.tuberculatiformis by the sheep and these findings 
initiated an investigation into the biological properties and active components of the 
plant [9,331 Basson et al. uncovered that S.tuberculatiformis possessed the ability to 
inhibit the estrus cycle in female rats in a dose dependent and reversible fashion. 
This supported the previously reported historical and traditional use of the plant 
infusion as a contraceptive [9]. In 1973, Liggins et al. showed that a surge in foetal 
cortisol, from the foetal adrenal, is the primary trigger to initiate parturition in karakul 
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sheep and this led to the hypothesis that ingestion of S.tuberculatiformis  interfered 
with steroidogenesis resulting in inhibition of this “trigger”” [332]. This hypothesis was 
further supported by the atrophy of the adreno-hypophyseal axis, increased size of 
female genitalia and mild testicular atrophy that have been noted at autopsy in 
karakul sheep which would suggest a degree of androgen blockade or anti-androgen 
activity [333].  
In 2003, Swart et al.  published a review on the active properties of the plant 
[8]. His group were unable to reproduce the prolonged gestation observed by Basson 
et al.  in female rats but instead rats fed with the S.tuberculatiformis extract 
underwent either foetal reabsorption in early pregnancy, or induced abortion in late 
pregnancy [8,9]. The group therefore decided to concentrate their efforts on the 
contraceptive properties as a possible bioassay for the active substances in the 
plant. Using the method described by Zarrow et al. the contraceptive properties could 
be extracted with methanol [334]. However, fractionation of the extract using active 
solvent partitioning and chromatographic procedures was associated with 
autocatalytic decomposition and polymerisation of the active compounds. The 
contraceptive activity could, however, be removed using trimethylammonium 
acetylhydrazide (Girard-T reagent) which isolates aldehydes and ketones. The 
derivatives isolated in this fashion were isolated by solvent partitioning and 
decomposed under acidic conditions to yield three substances (Figure 2.15) 
identified 1a, (1-(4-hydroxyphenyl)-ethanone; 1b, 1-(4-hydroxy-3-methoxyphenyl)-
ethanone, and 1c 4-hydroxybenxaldehyde. Only the ketones 1a and 1b showed 
biological activity in rats but neither could account for the contraceptive activity at the 
levels found in the crude extract. Owing to this, in 1975 Swart et al. began a re-
evaluation of the methodology as the extremely labile character of the active 
compounds required a more rapid and more sensitive biochemical micro assay [8]. 
Previously, Williamson and O’Donnell had described a bipyridyl derivative, 
metyrapone, with structural similarity to 1a and 1 b, that inhibited the terminal step in 
mammalian corticosteroidogenesis by binding to cytochrome P450-dependent 11β-
hydroxylase (CYP11B1) [335]. Based on this work Swart et al. were able to develop a 
micro-bioassay based on the spectral and catalytic properties of CYP11B1 [336–338]. 
The unique spectral properties of the cytochrome P450-dependent hydroxylases 
allows for the analysis of enzyme-substrate and enzyme-inhibitor difference 
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spectroscopy. This assay provided a rapid and sensitive screening method for the 
biologically active extracts of S.tuberculatiformis [8].  
 
 
 
 
 
 
 
 
 
Figure 2.15 Structure of isolated compounds from S.tuberculatiformis and metyrapone, the 
bipyridyl derivative described by Williamson and O’Donnell (1969) [335]. Reproduced from Swart 
et al. (2003) [8]. 
Although Ia and Ib  inhibited CYP11B1 it was clear that the shrub contained 
substances that were far more potent and two active fractions, S1 and S2, were 
subsequently obtained through methanol extraction, liquid ion exchange, ultra-
filtration and high performance liquid chromatography (HPLC). Both fractions, 
although extremely labile, inhibited sheep adrenal CYP11B1. S1 decomposed 
rapidly when isolated and was unsuitable for any further biological work [337].  S2 
could be maintained but only in a strictly controlled environment where it was 
protected against factors such as light, oxygen and a pH > 4. The instability of S2 
prevented sufficient amounts to be prepared for structure elucidation of the active 
substances through gas chromatography or mass spectrometry. Acetylation of S2 
followed by GC and fast atom bombardment mass spectrometry (FABMS) of the 
acetylated product was, however, successful and confirmed that S2 contained an 
aziridine as well as synephrine [339]. The decomposition of S2 is shown in Figure 
2.16. In a neutral or alkaline aqueous medium S2 spontaneously decomposed to 
synephrine that was always present in S2 in varying amounts. Acetylation of S2 
yielded the aziridine (acetic acid 4-(1-methyl-aziridin-2-yl)-phenyl ester) as well as an 
acetylated synephrine (Figure 2.16). This decomposition pattern was later confirmed 
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with electrospray mass spectrometry (ESMS) studies [340]. The isolated synephrine 
had no biological activity [8]. 
 
 
 
 
 
 
 
 
 
Figure 2.16 Decomposition and acetylation of S2 
Aziridines are known in nature as mitomycins. Mitomycins are highly reactive 
N tricyclic compounds with potent antibacterial and anti-cancer properties having a 
broad activity against a range of tumours [341,342]. Mitomycin C, the most potent 
mitomycin, has been used medicinally since the 1970’s for its activity against breast, 
stomach, oesophagus and bladder cancers [342,343]. The reactivity of the nitrogen-
containing three membered aziridine ring compounds has often necessitated the use 
of more stable precursors in clinical studies. The precursor would have the basic pre-
aziridine structure with the substitution of a good leaving group such as Cl¯. Once 
ingested by or injected into the animal, cyclisation occurs to yield the active aziridine 
in vivo (Figure 2.17). It was hypothesised that the labile nature of the active S2 could 
be ascribed to the aziridine, 2-(4-hydroxyphenyl)-1-methyl-aziridiniumchloride, which 
originated from a labile hydroxyphenyl precursor present in S2 [8]. They therefore 
designed a more stable precursor that would cyclise, with the loss of chlorine, to 
form the reactive aziridine in vivo. The precursor, 2-(4-acetoxyphenyl)-2-chloro-N-
methyl-ethylammonium chloride, dubbed Compound A, which was synthesised by a 
Ph.D. candidate, de Kock, in the laboratory (Figure 2.17) [344]. The structure of the 
precursor and its aziridine was confirmed by EI and FABMS and subsequently 
investigated as a model for the biological effects of Salsola tuberculatiformis 
Botschantzev [345,346]. 
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Figure 2.17 A) The cyclisation of aziridines and B) the chemical structure of CpdA. 
Adapted from Swart et al. (2003) [8]. 
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2.3 COMPOUND A 
CpdA was synthesised as an analogue of the active component in 
S.tuberculatiformis and would be expected to mimic the biological properties already 
exhibited by the S.tuberculatiformis S2 fraction. This was investigated by Louw et al. 
in two ways [346,347]. Firstly, they studied the contraceptive properties. The 
administration of dried S.tuberculatiformis and CpdA to female Wistar rats resulted in 
a prolonged di-estrus cycle, an effect which was reversible [346].  Secondly, they 
determined the influence of CpdA on CYP11B1 through the micro-bioassay 
developed by Swart et al. This assay showed that CpdA inhibited the binding of the 
natural substrate, deoxycorticosterone (DOC), to its enzyme, CYP11B1, comparable 
to S2 [347].  Further investigation revealed that CpdA produced a mixed inhibition of 
CYP11B1 with a stronger competitive than non-competitive element as well as 
inhibiting the 11β-hydroxylase  conversion of DOC. Comparison with other known 
inhibitors of CYP11B1, such as ketoconazole and metyropone, indicated that CpdA 
had a lower inhibitory capacity than other inhibitors [8,348,349]. These results indicated 
that CpdA did mimic properties of S.tuberculatiformis and led to further studies using 
CpdA. 
Louw et al. elucidated the possible mechanism of action of CpdA by 
demonstrating that CpdA interacted with steroidogenic enzymes and steroid binding 
globulins in plasma, displacing the endogenous steroids and affecting the 
bioavailability of these hormones in different target tissues. This caused a series of 
studies focused on CpdA and its interactions in the steroid pathways and possible 
therapeutic implications [350,351].  In 2008, Yemelyanov et al. showed that CpdA acted 
as a differential dual steroid receptor modulator that had the potential to be used as 
a novel PCa therapy [5]. They determined that CpdA could bind to the AR and GR 
resulting in nuclear translocation, although CpdA induced weaker translocation of the 
AR than the natural ligand DHT.  They also showed, through virtual docking, that 
CpdA was able to compete with steroids for binding to the AR and GR but CpdA 
exerted no significant effect on other steroid hormone receptors such as 
mineralocorticoids, progesterone, or oestrogen receptors [5,352,353]. 
Yemelyanov et al. demonstrated more biological properties of CpdA such as its 
ability to inhibit transactivation of both the AR and GR and enhancement of GR 
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transrepression [5]. As mentioned previously, in addition to DNA-binding dependent 
gene activation, there are DNA-binding independent mechanisms of gene regulation, 
mostly by GR-mediated repressor interactions or cross-talk between GR and other 
TF’s including NFκB, AP-1, p53, Ets-1, Elk-1, SRF, and NFAT.  GR transrepression 
is central to the anti-tumour and anti-inflammatory effects of glucocorticoids.  
Yemelyanov et al. also showed that CpdA and glucocorticoids had very similar 
transrepression profiles as they suppressed many pro-proliferative and anti-apoptotic 
transcription factors [5]. In PCa cell lines CpdA significantly decreased or delayed 
nuclear transport of NFκB and AP-1 proteins and it was suggested that cytoplasmic 
retention of NFκB and AP-1 could be the leading mechanism underlying CpdA 
inhibition of these factors. CpdA was also shown to have anti-inflammatory effects 
which are believed to be due to the blocking of inflammatory genes through GR 
mediated transrepression and the down regulation of TF’s including NFκB, T-bet and 
STAT6 as well as inhibition of expression of numerous pro-inflammatory cytokines 
and chemokines. The exact effects were shown to be dependent on the cell milieu. 
In PCa cell models which differentially expressed either AR or GR they showed 
strong cytostatic and apoptotic effects particularly in highly malignant PCa cell lines 
(PC3 and DUI45) with long term exposure to CpdA (4-8 days) [5]. In summary, CpdA 
interacted with the GR and AR while enhancing GR transrepression as well as 
inducing apoptosis in different PCa cell lines acting as a selective steroid modulator. 
Other studies suggested that CpdA's selective steroid modulation could be due to 
dimerisation of the GR. It was only in the PCa cells stimulated with DEX that 
significant GR dimer formation was detected and it was thus deduced that CpdA-
induced GR monomer formation was the mechanism by which CpdA enhanced 
transrepression but suppressed transactivation [354It is, therefore, not surprising that 
CpdA and DEX not only differ at the level of dissociating transactivation and 
transrepression, but also interfering differentially with the signal transduction 
pathway and the activation of NFκB, in the same cell type [354,355]. An encouraging 
finding was that CpdA does not affect a ligand-induced GR down-regulation in 
primary rheumatoid arthritis and therefore does not demonstrate acquired resistance 
[355,356].  
Although the list of reports on non-steroidal dissociated GR ligands, such as 
CpdA, is still growing not all studies contain sufficient data addressing side-effects.  
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CpdA appears to have little or no effect on GR mediated transactivation of important 
metabolic pathways which is why the common adverse side-effects of 
glucocorticoids have not been observed with CpdA. In animal models, CpdA did not 
lead to transactivation of important metabolic pathways and as a result did not 
induce hyperglycaemia and hyperinsulinemia after systemic chronic animal 
treatment. CpdA did not induce muscle wasting when it was used systemically in 
mdx mice or induce skin atrophy in rats and mice when applied topically [352,353]. 
More interestingly, CpdA did not affect the hypothalamopituitary axis significantly 
when assessed by corticosterone and ACTH serum levels [352,353]. It is now 
recognised that the adverse side-effects of glucocorticoids are mediated via 
transactivation and the anticancer and anti-inflammatory effects via transrepression 
making novel selective GR modulators like CpdA clinically more beneficial with less 
adverse side-effects [355]. 
Despite all the demonstrated and expected advantages for CpdA, side-effects 
arising during chronic in vivo treatment remain to be comprehensively analysed and 
there are some facts which have been noted which may be significant. CpdA has a 
relatively narrow therapeutic window and when used at high doses (~15 mg/kg) for 
longer periods it gradually induced apoptosis. This would also be expected to be 
experienced in healthy cells. The apoptosis may be induced by GR-independent 
metabolites of the compound and has been shown to be a dose dependent toxicity 
which could limit clinical development and would certainly influence dosing and the 
therapeutic window. CpdA, like its parent compound in S.tuberculatiformis, is an 
unstable molecule that readily decomposes into a cyclic aziridine structure when 
subjected to light, humidity, and a pH > 8. In vivo studies have always had to be 
carried out under well-controlled conditions to circumvent this problem and synthesis 
of more stable compounds using CpdA as a prototype are in progress [352,353].  
In the review by Lesovaya et al. in 2015  ten years of collaborative research on 
CpdA was summarised [353]. It emphasised the unusual biological properties of CpdA 
and highlighted its action as a dual steroid receptor ligand for the AR and the GR. 
CpdA exhibited anti-inflammatory and anti-androgen effects and selective 
glucocorticoid action. These properties are expected to translate into lower 
glucocorticoid-like adverse side-effects and reduce the likelihood resistance. Thus, 
CpdA and its prospective derivatives, are attractive candidates for clinical 
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applications [353]. The selective steroid modulation of CpdA is a mechanism of action 
that, in light of the previously discussed mechanisms of PCa progression, is clearly 
suited to novel chemotherapy in PCa. However, the difficulty in isolating and 
maintaining the active compounds of Salsola tuberculatiformis Botsch led to the 
research on the plant being abandoned for the synthetic derivative.  Since the main 
body of research to date has been performed with the synthetic CpdA analogue and 
not the original plant extract it remains unclear to what extent these potential benefits 
are shared by the S.tuberculatiformis crude extract and whether other or alternate 
compounds from S.tuberculatiformis would offer additional or complementary 
benefits. The aim of this investigation was a preliminary study in the comparative 
characterisation of the modulatory effects of CpdA and a crude Salsola 
tuberculatiformis Botsch extract on the AR and GR in PCa cells.   
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2.4 PROJECT OBJECTIVES 
This study assessed the biological properties of the S.tuberculatiformis crude 
extract with specific focus on its ability to mimic known properties of CpdA and on its 
effects on PCa. The specific aims which were investigated are as follows: 
1. The preparation of a methanol extract of S.tuberculatiformis and confirmation 
of biological activity using the CYP11B spectral assay. 
2. To investigate the effect of the S.tuberculatiformis crude extract on the 
androgen and glucocorticoid receptors in prostate cancer cell models using 
immunofluorescent analytical techniques. 
3. To determine the anti-proliferative effect in different prostate cancer cell 
models by firstly determining the potencies of CpdA and S.tuberculatiformis 
using viability assays followed by the assessment of apoptotic effects via 
caspase-3/7. 
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CHAPTER 3 
METHODOLOGY 
This chapter presents the protocols used in this study and this includes the 
sourcing of the general reagents, steroids, antibodies and plasmids as well as a 
description of the techniques used in cell culture. Protocols for immunofluorescence 
and the activity and apoptosis assays were developed for the purpose of this study 
as these had not previously been established as standard techniques used in our 
laboratory. Additionally methods for S.tuberculatiformis extraction and sourcing and 
the synthesis of CpdA are described. 
3.1 GENERAL REAGENTS 
3.1.1 GENERAL REAGENTS 
Penicillin-streptomycin, trypsin-EDTA and foetal calf serum were purchased from 
Gibco-BRL (Gaithersburg, USA). Corning® CellBIND® Surface plates were 
purchased from Corning® Life Sciences (NY, USA) and 8-well Lab-Tek® Chamber 
Slides, DAKO were purchased from Sigma-Aldrich (St. Louis, USA). Transparent 96-
well microplates were purchased from Greiner Bio-One International. Ham’s F12K and 
RPMI-1640 medium were also purchased from Sigma-Aldrich (St. Louis, USA). X-
tremeGENE HP DNA Transfection Reagent was purchased from Roche Diagnostics 
(Mannheim, Germany). Molecular grade agarose D1 LE was purchased from 
Whitehead Scientific, Brackenfell, RSA and GR Green stain was obtained from 
Excellgen, Inc., Rockville, MD, USA. 1 kb DNA ladder was purchased from Promega.  
Staurosporine, TNFα and Interleukin-1 were all purchased from Sigma-Aldrich (St. 
Louis, USA). DAKO mounting medium and Hoescht stain were purchased from 
Aligent Technologies (Santa Clara, USA). The Wizard® Plasmid isolation kit, the 
Luciferase Assay System, the CellTiter-Glo® Luminescent Cell Viability Assay and 
the Caspase-Glo® 3/7 Assay were purchased from Promega Biotech (Madison, WI, 
USA). The NucleoBond® Xtra Plasmid DNA Purification kit was purchased from 
Clontech Laboratories (Mountain View, USA). A bicinchoninic acid (BCA) protein 
determination kit was purchased from Pierce (Rockford, IL., USA). Trypan blue stain 
(0.4%) and cell count plates were purchased from Invitrogen (Eugene, USA).  All 
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other chemicals and reagents were sourced from reputable scientific supplies 
companies.  
3.1.2 STEROIDS 
Fluocinolone acetonide (6α, 9α-Difluoro-16α-hydroxyprednisolone 16, 17-
acetonide; FA), dihydrotestosterone (5α-androstan-17β-ol-3-one; DHT) and 11-
deoxycorticosterone (21-Hydroxy-4-pregnene-3, 20-dione; DOC) were purchased 
from Sigma-Aldrich (St. Louis, USA). All steroids were dissolved in absolute ethanol 
and added to the culturing medium in a final concentration of no more than 0.1% 
ethanol 
3.1.3 ANTIBODIES 
The polyclonal rabbit anti-AR(C-19) and anti-GR (H-250) IgG were purchased 
from Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA). The fluorescent 
secondary anti-rabbit antibody AlexaFluro®568 (A10042) was purchased from Life 
Technologies (Thermo Scientific).  
3.1.4 PLASMID CONSTRUCTS 
The plasmid expressing the human AR, pSVARo was obtained from Prof. F. 
Claessens (University of Leuven, Belgium). Prior to experiments, cells from 
cryogenic storage were routinely and aseptically streaked onto 1.5% Luria Bertani 
(LB)-agar plates containing 100μg/mL ampicillin. Plates were incubated at 37°C until 
well defined single colonies of ± 2 mm in diameter had formed. Single colonies were 
inoculated in 5 mL LB media, with antibiotics, and incubated at 37°C at 235 RPM for 
8 hours as initial cultures. This initial culture was used to inoculate a larger (100-
300ml) culture which was incubated at 37°C at 235 RPM for 12-16 hours. Plasmid 
DNA was extracted using a NucleoBond® Xtra Plasmid DNA Purification kit following 
procedure according to the manufacturer’s protocol said in 3.1.1. The identity of the 
constructs was verified by restriction enzyme digestion and subsequent agarose gel 
electrophoresis. The purity and concentration of the isolated DNA was determined 
by calculating the absorbance of the preparation at 260 and 280 nm. 
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3.1.4.1 Agarose Gel Electrophoresis 
Agarose gel electrophoreses of purified plasmids was performed with 1% molecular 
grade agarose D1 LE in TAE buffer.  GR Green stain (0.01% solution) was added to the 
agarose-TAE mixture prior to gel formation. DNA samples were mixed in a ratio of 1:2 with 
Ficoll Orange loading dye (0.1% Orange G, 20% Ficoll, 10 mM EDTA). Electrophoresis was 
initially carried out at 75 V until DNA samples entered into the gel matrix upon which an 
increase to 110 V was applied. In all cases a 1 kb DNA ladder was used as a molecular 
size marker. Following electrophoreses, agarose gels were visualised with a UV 
transilluminator and analysed with E-Capt, version 12.9 for Windows (Vilber Lourmat, 
Marne-la-Vallée, France).  
3.1.5 TISSUE CULTURE 
Three PCa cell lines were included in this study, LNCaP, PC-3 and PC-3 transfected 
with AR. LNCaP cells are a widely used cell model representing an androgen 
dependent PCa model with low metastatic potential and express the AR, while PC-3 
cells represent a model for androgen independent PCa with a high metastatic 
potential expressing the GR. PC-3 transfected with the AR express both the AR and 
the GR. LNCaP cells were originally derived from the left supraclavicular lymph node 
of a 50-year-old Caucasian male with metastatic PCa. The cells contain a ligand-
binding domain-mutated version of the AR (T877A) [77]. PC-3 was originally derived 
from bone metastasis of grade 4 PCa in a 62 year old Caucasian male. Both PC3 
and LNCaP cells were purchased from the European Collection of Cell Cultures 
(ECACC).  
LNCaP cells were cultured in RPMI-1640 media supplemented with 10% foetal 
calf serum (FCS), 1.5 g NaHCO3/L (pH 7), 2.5 g D-(+)-Glucose, 1% HEPES, 1% 
sodium pyruvate and 1% penicillin-streptomycin and at all stages cultured using 
Corning® CELLBIND® surface plates. PC3 cells  were cultured in Ham’s F12K media 
supplemented with 10% foetal calf serum (FCS), 1.5 g NaHCO3/L (pH 7), 2.5 g D-
(+)-Glucose, 1% HEPES, 1% sodium pyruvate and 1% penicillin-streptomycin.  Cells 
were seeded at a density of 100 000 cells/ml and all cell lines were cultured at 37°C, 
in an atmosphere of 90% humidity and 5% CO2. All cells were screened for 
mycoplasma infection and were mycoplasma free and were passaged for fewer than 
6 months from the time of resuscitation. Both LNCaP and PC3 cells were plated in 
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96-well plates at 100 000 cells/ml. After 24 hours the PC3 cells were transfected with 
the pSVARo plasmid using X-tremeGENE HP DNA transfection reagent. After a 
concurrent 24 hour period the PC3 and LNCaP cells were treated for 16 hours with 
FA, DHT, CpdA, S.tuberculatiformis extract, control and vehicle. 
3.1.6 S.TUBERCULATIFORMIS EXTRACT 
Based on the techniques of Zarrow et al., it was confirmed that the contraceptive 
properties of S.tuberculatiformis could be extracted with methanol. The following 
extraction method was developed [9,334]. Owing to the labile nature of the 
S.tuberculatiformis extract, it was protected from light and O2 at all stages of 
preparation. The non-polar compounds were first removed by soxhlet extraction of 
20 grams of ground S.tuberculatiformis with 200ml of dichloromethane for 8 hours. 
Following this preliminary extraction, the bio-active polar compounds were obtained 
by further soxhlet extraction with 200ml of methanol for 8 hours. The methanol was 
removed by solvent evaporation. The resultant extract was resuspended in 50ml of 
analytical grade water and centrifuged at 10 000xg for 5 minutes before filtration 
through a 0.45μm pore size filter. The S.tuberculatiformis extract was aliquoted into 
1.5ml eppendorf tubes and stored at - 80˚C, protected from light 
In order to determine the amount of plant material extracted from 20 grams of 
S.tuberculatiformis, the concentration of the resuspended extract was determined by 
pipetting 1ml into a vial and weighing it on an analytical scale. The vial was then 
placed in the oven for approximately 2 days or until the extract was dry and all water 
had evaporated. Once dried, the vial was weighed and the mass of extracted plant 
material per mL determined. The calculated concentration was thus assumed for all 
stored aliquots used in subsequent studies.  
3.1.7 COMPOUND A (2-(4-ACETOXYPHENYL)-2-CHLORO-N-METHYL-
ETHYLAMMONIUM CHLORIDE) 
CpdA was acquired from Ms. Liezel Swart, a fellow student, who synthesized the 
compound in the department of Biochemistry at the University of Stellenbosch. 
Chromatography was performed for verification.  
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3.2 P450 DIFFERENCE SPECTRAL ASSAY 
The P450 difference spectral assay, developed by Swart et al, was used to 
confirm inhibition of CYP11B1as an indicator of the biological activity in 
S.tuberculatiformis crude extract and CpdA [8,336]. 
The cytochrome P450 enzymes are a group of haemoproteins containing 
between 400 and 500 amino acids, depending on the type of P450, and a single 
haem prosthetic group [357,358]. The distal ligand of the haem moiety is a thiolate 
anion from a cysteine residue (Figure 3.1) [359]. It is the iron contained in the haem 
group which gives cytochrome P450 enzymes their unique spectral properties. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Representation of a P450 enzyme bound camphor (P450CAM). The enlarged active 
site region shows the camphor substrate, haem moiety and cysteine residue which forms the distal 
haem ligand. Dotted circle indicates the water molecule that forms the sixth axial ligand of the haem 
iron (Exists only in the substrate free form). In the representation of the full enzyme the protein 
backbone is shown in green, the haem moiety in blue and the substrate is coloured according to 
atomic species.  Red; Oxygen, Grey; Carbon, Light Blue; Nitrogen, Yellow; Sulphur, Dark Blue; Iron. 
Reproduced from Segall (1997)[360]. 
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Fe3+, in the haem system, can exist in two spin states; a high spin (HS) and a low 
spin (LS). Intermediary spin states are possible but not normally found in biological 
systems. These two spin states are characterised by distinct traits, as follows [361]: 
High Spin State [s=5/2]: 
 The five 3d electrons are maximally unpaired 
 Five-fold coordinated Fe3+ is found in the HS state 
 Ionic radius is larger in the HS 
 The Fe3+ moves out of the plane of the porphyrin ring because the central cavity is 
too small 
Low Spin State [s = 1/2]: 
● The five 3d electrons are maximally paired 
● Six-fold coordinated Fe3+ is found in the LS state 
● Ionic radius is smaller in the LS  
The HS and LS states are not independent, but exist in equilibrium. The 
differences in the absorption and extinction coefficients between the two bands at 
390nm and 420nm allow the equilibrium constant between the spin states and hence 
the fraction of HS character to be determined. The equilibrium between these states 
may be affected by many factors such as changes in the conformation of the 
enzyme which alter the nature of the binding of a ligand. 
The nature of the axial haem ligands has an important effect on the LS-HS 
balance: A strong axial field will bring about a relatively large d-orbital splitting, 
favouring the LS state. For example, when comparing the UV absorption spectra of 
CO complexes with haemoglobin (histidine axial ligand) and P450 (cysteine ligand), 
the axial ligand field strength due to histidine is much stronger than that due to 
cysteine. Correspondingly the UV absorption band due to the d → d transition in CO-
haemoglobin occurs at 420nm, while that due to CO-P450 occurs at 450nm. Hence 
the name P450 enzymes [362,363]. 
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Owing to these spectral properties there are three types of ligand binding which may be 
identified by changes in absorbance in the Soret region (Figure 3.2):  
1. Type I spectrum [364–366]: 
The spectrum is associated with the binding of a substrate. It is characterised 
by a minimum in the Soret absorption band at 420nm and a maximum at 
390nm with an isobestic point at 407nm. This indicates a change from LS to 
HS state of the ferric iron. X-ray crystallography of substrate-bound 
complexes of the P450 enzyme show that the iron-ligated water molecule is 
displaced in these cases, changing the Fe3+  from a 6-fold to a 5-fold 
coordination state. The Fe3+ ion is also seen to move out of the plane of the 
haem.  
2. Type II spectrum [367–369]: 
The spectrum is characterised by a maximum absorption between 425nm and 
435nm and a minimum at 390nm with an isobestic point at approximately 
419nm. This represents an increase in the LS character of the Fe3+. This 
spectral change is associated with the interaction of inhibitors which bind 
directly to the Fe3+, replacing the water molecule as the sixth axial ligand. 
3. Reverse type I spectrum: 
The spectrum is a `mirror image' of the type I spectral change, with a 
maximum at 420nm and a minimum at 390nm. This is similar to a type II 
change, except that there is no shift in the location of the maxima. The exact 
nature of this interaction is not known and it may be that the ligand binds to a 
different site and not in the active pocket of the enzyme. 
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Figure 3.2 Difference spectra obtained from the addition of a substrate or inhibitor to a 
cytochrome P450 enzyme. The black and red lines represent the type I and type II spectra, 
respectively. Indicated on the graph is the wavelength of the maxima, minima and isobestic points of 
the type 1 (blue lines) and type 2 (red lines) difference spectra. Reproduced and adapted from Omura 
(1993) [370]. 
Substrate analogues may be similar to the natural substrates. However, structural 
differences between these analogues and natural substrates result in differences in binding 
to the active site. The crystal structures of complexes of substrate analogues 
with P450CAM show that the Fe3+-coordinated water molecule is retained and a high fraction 
of the LS character of the Fe3+ remains [365,371,372]. The stabilisation of the LS state is 
believed  to be primarily due to the bound water molecule [366]. The redox potentials of the 
substrate analogue-bound complexes fall between those of the substrate-free and 
substrate-bound systems. Indeed, a linear free energy relationship between the redox 
potential and spin state has been found [373]. 
Many classes of molecules may inhibit the action of a P450 enzyme. For 
example, small molecules such as CO and NO, which compete with O2 in binding to 
the reduced haem iron, metal ions (e.g. CO2+) and mechanism based inhibitors such 
as chloramphenicol [362,374,375]. This investigation was concerned with molecules 
which compete directly with the substrate molecule binding in the active site. These 
ligands all contain an electron negative atom which coordinates directly with the 
haem Fe3+, displacing a water molecule as the sixth axial ligand, as demonstrated 
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by crystal structures of P450CAM complexed with inhibitors such as metyrapone and 
phenylimidazole [367]. The UV absorption spectra of the enzymes display a type II 
shift on binding of such molecules, indicating an increase in the LS character of 
the Fe3+ [374,376]. 
Thus using these unique spectral properties the binding of a natural substrate 
can be assayed. In addition, the enzyme/substrate interaction (complex formation) 
can also be assessed by assaying the degree to which a compound may either 
inhibit the natural substrate from binding or either may itself bind to the enzyme in 
the absence of substrate. This technique was applied to both CpdA and the 
S.tuberculatiformis crude extract to demonstrate biological activity using the spectral 
properties of sheep adrenal CYP11B1. 
3.2.1 PREPARATION OF A CYP11B1 CONTAINING MITOCHONDRIAL 
ACETONE POWDER FROM OVINE ADRENALS: 
In order to obtain a CYP11B1 containing preparation, fresh ovine adrenal glands 
were harvested perimortem from Tomis Abattoir & Fresh Meats Wholesalers 
(Hermon, South Africa) and stored at - 20˚C. P450-enriched adrenal mitochondrial 
acetone powder from ovine adrenals was prepared as previously published [377]. In 
order to avoid degradation, the mitochondrial isolation and all subsequent work with 
the preparation was performed at 4˚C. The adrenal glands were decapsulated and 
washed in 0.15M KCl solution (pH 7.4) before being re-suspended in buffer A (10mM 
Tris-HCl, 1mM EDTA, 0.25M sucrose, pH 7.4) in a 1:3 ratio. The decapsulated 
adrenals (100 g) were firstly homogenised with a Waring-Blender after which the 
resulting adrenal homogenate was homogenised with a Potter-Elvejhem glass 
homogeniser. The homogenate was subsequently centrifuged at 1000 xg for 20 
minutes to remove cellular debris and fat cell. The supernatant was centrifuged at  
12 000 xg for 15 minute, to yield the P450-enriched mitochondrial pellet. This P450-
enriched mitochondrial pellet was washed three times by resuspension and 
homogenising with a Potter-Elvejhem glass homogeniser. The first resuspension 
was in 200ml of Buffer B (10 mM Tris-HCl buffer, containing 1mM EDTA, 0.25 M 
sucrose and 1% (m/v) BSA, pH 7.4) followed by two resuspensions in Buffer C 
(10mM Tris-HCl, 1mM EDTA, 0.25M sucrose, 1% BSA, pH 7.4). After each wash 
step the resuspended pellet was centrifuged at 12 000xg for 15 minutes. The 
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mitochondrial pellet was frozen with liquid nitrogen and lyophilized overnight. The 
dried pellet was resuspended in 100 mL dry acetone and homogenised with the 
Potter-Elvejhem glass homogeniser in order to remove residual lipids. The 
homogenate was subsequently centrifuged for 15 minutes at 12 000 xg. The 
supernatant was decanted and the mitochondrial acetone pellet lyophilized 
overnight. The lyophilized powder was stored at -20°C.  
Verification of CYP11B1 activity was performed using a P450 spectral assay. The 
mitochondrial powder was resuspended and homogenised, with a Potter Elvejhem 
homogeniser, in phosphate buffer (0.1M phosphate buffer, 10% ethylene glycol, pH 
7.4) at a concentration of 2mg/ml.  The mitochondrial homogenate was rested on ice 
for 10-15 minutes before sonication. Sonification was carried out for 5 mins at 60 
Watts. However, in order to avoid over-heating of the mitochondrial preparation and 
loss of enzyme activity one minute intervals were included between each 
consecutive minute of sonication. CO was bubbled through the mitochondrial 
sonicate to saturate the binding sites of the heme iron. Equal volumes (1.5 mL) of 
the mitochondrial preparation were subsequently divided into two optically matched 
1.5 quartz cuvettes and a corrected baseline was recorded between 400-500 nm. 
Solid sodium dithionite (1 – 2 mg) was subsequently added to the sample cuvette 
and the contents inverted to dissolve the sodium dithionite, reducing the heme-iron 
from the ferric to the ferrous state. A difference spectrum was recorded between 400 
- 500 nm. The P-450 content was calculated using an extinction coefficient of 91 cm-
1mM-1and a path length of 1cm  [357].  
3.2.3 CYP11B1 DIFFERENCE SPECTRA 
Mitochondrial powder, re-suspended in phosphate buffer (2 mg/mL), was 
homogenised and sonicated for 5 minutes as described above (3.2.1). A substrate-
induced difference spectrum was obtained by pipetting an equal volume (1496µL) of 
the mitochondrial suspension into two optically matched cuvettes and a corrected 
baseline was recorded between 360-500nm. DOC (4 μl, 1.2 mM) was added to the 
sample cuvette resulting in a final concentration of 3.2μM. An equal volume of 
absolute ethanol was added to the reference cuvette. The content of both cuvettes 
were inverted gently to ensure uniformity and a difference spectrum recorded 
between 360-500 nm.  
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The influence of the compounds on the substrate-induced difference spectrum was 
subsequently assayed to determine whether the compounds were able to inhibit the 
substrate from binding to CYP11B1. The mitochondrial suspension (3480 µL) was 
mixed with CpdA (20 µL, final concentration) or extract (20 µL, final concentration) to 
obtain a final volume of 3500 µL. An equal volume (1496µL) was pipetted into two 
optically matched cuvettes and a corrected baseline was recorded between 360-
500nm. DOC (4 µL, final concentration, 1.2 mM) was added to the sample cuvette 
resulting in a final concentration of 3.2μM. An equal volume of absolute ethanol was 
added to the reference cuvette. The content of both cuvettes were inverted gently to 
ensure uniformity and a difference spectrum recorded between 360-500 nm. The 
inhibition of the compounds on the substrate-induced difference spectrum was 
indicated by a decrease in amplitude, i.e. decreased maximum absorbance at 390 
nm and an increase in minimum absorbance at 420 nm. 
From this difference spectrum the percent inhibition can be calculated owing to 
the discrepancy in minima between the samples.  
Percent Inhibition (%) = 
100 − [
CS OD dist (A390 − A420)
S OD dist. (A390 − A420)
× 100] 
Where CS is substrate plus CpdA or extract and S is substrate 
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3.3 AR AND GR NUCLEAR TRANSLOCATION 
Immunofluorescence or cell imaging techniques rely on the use of antibodies to 
label a specific target antigen with a fluorescent dye (also called fluorophores or 
fluorochromes). Antibodies that are chemically conjugated to fluorophores are 
commonly used in this technique. The fluorophore allows visualization of the target 
distribution in the sample under a fluorescent microscope (e.g. confocal 
microscopes) (Figure 3.3). There are two immunofluorescence methods depending 
on whether the fluorophore is conjugated to the primary or the secondary antibody. 
The direct method uses a single antibody directed against the target of interest and 
in this method the primary antibody is conjugated to the fluorophore. The indirect 
method uses two antibodies, the primary antibody is unconjugated and a 
fluorophore-conjugated secondary antibody directed against the primary antibody is 
used for detection. In this study the indirect method was used to determine if 
S.tuberculatiformis and CpdA induced nuclear translocation of the AR and GR.  
3.3.1 IMMUNOFLUORESCENCE 
LNCaP and PC-3 cells were cultured as previously described in 3.1.5. LNCaP 
cells were plated into an 8-well Chamber Slide at a seeding density of 4.5ᵡ104 cells 
per well (300μl per well) and PC-3 cells were plated into an 8-well Chamber Slide at 
a seeding density of 3.0ᵡ104 cells per well (300μl per well). After 48 hours LNCaP, 
PC3 and AR transfected PC3 cells were incubated with test compounds, 1 μM FA, 1 
μM DHT, 10 μM CpdA, 0.03 mg/ml S.tuberculatiformis extract and vehicle (0.1% 
EtOH). Relevant controls were included; transfection control, without test compound, 
positive and negative controls. 
After 16 hours of exposure to the relevant compounds the cells were fixed with 
4% paraformaldehyde in PBS (0.01M solution, pH 7.4) for 10 minutes at room 
temperature. The cells were washed 3 times with PBS and were subsequently 
permeabilised with PBS containing 0.1% Triton X-100 for 10 minutes at room 
temperature. The wash step was repeated before blocking with 1% BSA in PBS 
buffer containing 0.1% Tween 20 (PBST) for 1 hour at room temperature. The 
primary antibodies (anti-AR IgG and anti-GR IgG) were diluted according to the 
manufacturer’s specifications in PBST containing 1% BSA and added to the cells 
after which the cells were incubated overnight in a humidified chamber at 4˚C. The 
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cells were subsequently washed and incubated in the dark with a fluorescent 
labelled secondary antibody in PBST (1% BSA) for 1 hour at room temperature 
(Figure 3.3). The wash step was repeated prior to incubation with 0.1μg/ml Hoescht 
DNA stain for 3 minutes at room temperature. Cells were rinsed with PBS before 
applying a drop of fluorescent mounting medium and stored at -20˚C protected from 
light, this preserved the fluorescence of the samples and allows the sample to last 
for a prolonged period (± 1 year). The fluorescence was measured with a confocal 
microscope and the images were analysed with ZEN lite (ZEISS Microscopy). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Range of fluorescent secondary antibodies available. The bold box represents the 
secondary antibody used in this experiment. 
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3.4 CELL VIABILITY AND APOPTOSIS ASSAYS 
3.4.1 CELLTITER-GLO® LUMINESCENT CELL VIABILITY ASSAY 
The CellTiter-Glo® Luminescent Cell Viability Assay was used to determine the 
potency and IC50 of both CpdA and the S.tuberculatiformis extract.  The Cell Viability 
Assay is a homogeneous method to determine the number of viable cells in culture 
based on the quantification of ATP present in the cells, which signals the presence of 
metabolically active cells. This assay relies on the properties of a proprietary 
thermostable luciferase (Ultra-Glo™ Recombinant Luciferase), which generates a 
stable “glow-type” luminescent signal with a half-life of greater than five hours.  The 
homogeneous “add-mix-measure” format results in cell lysis and generation of a 
luminescent signal proportional to the amount of ATP present. The amount of ATP is 
directly proportional to the number of cells present in culture in agreement with 
previous reports (Figure 3.3A). The mechanism for this luminescence is illustrated in 
Figure 3.3B 
LNCaP and PC-3 cells were cultured as previously described and plated in 96-
well plates at a density of 100 000 cells/ml. After incubating test compounds for 16 
hours the cells were equilibrated at room temperature for approximately 30 minutes. 
The CellTiter-Glo® Luminescent Cell Viability Assay was carried out in accordance 
with the manufacturer’s protocol. 100ul of CellTiter-Glo® reagent was added per well 
and incubated in the dark at room temperature for 30 minutes. Luminescence was 
measured on a luminometer or spectrophotometer.  
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Figure 3.4: A) The direct correlation between cell number and Luminescence and B) the 
generation of luminescence in the CellTiter-Glo® Luminescent Cell Viability Assay 
B 
The cell is a source of ATP in 
the Luciferase Reaction, so the 
luminescence produced is 
proportional to the number of viable 
cells 
A 
Cell number correlates with 
luminescent output. 
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3.4.2 APOPTOSIS ASSAY 
 The ability of CpdA and S.tuberculatiformis extract to trigger apoptosis was 
measured using the Caspase-Glo3/7 assay. A key feature of caspases in the cell is 
that they are present as inactive precursors, termed pro-caspases, which remain 
inactive until a specific biochemical change causes their activation. Caspase-3 has a 
typical role in apoptosis, where it catalyses chromatin condensation 
and DNA fragmentation. Caspase-3 shares many of the typical characteristics 
common to all currently-known caspases.  Its active site contains a cysteine residue 
(Cys-163) and histidine residue (His-121) that stabilize the peptide bond cleavage of 
a protein sequence to the carboxy-terminal side of an aspartic acid when it is part of 
a particular 4-amino acid sequence. This specificity allows caspases to be highly 
selective, with a 20,000-fold preference for aspartic acid over glutamic acid. Each 
pro-caspase has an N-terminal large subunit of approximately 20 kDa followed by a 
smaller subunit of approximately 10 kDa. These subunits are called p20 and p10, 
respectively.  
Caspase-3 is activated in the apoptotic cell both by extrinsic and intrinsic 
pathways as previously discussed. The precursor of caspase-3 is required because 
if unregulated, caspase activity would kill cells indiscriminately. As an executioner 
caspase, the pro-caspase-3 has virtually no activity until it is cleaved by an initiator 
caspase after apoptotic signalling events have occurred (Figure 3.5).   
 
 
 
 
 
 
 
 
Figure 3.5:  Basic schematic of the caspase cascade pathway 
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LNCaP and PC-3 cells were cultured as previously described in 3.1.5 and plated 
in 12-well plates at a density of 100 000 cells/ml. After the 16 hour-incubation period 
with test compounds the cells were washed with PBS (0.01M solution) before adding 
passive lysis buffer (100 μL/ well) and freezing the cells at -80°C for 3-24 hours. The 
Caspase-Glo® 3/7 Assay was carried out in accordance with the manufacturer's 
protocol.  The samples were thawed at room temperature for approximately 30 
minutes. Lysate (25μl per a well) was then added to a 96-well plate followed by 
Caspase-Glo® 3/7 reagent (25μl per a well; 1:1 ratio). The plate was incubated, in 
the dark, at room temperature for approximately 30 minutes to 3 hours. The 
luminescence was read on a luminometer or spectrophotometer. The subsequent 
data was normalised with the protein concentration of each well. 
2.2.2 Protein determination 
Protein concentrations were determined using the Pierce BCA method according 
to the manufactures instructions. Each thawed lysed sample, 10 μL, was placed in a 
96 well transparent microplate together with a range of bovine serum albumin (BSA) 
standards prepared in passive lysis buffer (Table 3.1.). A BCA working reagent was 
prepared by mixing Reagent A and Reagent B in a 50:1 ratio and 200 μl of the 
working reagent was pipette into each well. Samples were incubated at 37°C for 30 
minutes. Thereafter, the absorbance at 540 nm was measured on a Spark™ 10M 
multimode microplate reader. The average absorbance measurement of the blank 
(passive lysis buffer) replicates was subtracted from the measurements of all other 
individual standard and unknown sample replicates. A standard curve was generated 
by plotting the corrected absorbance for each BSA standard versus concentration. 
The generated standard curve was subsequently used to determine the protein 
concentration for each unknown sample.   
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Table 3.1 Preparation of standards from BCA protein determination. 
 
 Lysis buffer volume  
(μl) 
Volume and Source of BSA 
(μl) 
Final [BSA]  
 (μg/ml) 
A 0 300 of Stock (2 mg/ml) 2000 
B 125 375 of Stock (2 mg/ml) 1500 
C 325 325 of Stock (2 mg/ml) 1000 
D 175 175 of B dilution 750 
E 325 325 of C dilution 500 
F 325 325 of E dilution 250 
G 325 325 of F dilution 125 
H 400 100 of G dilution 25 
I 400 0 0 = blank 
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3.5 STATISTICAL ANALYSIS 
The Graph Pad Prism® software (version 6) was used for data manipulations, 
graphical representations and statistical analysis. Non-linear regression and 
sigmoidal dose response were used in cell viability experiments. The effect of 
S.tuberculatiformis extracts and CpdA on cell viability and growth were analysed 
using one-way ANOVA followed by Bartlett's multiple comparisons test. All 
compound treatments were compared to the control. Statistically significant 
differences are indicated by *, ** or *** for p<0.05, p<0.01 or p<0.001, respectively.  
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CHAPTER 4 
RESULTS 
In this chapter the results of the study are presented. Biological activity of the 
S.tuberculatiformis extracts and CpdA is demonstrated followed by evidence for 
nuclear translocation through cell imaging for both the S.tuberculatiformis extract and 
CpdA. Both the S.tuberculatiformis extract and CpdA caused nuclear translocation in 
the AR and the GR receptors but the effect of CpdA on translocation of the GR 
receptors was weaker than that of S.tuberculatiformis and FA. Anti-proliferative 
activity was evaluated by cell viability and apoptosis assays for CpdA and 
S.tuberculatiformis extracts, both individually and comparatively. Both demonstrated 
reduction in cell growth with CpdA showing greater potency. Neither CpdA nor 
S.tuberculatiformis extracts were able to induce apoptosis.  
4.1 BIOLOGICAL ACTIVITY 
A method for screening for biologically active components in S.tuberculatiformis 
extract was previously developed in this laboratory [8,336]. Despite the practical 
difficulties presented by the exceptionally labile nature of the extract this bioassay 
which is based on the spectral properties of CYP11B1, has proven to be a rapid and 
sensitive evaluation of biological activity. It was through this screening method that 
Swart et al. hypothesised that the active component in S.tuberculatiformis originated 
from a labile aziridine precursor and this resulted in the synthesis of CpdA [8].   The 
bioassay was used to determine the effects of CpdA and S.tuberculatiformis extract 
on the spectral properties of CYP11B1 that had been partially purified from ovine 
adrenals. This bioassay showed that the compounds, CpdA and S.tuberculatiformis 
extract, possessed biological activity and could therefore be used in further 
experiments.  Due to their labile nature, screening for biological activity occurred 
prior to all experiments to ensure that the S.tuberculatiformis crude extract and CpdA 
were active.  
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4.1.1 CYTOCHROME P450 ACTIVITY ASSAY 
A P450 activity assay was first performed on the mitochondrial preparation.  This 
was to ensure that the mitochondrial-bound P450 enzymes were pure, intact and 
active as well as to determine the concentration of the P450. The mitochondrial 
suspension possessed active P450 enzymes.  As shown in Figure 4.1, a maximum 
peak at 450nm and a deep trough at ± 408nm indicated that the mitochondrial 
suspension was free from cytochrome P420, the inactive form of P450, 
characterised by a peak at 420nm. The slight shoulder observed around the 
isobestic point (± 425nm) can be attributed to the presence of cytochrome b5. The 
CO-induced difference spectrum of P450-enriched mitochondrial powder indicated 
that it could be used to screen for biological activity of the S.tuberculatiformis extract 
and CpdA. The P450 concentration of a 2 mg/mL mitochondrial preparation was 
calculated at 0.632 nmol P450/ mg protein using a millimolar extinction coefficient of 
91[338]. Thus ±100g of adrenal tissue yields ±2g of mitochondrial powder and a total 
of ±1264 nmol P450. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Sodium dithionite-reduced carbon monoxide-induced difference spectrum of a 
crude mitochondrial suspension. Mitochondrial preparation in 0.1M phosphate buffer, 10% 
ethylene glycol, pH 7.4, 2mg/ml; [P450], 0.632nmol P450/mg protein. 
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4.1.2 SUBSTRATE-INDUCED DIFFERENCE SPECTRA 
The influence of CpdA (dissolved in H2O) and the S.tuberculatiformis crude 
extract on a DOC-induced difference spectrum is shown in Figure 4.2. DOC is the 
natural substrate for cytochrome CYP11B1 and elicits a Type 1 difference spectrum 
when incubated with the mitochondrial powder isolated from ovine adrenals. The 
DOC-induced Type I difference spectrum exhibited an absorbance maximum at 390 
nm and an absorbance minimum at 420 nm. Other compounds, that are not 
substrates for CYP11B1, may also bind to the enzyme and elicit a difference 
spectrum indicating their effect on the enzyme [378].  
 Figure 4.2 shows that CpdA and the S.tuberculatiformis extract inhibited the 
Type I DOC-induced difference spectra as a shift in absorbance is observed. The 
minimum absorbance at 420nm increased while the maximum absorbance at 390nm 
decreased shift. Both CpdA and S.tuberculatiformis inhibited the DOC-induced type I 
spectra by 49.2% and 61.2%, respectively (Table 4.1). 
 
Table 4.1 Inhibition of CpdA and S.tuberculatiformis extract on DOC-induced spectrum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DOC CpdA S.tuberculatiformis 
420nm -0.0132 0.0001 0.0047 
390 nm 0.0062 0.0100 0.0122 
OD 0.0194 0.0098 0.0075 
% Inhibition n/a 49.216 61.155 
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Figure 4.2 Influence of CpdA and the S.tuberculatiformis extract on the DOC-induced type I 
difference spectrum. Mitochondrial preparation in 0.1M phosphate buffer, 10% ethylene glycol, pH 
7.4, 2mg/ml; ([P450], 0.632 P450/mg protein; [CpdA], 0.0057 mg/ml; [S.tuberculatiformis extract],  
0.17 mg/ml.  
 
 
 
 
 
 
 
 
 
Control (DOC) 
CpdA 
S.tuberculatiformis 
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4.2 NUCLEAR RECEPTOR TRANSLOCATION 
Yemelyanov et al. investigated the effect of CpdA on the function of steroid 
hormone receptors, specifically androgen and glucocorticoid receptors, in a set of 
prostate cancer cell-lines with different AR/GR status [5]. This, along with virtual 
docking, showed that CpdA interacted with the receptors and induced translocation. 
We therefore set out to determine if the S.tuberculatiformis extract, like its synthetic 
analogue CpdA, would also interact with these receptors and induce translocation in 
cell-lines expressing the AR or and/or the GR . However, owing to the unrefined 
nature of the extract virtual docking was not a feasible option. Thus 
immunofluorescence was used in the different cell-lines to show translocation and 
inferred interaction of the S.tuberculatiformis extract with the androgen and 
glucocorticoid receptors. 
4.2.1 IMMUNOFLUORESCENCE OF THE ANDROGEN RECEPTOR 
For the androgen receptor two PCa cell-lines were utilised: androgen-sensitive 
LNCaP cells, that possess a mutated promiscuous AR, (AR+/GR-) and the highly 
malignant androgen-independent PC3 cells that had been transiently transfected 
with a wild type AR (AR+/GR+). The AR/GR status of these cell-lines has previously 
been published making them ideal for steroid hormone receptor investigations. The 
PC3AR+ and LNCaP cells were cultured as described previously and treated for 16 
hours with a vehicle, 1μM DHT, 10μM CpdA and 0.03mg/ml S.tuberculatiformis 
extract.  
The immunostaining revealed that, similar to the natural ligand DHT, both CpdA 
and the S.tuberculatiformis extract induced significant AR nuclear translocation. 
Results showed that the S.tuberculatiformis extract and CpdA induced translocation 
in both LNCaP (Figure 4.3A) and PC3AR+ (Figure 4.3B) cells by the high 
accumulation of receptor (red) fluorescence within the area that was distinguished as 
the nucleus (blue). Both cell lines showed similar staining and demonstrated that 
both S.tuberculatiformis extract and CpdA interacted with the wild type AR and the 
mutated AR. A low level of translocation in LNCaP cells was also demonstrated in 
the negative control possibly due to the promiscuous nature of the mutated AR. 
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Figure 4.3 Immunofluorescence analyses of AR Translocation. A) PC3AR+ cells and B) 
LNCaP cells. Bottom panels: AR receptor identification, nucleus fluoresced with Alexa Flour 568 
secondary antibody bound to polyclonal rabbit anti-AR (C-19) antibody; Top panels: nucleus 
fluoresced with Hoechst stain; Cells were exposed to vehicle control, DHT, CpdA, S.tuberculatiformis 
extract for 16 hours. Fluorescence was measured with a confocal microscope and the images were 
analysed with ZEN from ZEISS Microscopy. 
Negative Control:  
0.1% EtOH 
Positive Control:  
1μM DHT 
CpdA:  
10μM 
S.tuberculatiformis:  
0.03 mg/ml 
Negative Control:  
0.1% EtOH 
Positive Control:  
1μM DHT 
CpdA:  
10μM 
S.tuberculatiformis:  
0.03 mg/ml 
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4.2.2 IMMUNOFLUORESCENCE OF THE GLUCOCORTICOID RECEPTOR 
The same strategy was used to study the effects of the S.tuberculatiformis extract 
on GR localisation in parental PC3 (AR-/GR+) PCa cells. The PC3 cells were cultured 
as previously described and treated for 16 hours with a vehicle, 1μM FA, 10μM 
CpdA and 0.03mg/ml S.tuberculatiformis extract.  
The immunostaining (Figure 4.4) revealed that, similar to the GR agonist FA, the 
S.tuberculatiformis extract induced GR nuclear translocation. Interestingly, CpdA 
also induced GR nuclear translocation but to a significantly lesser extent than either 
the glucocorticoid FA or the S.tuberculatiformis extract. Results showed that the 
S.tuberculatiformis extract induced translocation in PC3 cells by the high 
accumulation of receptor (red) fluorescence within the area that was distinguished as 
the nucleus (blue).  
Thus it was demonstrated that the S.tuberculatiformis extract and CpdA 
interacted with the GR resulting in nuclear translocation of the receptor but CpdA’s 
effect appeared weaker than either the synthetic glucocorticoid FA or the 
S.tuberculatiformis extract.  
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Figure 4.4 Immunofluorescence analyses of GR Translocation in PC3 cells. Bottom 
panels: GR receptor identification, nucleus fluoresced with Alexa Flour 568 secondary antibody bound 
to polyclonal rabbit anti-GR (H-250) antibody; Top panels: nucleus fluoresced with Hoechst stain. 
Cells were exposed to vehicle control, DHT, CpdA, S.tuberculatiformis extract for 16 hours. 
Fluorescence was measured with a confocal microscope and the images were analysed with ZEN 
from ZEISS Microscopy. 
  
Negative Control:  
0.1% EtOH 
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4.3 ANTI-PROLIFERATIVE PROPERTIES 
It has been shown that AR blockade in combination with activation of GR 
signalling, specifically GR-mediated transrepression, results in the inhibition of PCa 
cell growth. Since Yemelyanov et al. reported the dual-receptor modulating 
properties of CpdA, in terms of the AR and GR, as well as the resultant anti-
proliferative effect of  CpdA on PCa the effect of S.Tuberculatiformis  proliferation 
was therefore investigated [5]. They showed that CpdA inhibited cell growth and 
induced apoptosis in various PCa cell-lines. Since CpdA is a synthetic analogue of 
active compounds in the S.tuberculatiformis extract, the biological properties of 
CpdA should be mimicked by the crude extract. The immunofluorescence assays 
from this study confirmed that the S.tuberculatiformis extract interacted with the AR 
and GR producing translocation supporting the potential modulatory effect. The next 
step in this study was to analyse the effect of S.tuberculatiformis extract on the 
proliferation of PCa cells. 
4.3.1 CELL VIABILITY ASSAY 
In order to determine the proliferative and apoptotic effects of CpdA and the 
S.tuberculatiformis extract it was necessary to firstly determine the effective dosage. 
The CellTiter-Glo® Luminescent Cell Viability Assay was used to determine the IC50 
in the three cell models, LNCaP, PC3 and PC3AR+, for CpdA and the 
S.tuberculatiformis extract. The cells were treated with increasing concentrations of 
CpdA (0.003 – 0.019 mg/ml) and the extract (0.031 - 1 mg/mL) and incubated for 16 
hours prior to measurement of ATP production. The resulting data was fitted to 
sigmoidal dose-response curves and analysed to determine the potency (IC50) of 
each compound on the different cell models (Figure 4.5A and 4.6A). 
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Figure 4.5 Dose-dependent curve and cell growth inhibition of LNCaP, PC3 and PC3AR+ 
cells for CpdA. A) The potency (IC50) of CpdA and B) the effect on cell growth. Cells were incubated 
for 16 hours with CpdA, (0.003 – 0.019 mg/ml) and the subsequent data was fitted to sigmoidal dose-
response curves.  Results are shown as means ±SEM of three independent experiments performed in 
triplicate. 
A 
B 
CpdA  
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Figure 4.6 Dose-dependent curve and cell growth inhibition of LNCaP, PC3 and PC3AR+ 
cells for S.tuberculatiformis. A) The potency (IC50) of S.tuberculatiformis and B) the effect on cell 
growth. Cells were incubated for 16 hours with S.tuberculatiformis, (0.031 - 1 mg/mL), and the 
subsequent data was fitted to sigmoidal dose-response curves.  Results are shown as means ±SEM 
of three independent experiments performed in triplicate. 
A 
B 
S.tuberculatiformis 
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 The results obtained in this study showed that treatment with both CpdA and 
S.tuberculatiformis extract resulted in decreased cell growth (Figures 4.5B and 
4.6B).  An IC50 of ±0.01 mg/ml (Table 4.2) for CpdA was obtained regardless of the 
cell type used (p>0.05) (Figure 4.5A). This indicated that the potency of CpdA was 
unaffected by the presence of the AR and GR as PC3 (AR-/GR+) and PC3AR+ 
(AR+/GR+) cells were as sensitive to CpdA as the LNCaP (AR+/GR-) cells. It can be 
hypothesised that the CpdA mechanism of action for cell death was independent of 
these steroid receptors. In contrast, the IC50 (Table 4.2) for the S.tuberculatiformis 
extract was influenced by the presence of the AR as PC3 (AR-/GR+) cells had an 
IC50 of 0.14 mg/ml while the LNCaP (AR+/GR-) and PC3AR+ (AR+/GR+) cells produced 
an IC50 of 0.20 mg/ml and 0.23 mg/ml, respectively (Figure 4.6A). There was a 
significant (p<0.001) difference (Figure 4.7) in the IC50 obtained with the 
S.tuberculatiformis extract between the cell lines with the IC50 being 1.4-1.6 fold 
higher in the two cell-lines containing the AR, LNCaP and PC3AR+ than in the PC3 
cells. The data indicates that the presence of the AR decreased the potency of the 
S.tuberculatiformis extract, which suggests that the AR interferes with the 
S.tuberculatiformis compounds, or with the extract, resulting in a pro-survival effect. 
It appeared that CpdA was more potent than the S.tuberculatiformis extract which 
could be expected as the S.tuberculatiformis extract is a crude extract and its active 
components are diluted in the impure extract influencing the potency. However, the 
difference in receptor susceptibility indicated that CpdA and the S.tuberculatiformis 
extract possess different sensitivities.  
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Table 4.2 IC50 of CpdA in PCa cell models, LNCaP, PC3 and PC3AR+ generated from 
sigmodal dose-response curves. 
  
IC50 (mg/ml) – Potency 
 CpdA S.tuberculatiformis 
LNCaP 0.01002 0.2040 
PC3AR+ 0.00938 0.2279 
PC3 0.00921 0.1437 
Fig 4.7 Comparative analysis of IC50 value CpdA and S.tuberculatiformis in LNCaP, 
PC3AR+ and PC3. Treatments were analysed using one-way ANOVA. Not significant, ns; 
p<0.001, ***.  
 
S.tuberculatiformis CpdA 
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4.3.2 APOPTOSIS ASSAY      
The Caspase-3 assay was used in order to determine if cell death, which resulted 
from CpdA and the S.tuberculatiformis extract treatment, could be attributed to 
apoptosis. The Caspase-Glo3/7 assay was carried out to determine if caspase-3 was 
upregulated in the two cell models, PC3 and PC3AR+ treated with CpdA and the 
S.tuberculatiformis extract. The cells were treated with a range of concentrations, 
CpdA, 0.0025 - 0.01 mg/mL and the S.tuberculatiformis extract, 0.075 – 2 mg/mL, 
which spanned concentrations below the IC50. TNFα, 0.2 μM, FA 1 μM, and DHT, 1 
μM were included as controls. Cells were exposed for 16 hours prior to 
measurement of luminescence production. The resulting data was calculated relative 
to the untreated cells and are expressed as the fold change over the vehicle control.  
Results obtained showed that neither treatment with CpdA nor the 
S.tuberculatiformis extract resulted in increased caspase-3 production, implying that 
the cell death demonstrated was not initiated via the caspase cascade (Figures 4.8A 
and 4.8B). This result was comparable in both cell models and was therefore 
assumed to be unaffected by the AR/GR expression in the cell models. Not only was 
there no significant difference in caspase production by CpdA or the extract in the 
PC3 or in the PC3AR+ cells but there was also no significant difference between the 
two cell-lines (Figure 4.9) . Although this showed that apoptosis was not initiated via 
the caspase cascade it does not exclude other mechanisms of apoptosis induction 
such as through the extrinsic pathway and Bcl-2 family. Apoptosis cannot therefore 
be fully excluded, but no activation of the caspase pathway could be shown in this 
investigation. 
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Figure 4.8 Analyses of induction of caspase 3 expression A) in parental PC3 cells (AR-) and B) 
in transfected PC3AR+ cells (AR+).  Cells were exposed to compounds for 16 hrs, [CpdA], 0.0025 - 
.01 mg/mL; extract, 0.075 – 2 mg/mL; TNFα, 0.2 μM, FA 1 μM; and DHT, 1 μM. Caspase expression 
was calculated relative to the negative control (untreated) and is expressed as the fold change over 
this control. Data was analysed using one-way ANOVA followed by Bartlett's multiple comparisons 
test and are shown as means ±SEM of three independent experiments performed in triplicate.  
B 
A 
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Figure 4.9 Analyses of induction of caspase 3 expression in both parental PC3 cells (AR-) 
and transfected PC3AR+ cells (AR+).  Cells were exposed to compounds for 16 hrs, [CpdA], 0.0025 - 
.01 mg/mL; extract, 0.075 – 2 mg/mL; TNFα, 0.2 μM, FA 1 μM; and DHT, 1 μM. Caspase expression 
was calculated relative to the negative control (untreated) and is expressed as the fold change over 
this control. Data was analysed using one-way ANOVA followed by Bartlett's multiple comparisons 
test and are shown as means ±SEM of three independent experiments performed in triplicate. NT, not 
transfected.  
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CHAPTER 5 
DISCUSSION 
This chapter summarises the major findings in relation to the research aims and 
objectives.  In light of these findings, recommendations are presented for possible 
future research. In light of these findings potential avenues for future studies are 
discussed. 
5.1 INTRODUCTION 
The role of androgens in PCa is now a well-developed concept and many of 
the mechanisms for the role of androgens in PCa proliferation and progression are 
becoming clearer. AAT has been the first line treatment for PCa since Huggins and 
Hodge demonstrated that PCa was dependent on androgens for growth and survival 
[25]. However, it has become apparent that this treatment is “a Band-Aid for a bullet 
wound” as eventually, within 5 years, most tumours become CRPC. Despite this the 
AR remains a critical factor in PCa initiation and progression. The treatment for 
CRPC is limited and palliative with little to no increase in patient survival [48,58–61,379]. 
Docetaxel was the first chemotherapeutic agent that, combined with prednisone (a 
synthetic corticosteroid drug), resulted in increased survival [380]. Docetaxel is a 
taxane and these chemicals initiate the apoptotic process by binding to β-tubulin and 
promoting its polymerization. Since its discovery several other compounds have also 
shown increased survival such as abiraterone and enzalutamide [381,382]. However, 
these treatments are accompanied by severe toxicity as well as other adverse side-
affects, and patients may develop resistance to clinical approaches. Since 
androgens and the AR remain important even in progression, therapies which target 
the AR remain of interest even as the PCa becomes castration resistant. Indeed, 
selective steroid modulation appears to present an ideal target for management of 
both early and late-stage disease and this is one of the reasons the research on 
CpdA has been, and remains, promising. However, its clinical application is 
hampered by restricting factors in respect to limitations due to its labile nature, 
toxicity and narrow therapeutic window. 
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Owing to the difficulty in isolating and maintaining the active compounds of 
S.tuberculatiformis and the initial assumption that CpdA was an accurate model for 
the active compounds of S.tuberculatiformis, S.tuberculatiformis bioactive 
compounds have not been as extensively characterised as CpdA. It is difficult to 
draw exact comparisons of the mechanisms and effects between CpdA and the 
S.tuberculatiformis extract since most of the knowledge is based on the results of 
CpdA alone. CpdA is a synthetic analogue based only on partial structures obtained 
from a single fraction of S.tuberculatiformis. It is plausible that there may be 
significant differences between the bioactive compound(s) and CpdA thus presenting 
further opportunities for the extraction of alternative compound(s), perhaps less 
labile, with equal or additional therapeutic potential. CpdA has been shown to mimic 
certain biological properties of the S.tuberculatiformis extract but since it is not an 
identical compound it cannot be expected to show identical activity. Thus further 
investigation of the S.tuberculatiformis extract must begin by determining if 
compounds possess the same or similar characteristics as CpdA that have been 
proven therapeutically beneficial. This study was undertaken as a preliminary 
investigation to determine if S.tuberculatiformis extract mimics CpdA as a selective 
steroid receptor modulator with anti-proliferative properties. 
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5.2 S.TUBERCULATIFORMIS EXTRACT INHIBITS CYP11B1 
SUBSTRATE BINDING 
CYP11B1 is an enzyme located in the zona faciculata in the adrenal and is 
the terminal enzyme in glucocorticoid biosynthesis.  It exists in 2 isoforms CYP11B1 
and CYP11B2, with the latter expressed in the z glomerulosa only. CYP11B1 is a  
mitochondrial cytochrome P450 localised to the inner membrane of the adrenal 
cortex mitochondria where is converts DOC to corticosterone and deoxycortisol to 
the potent glucocorticoid, cortisol (Figure 5.1) [383]. CYP11B1 was identified as a key 
enzyme in an investigation into the syndrome of prolonged gestation and foetal post-
maturity induced in Karakul sheep by the consumption of S.tuberculatiformis [9]. The 
termination of gestation is characterised by the rise in foetal cortisol which is required 
to initiate birth in sheep with CYP11B1 playing a critical role.  The inhibition of 
CYP11B1 was therefore used as a bioassay to screen the S.tuberculatiformis extract 
for biologically active compounds that could lead to the extension of gestation in 
sheep. Although the active compounds in S. tuberculatiformis could not be 
unequivocally identified, a synthetic analogue, CpdA, was synthesised that had the 
same effect on the CYP11B1 enzyme system as the S.tuberculatiformis extract. In 
this investigation the first goal was to indicate the biological activity of a freshly 
prepared S.tuberculatiformis extract and CpdA with the CYP11B1 spectral assay. 
Figure 4.2 clearly shows that CpdA and the S.tuberculatiformis extract were 
biologically active as they both inhibited the DOC-induced type I difference spectrum 
of CYP11B1.  It is interesting to note that CpdA in solution, even when protected 
from light, oxygen and inconsistent temperatures, could not be stored in its active 
form as long as the S.tuberculatiformis extract. After 2-3 weeks CpdA lost its 
biological activity completely while the S.tuberculatiformis extract maintained activity 
for longer periods with loss of biological activity occurring gradually and only after ±1 
month. This suggests that stabilising factors within the crude extract may preserve 
the biological activity and enhance therapeutic benefits. One explanation of this is 
based on observations by Louw et al.  who demonstrated that both CBG and SHBG 
may be involved in the stabilization of CpdA in plasma suggesting a mechanism 
whereby the S.tuberculatiformis extract, which is highly reactive and labile in vitro, 
may be biologically active in vivo due to stabilizing factors [350].   
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Figure 5.1 Corticosteroid pathways. Sequential dehydrogenation and hydroxylation reactions to 
form DOC. DOC is converted to corticosterone by CYP11B1. Reproduced and adapted from Petrelli 
and Stewart (1998) [384]. 
Yemelyanov et al. have determined additional biological activities of CpdA which 
have not been previously shown in S.tuberculatiformis, namely the induction of 
steroid receptor translocation, the inhibition of steroid receptor transactivation, the 
induction of GR transactivation via the inhibition of various transcription factors 
including AP-1 and NFκB, as well as anti-proliferative activity and increased 
apoptosis which correlated with an increase in caspase- [5]. They showed that the 
cytostatic effect of CpdA is receptor dependent and, using virtual docking analysis, 
that CpdA shares binding cavities in the AR and GR ligand binding domains. Thus in 
these studies, CpdA acts as a competitive agonist, displacing steroids from their 
receptors and increasing free steroids as a consequence. Louw et al. demonstrated   
that the percentage of free plasma corticosterone increased during treatment with 
both S. tuberculatiformis and CpdA but, on termination of the treatment, the 
percentage of free corticosterone returned to control levels. These changes were 
associated with a decrease in CBG-bound corticosterone which also, after treatment, 
increased to control values [346]. These studies support a similar mechanism of action 
for S.tuberculatiformis extract and CpdA.  
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5.3 LNCAP AND PC3 CELL-LINES 
 LNCaP and PC3 PCa cell lines were used in this study. LNCaP cells were 
initially derived from a supraclavicular lymph node adenocarcinoma metastasis 
which is reflected in their name −lymph node-cancer of the prostate (LNCaP). This 
cell line is relatively slow growing with a doubling time of 60-72 hours. Most cell 
models derived from metastatic deposits are androgen independent (AI) as 
metastasis is usually a feature of progression to CRPC. There has been a paucity of 
androgen dependent (AD) cell-lines which has impeded research into early cancer 
initiation and proliferation. LNCaP cells are androgen sensitive and express the AR 
which makes them suitable for studying androgen sensitive diseases. However this 
cell line contains a T877A mutation in the LBD of the AR resulting in promiscuous 
binding to a range of steroid compounds [78,385]. This mutant AR exhibits strong AR 
transcriptional activity and confers increased cell growth and/or abrogated apoptotic 
signals in PCa cells in response to androgen treatment [385]. AR mutations have been 
reported in a subset of metastatic PCa and some of these mutations, such as the 
one exhibited in LNCaP cells, are associated with stimulation of the cells by other 
steroids and anti-androgens, causing concern over the use of drugs such as 
finasteride for the treatment of PCa [386]. LNCaP cells express low levels of 5α-
reductase, in comparison to the 17βHSD isoforms, while not expressing the GR and 
contain a frameshift mutation in the PTEN gene that causes a down-regulation of 
PTEN resulting in constitutive activation of either P13-kinase or Akt, which can 
induce cellular transformation [387]. On the other hand, LNCaP cells produce PSA 
and PSMA and still possess the p53 protein, albeit it contains a silent mutation, and 
these are often not present in late-stage disease [387,388]. This makes the LNCaP cell-
line currently the best candidate for early stage PCa research. 
PC3 cells were derived from a lumbar bone metastasis of a grade IV prostatic 
adenocarcinoma from 62-year-old Caucasian male. In contrast to LNCaP cells, this 
cell model has a high growth rate, with a doubling time of ~25 hours and expresses 
the wild type GR while no AR is present [257,389]. Thus PC3 cells are considered an AI 
cell-line. In addition to the lack of an AR, PC3 cells also do not produce PSA and 
PSMA, and has been shown to possess 5α-reductase activity [389,390]. PC3 cells have 
a deletion mutation of the p53 gene as well as exhibiting homozygous deletions of 
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the PTEN gene or parts thereof [389,391]. This makes PC-3 cells a highly aggressive 
form of PCa that is resistant to most forms of current PCa therapy. This can be 
shown through the inability of pro-apoptotic initiators such as TNF-α and 
staurosporine, to affect these cells. Therefore, unlike LNCaP cells, PC3 cells are 
considered to be a CRPC model and a representative of late stage PCa. 
By using both cell lines it is possible to study the effects of compounds on 
different stages of PCa (Table 5.1). PC3 cells are useful in investigating the 
biochemical changes in advanced PCa and in assessing their response to 
chemotherapeutic agents while LNCaP cells represent the earlier stage in which 
interventions preventing the progression of PCa to CRPC can assessed. It is also 
possible, by using both cell lines, to demonstrate selective steroid receptor activity. 
 
Table 5.1 Summary of LNCaP and PC3 cell-lines and their differing phenotypes 
Cell-
Lines 
AR 
Androgen 
Sensitivity 
GR 
5α-
reductase 
PSA PSMA PTEN p53 Stage 
LNCaP + AS - + + + + + Early 
PC3 - AI + + - - - - Late 
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5.4 S.TUBERCULATIFORMIS EXTRACT TRANSLOCATES THE AR 
AND GR 
The ability of the S.tuberculatiformis extract to interact with the AR and the 
GR was investigated in LNCaP, PC3 and transiently transfected PC3AR+ to determine 
if nuclear translocation of these receptors occurs. This was achieved using 
immunofluorescence to indicate receptor translocation in the different cell models. 
The results showed that both the S.tuberculatiformis extract and CpdA interacted 
with the AR and GR causing translocation (Figures 4.3 and 4.4).  
Yemelyanov et al. produced similar results with CpdA (Figure 5.2)  using 
LNCaP cells that had been stably transfected with a wild type GR [6]. Their results 
showed that CpdA translocated both the AR and the GR. The AR was affected with 
the same intensity as the natural ligand DHT but CpdA appeared to have a weaker 
effect on the GR when compared to the agonist FA. Our results confirmed this effect 
of CpdA including the reduced translocation of the GR. However, the intensity of the 
signal obtained with the S.tuberculatiformis extract and CpdA was similar, 
suggesting their ability to translocate the AR was comparable. Interestingly, although 
both CpdA and S.tuberculatiformis extract also caused translocation of the GR, the 
intensity obtained with the S.tuberculatiformis extract was greater, similar to that of 
the FA agonist, suggesting the extract enhances translocation to the GR more so 
than CpdA. This suggests that S.tuberculatiformis extract has a greater translocation 
ability in terms of the GR than CpdA and a comparable translocation ability in terms 
of the AR. In order to confirm this we transiently transfected PC3 cells with the wild 
type AR to determine whether the translocation induced by CpdA and the 
S.tuberculatiformis extract would be similar.  LNCaP cells possess a mutated AR, as 
previously discussed, which broadens their range of ligands which could influence 
the intensity of the signalling. Our results showed that both CpdA and 
S.tuberculatiformis extract remained comparable, indicated by the intensities 
achieved in the translocation of the wild type AR. The effect was weaker than that 
observed with mutated AR which could be attributed to the promiscuity of the 
mutated receptor. The question, however, remains as to whether the increased 
activity on the GR for S.tuberculatiformis extract will translate to increased benefit 
clinically. 
Stellenbosch University  https://scholar.sun.ac.za
98 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 CpdA induced A) AR translocation and B) GR translocation. Immunofluorescent  
of nuclear translocation of AR (A) and GR (B) in cells treated for 16 h with DHT (10-6 mol/L), FA (10-6 
mol/L), and CpdA (10-5 mol/L). Reproduced from Yemelyanov et al. (2008) [5].  
The AR and GR play opposing roles in PCa progression and have long since 
been involved in PCa therapies. Compounds that can interact selectively with both 
receptors, favouring AR blockade and GR transrepression, provide a promising 
treatment mechanism that is anti-proliferative with reduced side effects, particularly 
those which are glucocorticoid mediated. Yemelyanov et al. have shown that CpdA 
inhibits transactivation of AR- and GR-mediated genes together with enhancement of 
GR transrepression due to the translocation of the receptors [5]. GR transrepression 
is associated with anti-inflammatory responses that impede PCa progression. 
Enhanced GR transrepression would therefore appear to be a beneficial factor in 
compound potency and anti-proliferation and anti-inflammatory effects and results 
obtained in this study indicate that the S.tuberculatiformis extract is as effective as 
CpdA in this regard, if not more so. 
Inhibition of AR-mediated transactivation holds potential for early PCa therapy 
as the AR stimulates proliferation by blocking apoptosis through the P13k/Akt 
pathway. This pathway is constitutively active in most PCas as the gene encoding 
PTEN, the inhibitory protein of this pathway is often found to have been mutated or 
deleted altogether. Thus inhibition of the AR “switches-off” this pathway in PCa 
allowing pro-apoptotic proteins, such as TNFα, to initiate apoptosis. Yemelyanov et 
al. have demonstrated this mechanism for the activation of the AR by CpdA [352]. 
B 
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Owing to the unavailability of ARE.luc and GRE.luc plasmids in our laboratory these 
experiments were not conducted with S.tuberculatiformis. However, the comparable 
intensities of translocation obtained with CpdA and S.tuberculatiformis extract 
suggest this effect is shared by the two compounds and that S.tuberculatiformis 
extract inhibits transactivation of the AR and the GR while enhancing GR 
transrepression.  Pending confirmation there remains potential for the enhanced GR 
response to translate to improved clinical efficacy for S.tuberculatiformis extract over 
CpdA. Further clarification is, however, still required. 
The implications for CRPC are less impressive as often PCa becomes CRPC 
through mutations, co-regulators or by bypassing the AR entirely. AR blockade is 
then clinically irrelevant. PC3 cells have bypassed the AR and therefore the inhibition 
of the AR in this cell line would be expected to have no beneficial effect. Indeed, 
several studies have shown that the AR may have an inhibitory effect on advanced 
CRPC growth, implying that the AR blockade in these circumstances would be 
counterproductive [392–394]. However an interesting study was recently published by 
Schweizer et al. [395]. In this investigation a small cohort of men with CRPC was 
studied and it was postulated that if CRPC were to be flooded with T, apoptosis may 
be initiated due to hormonal shock. The cells could also react by down regulating the 
AR allowing the PCa cells to once more respond to AAT.  Although small, the study 
yielded promising results. PSA reductions were seen in all of the 10 subjects, 
including four in whom PSA levels remained unchanged during the trial but were 
reduced when T-blocking drugs were recommenced after the T-shock treatment. 
These results suggest that pulsed high dose T therapy may have the potential to 
reverse the resistance to AAT that characterises CRPC which would render agents 
acting through an androgen blockade therapeutically beneficial once more [395 This 
mechanism could certainly be postulated to enhance or extend the therapeutic effect 
of T blocking drugs including S.tuberculatiformis and CpdA in CRPC. 
Additionally, studies have demonstrated that activation of GR signalling can 
maintain an active AR pathway under androgen-deprived conditions in PCa, despite 
the previous reports on the tumour-suppressive activities of the GR. It appears the 
liganded GR acts as an anti-AR in the presence of androgens but as an AR agonist 
in the absence of androgen [79,311,312,315,316]. Thus the inhibition of the GR in CRPC, 
such as that represented by PC3, could be beneficial by sensitising these aggressive 
Stellenbosch University  https://scholar.sun.ac.za
100 
 
B 
A 
cells to pro-apoptotic treatments through blocking of the constitutively active 
P13k/Akt pathway. Furthermore, restitution of the androgen sensitivity potentially will 
restore the GR to anti-AR activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 CpdA-induced inhibition of transcription activity of A) AR and B) GR. For 
luciferase reporter assay, cells were transfected with MMTV-Firefly luciferase (A) or TAT-Firefly 
luciferase (B) reporters and Renilla luciferase reference reporter. Firefly luciferase activity was 
normalized against Renilla luciferase activity to equalize for transfection efficacy. LNCaP-GR sells 
were treated with CpdA (0.1–10 μmol/L), DHT (10 μmol/L), FA (10 μmol/L), AR antagonist Casodex 
(Cdx; 100 μmol/L), and GR antagonist RU486 (100 μmol/L) for 32 h. Columns, mean results of one 
representative experiment (three wells per experimental group); bars, SD. Reproduced from 
Yemelyanov et al. (2008) [5]. 
It is evident that CpdA has shown promise as a novel therapeutic agent for 
PCa therapy with the S.tuberculatiformis extract appearing to mimic many of these 
mechanisms and sharing many of the proven properties of CpdA while it may 
possess additional benefits as evidenced by the greater translocation induction of 
the GR receptor.  It can be hypothesised that extracts of S.tuberculatiformis could 
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provide improved therapeutic options and warrant further studies into the active 
fractions and potential stabilizing cofactors within the crude extract.    
5.5 S.TUBERCULATIFORMIS EXTRACT INHIBITS PCA CELL 
GROWTH  
The ability of S.tuberculatiformis extract to inhibit cell growth and cause cell 
death  in PCa cell lines was investigated in LNCaP and PC3 cells, both the parental 
line and the transiently transfected PC3AR+. These studies were performed to 
demonstrate the anti-proliferative potential and to determine the relative potencies 
and efficacies of the two compounds. Inhibition of cell growth was demonstrated 
using cell viability assays and showed the effects of S.tuberculatiformis extract and 
CpdA on PCa cells with specific AR/GR status which correlate to the stage of PCa 
progression. Finally, apoptotic assays were performed using the Caspase-3/7 assay 
to determine if the cell death could be ascribed to an apoptotic mechanism resulting 
in initiation of the caspase cascade.  
CpdA was shown to possess an IC50 of 0.01 mg/ml in all the cell-lines. Thus 
the potency of CpdA was unaffected by the steroid receptor expressed in the cell, 
also supporting therapeutic benefits in early and late-stage disease (Table 4.2, 
Figure 4.5). This could be explained in several ways. Anti-proliferative effects may be 
triggered through the GR and the AR or may include additional pathways that are 
independent of the AR and the GR. Figure 4.5B shows the effect of different 
concentrations of CpdA on cell growth of the three cell models.  Notable changes in 
cell growth were demonstrated between 0.016-0.013 mg/ml and 0.013-0.006 mg/ml 
demonstrating a dose dependent effect but suggesting a relatively narrow 
therapeutic range separating ineffective dose and possible toxicity. Another 
observation with this experiment was marked intra-study variability, evident in the 
error bars (Figure 4.5), with less variability seen in the PC3 cell lines. This is 
probably due to the fact that obtaining tight data with cell growth assays – 
reproducible from one experiment to the next - is extremely difficult. In addition 
LNCaP cells do not always adhere so well and so are often lost when media is 
replenished/supplemented whereas PC3 cells firmly adhere and this could result in 
the discrepancies of the error bar with the LNCaP cells. 
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In a similar study by Yemelyanov et al. CpdA was found to inhibit PCa cell 
growth [5].  The growth of PC3, DU145, and parental LNCaP cells, when exposed to 
CpdA, was significantly impeded (reduced 50- to 100-fold) with an effective 
concentration range of 10-5 to 10-6 mol/L (0.02 - 0.0026 mg/ml) (Figure 5.3). This 
finding is congruent with the results presented in the present study on the effects of 
SF and CpdA on cell growth although their reported IC50 values varied between the 
different cell models. The experiment by Yemelyanov et al. was carried out over 
several days, and as such, effects on proliferation were assayed using repeat doses.  
The present investigation, in contrast, was performed by increasing the strength of 
single doses with a shorter incubation of 16 hours assaying effects on cell growth in 
the log phase perhaps. In this study the IC50 for CpdA did, however, fall within the 
range previously reported. Yemelyanov et al. also treated their cell-lines with CpdA 
at a relatively high dose (0.026mg/ml - 10-5M) for 1-12 days showing that, in 
comparison to the untreated cells, CpdA treated cell-lines had inhibited growth which 
was also demonstrated in this study (Figure 5.4 and 4.5). Thus it appears clear that 
CpdA, at these concentrations, causes inhibition of PCa cell growth. 
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Figure 5.4 CpdA induced inhibition of cell growth in PCa cell models. A) Dose-response effect of 
CpdA on PCa and normal prostate cell growth. RWPE-1 (Healthy prostate cell-line) and different PCa 
cell-lines were treated with increasing concentrations of CpdA (10-9-2x10-5 M) for 5 days. Cells were 
counted using a haemocytometer. The average number of cells/well (+/- S.D.) is presented. Results of 
one representative experiment are shown. B) and C) show the effect of CpdA on the growth of 
prostate cells in monolayer. RWPE-1 and PC3, DU145, and LNCaP cells were treated with 0.01% 
DMSO (control) or CpdA (10-5 mol/L) for 1 to 12 days. Points, average number of cells per well for one 
representative experiment; bars, SD. Reproduced from Yemelyanov et al. (2008 [5]. 
In our study the same experiment on cell growth was also carried out for the 
S.tuberculatiformis crude extract. Interestingly, the S.tuberculatiformis extract yielded 
data showing less intra-study variation and the presence of S.tuberculatiformis 
extract resulted in growth differences between the cell lines. LNCaP cells were most 
sensitive between 0.125-0.063 mg/ml limiting its dosage range (Figure 4.6B). This 
could be due to the mutated AR receptor indicating interference of AR in 
S.tuberculatiformis extract mechanisms. Importantly, unlike CpdA, the potency of the 
S.tuberculatiformis extract was affected by the steroid hormone status of the different 
cells. Parental PC3 cells had a significantly lower IC50 than LNCaP and PC3AR+ cells 
(Figure 4.7). PC3 cells exhibited an IC50 of 0.14 mg/ml while LNCaP and PC3AR+ 
cells had IC50’s of 0.2 and 0.22 mg/ml, respectively. The presence of AR apparently 
decreased S.tuberculatiformis extract potency which further indicated interference of 
AR in the S.tuberculatiformis extract mechanism. This effect was not observed with 
CpdA. 
Another possibility for this observation is suggested by several studies that 
have shown that AR up-regulation in PC3 cells resulted in an inhibitory effect. 
Litvinov et al. transfected PC3 cells with a functional AR under a strong promoter 
and found overexpression of AR in PC-3 cells led to suppression of cell growth 
suggesting AR might play a negative role for basal intermediate-like tumour cell 
growth [248,257]. Another study supporting this hypothesis showed that Lenti-AR 
transduced PC3 and DU145 cell-lines expressed transcriptionally functional AR 
protein at appropriate physiological levels. Expression and engagement of AR 
protein in PC3-Lenti-AR cells resulted in transactivation of p21 and subsequent 
growth inhibition of these cells in culture and in mouse xenografts. Such growth 
inhibition was not observed in DU145-Lenti-AR cells. These findings suggest that the 
observed difference in IC50 between parental PC3 cells and PC3AR+ may be due to 
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S.tuberculatiformis extract inhibition of the AR resulting in its inhibitory effect being 
blocked thus desensitising the cells to the S.tuberculatiformis extract. 
Overall, both CpdA and S.tuberculatiformis extract led to cell death at higher 
concentrations, but the S.tuberculatiformis extract appeared to have a dose 
dependent effect on cell growth. The effects of the S.tuberculatiformis extract on cell 
growth was reduced by the presence of the AR and GR receptor, observed in cell 
growth only declining in PC3 and PC3AR+ at higher concentrations that in LNCaP 
cells, while CpdA was unaffected by the AR/GR status. This would potential imply 
that CRPC may be a more sensitive target for the S.tuberculatiformis extract in early 
disease.  
The results from the cell viability experiments suggest that the 
S.tuberculatiformis extract and CpdA have overlapping but not identical mechanisms 
initiating cell growth inhibition and again support the possibility that alternate 
compounds derived from S.tuberculatiformis extract might have the potential to 
improve those therapeutic benefits demonstrated by CpdA. 
5.5.1 S.TUBERCULATIFORMIS EXTRACT AND CPDA DO NOT INDUCE 
APOPTOSIS 
Cell death occurs either due to external injury or trauma which precipitates 
necrosis directly related to the injury or due to initiation of programmed cell death 
(PCD) or apoptosis.  Whereas apoptosis is an inherent, controlled cellular death 
program, the conceptual counterpart, necrosis, is a more chaotic way of dying, which 
results from circumstances outside the cell, and is characterized by cellular edema 
and disruption of the plasma membrane, leading to release of the cellular 
components and inflammatory tissue response [105,396]. PCD or apoptosis is the 
natural pathway whereby the body kills off mutated or damaged cells. 
Therapeutically the best mechanism for chemotherapeutic drugs is to initiate a 
pathway that results in apoptosis, particularly if this can be directed to specific cell 
populations which are diseased. In this study a caspase 3/7 apoptosis assay was 
used to determine if the S.tuberculatiformis extract and CpdA initiated apoptosis as 
part of their anti-proliferative properties. Caspase 3 has been called the "henchman 
that goes around and executes the cell" because it is the final caspase in the 
cascade and once activated apoptosis is guaranteed [397]. This experiment was 
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carried out in PC3 and PC3AR+ as the LNCaP exhibited unpredictable and varied 
results in the cell viability assay. 
In our study neither CpdA nor S.tuberculatiformis extract exhibited a 
significant increase in caspase-3 activity, regardless of steroid receptor status. It was 
therefore not possible to demonstrate apoptosis as part of their mechanisms of 
action (Figure 4.8A and 4.8B). There was also no significant difference between 
CpdA and the S.tuberculatiformis extract on caspase activity (Figure 4.9). As far as 
CpdA is concerned this was in contrast to the findings of Yemelyanov et al [5]. 
However, as mentioned previously, our cells were exposed to CpdA and 
S.tuberculatiformis extract for 16 hours only and it may be necessary to expose cells 
to longer incubation periods. Yemelyanov et al. treated PCa cells for 3-6 days with 
CpdA (10-5 mol/L) and observed increased activity of several caspases including 
caspase-3 (Figure 5.5). However, the induced caspase activity did not necessarily 
result in apoptosis. When compared to the positive control, TNFα, the CpdA 
caspase-induced activity was significantly lower, specifically caspase-3. Despite this, 
CpdA treatment did sensitize the PCa cells to TNFα induced apoptosis. This is 
probably due to the ability of CpdA to inhibit the Akt pathway through GR and AR 
activation lifting the constitutive inhibition on TNFα. 
 
 
 
 
 
 
 
 
Figure 5.5 CpdA-induced apoptosis through Caspase Cascade Initiation. Evaluation of 
caspase activity after CpdA treatment by ApoAlert Caspase Assay. DU145 cells were pretreated with 
0.01% DMSO (control) and CpdA (10-5 mol/L) for 3 and 6 d. TNF-a (10 ng/mL) was applied for 24 h. 
Columns, average caspase activity per experimental group in one representative experiment; bars, 
SD. Reproduced from Yemelyanov et al. (2008) [5]. 
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Additionally, Yemelyanov et al. performed this caspase assay in DU145 cells 
[5]. DU145 and PC3 cells are aggressive PCa cell-lines resistant to multiple pro-
apoptotic stimuli [398]. DU145 cells have distinct metabolic differences to PC3 cells 
that result in different sensitivities, such as DU145 being sensitive to TNFα apoptotic 
induction while PC3 cells remains resistant to it [399]. There are two genetic 
differences of note here as PC3 cells have a double homologous deletion mutation in 
the PTEN gene and so cannot express PTEN and they have a knock-out p51 gene 
while DU145 cells have a single deletion mutation in the PTEN gene, and can 
therefore still express it, and these cells also express a mutated p51 [400,401]. 
Therefore CpdA and the S.tuberculatiformis extract may not have induced apoptosis 
in PC3 cells because p51 stimulates PTEN activity which in turn inhibits the P13k/Akt 
pathway which is responsible for inhibition of TNFα induced apoptosis []. Since 
DU145 cells still possess these proteins CpdA, and by extension possibly the 
S.tuberculatiformis extract may still enhance pro-apoptotic stimuli.      
Interestingly, Yemelyanov et al. also showed that CpdA’s cytostatic effects 
were greatly influenced by the GR. They determined this in two ways. First they 
compared the effect of CpdA in the stably transfected LNCaPGR+ cells and parental 
LNCaP cells.  LNCaPGR+ cells were significantly more sensitive to growth inhibition 
by CpdA than the parental LNCaP cells (Figure 5.5). Secondly, they inhibited GR 
expression, 70% - 80% in PC3 and LNCaP-GR cells using the siRNA approach 
(Figure 5.6). This GR blockage resulted in a drastic loss of sensitivity to CpdA 
induced cell death. These finding correlate with the sensitivity exhibited by the 
S.tuberculatiformis extract in the cell viability assay where the parental PC3 (GR+) 
cells were more sensitive to the S.tuberculatiformis extract induced cell death. The 
same results were not seen in the CpdA cell viability assay, perhaps due to the short 
treatment incubation period. This could indicate that CpdA’s effects required 
prolonged exposure whereas the effect of the S.tuberculatiformis extract was 
observed in a shorter incubation period. Importantly, Yemelyanov et al. also showed 
that RWPE-1 cells (normal prostate cells) were resistant to the growth inhibitory 
effects of CpdA, making CpdA an ideal candidate for PCa therapy. We did not test 
the S.tuberculatiformis extract on healthy prostate cancer cells, but our results 
exhibit similar sensitivities which may translate into similar selectivity, particularly as 
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Yemelyanov et al. have proposed that this selectivity is due to the AR and GR 
mediated signalling. 
 
 
 
 
 
 
 
Figure 5.6 The inhibitory effects of CpdA are dependent on the steroid receptor expression 
in the cells, specifically the GR.  Down-regulation of GR expression by siRNA decreases CpdA 
effect on PC cell growth. LNCaP-GR (A) and PC3 (B) cells were transfected with siRNA against GR 
(GR-siRNA) or scrambled siRNA (sc-RNA) as a negative control. Cells were treated with 0.01% 
DMSO (control) or CpdA (10-5 mol/L) for 8 d. Bar graphs represent quantification of CpdA effect on 
LNCaP (A) and PC3 (B) treated with GR-siRNA and sc-RNA. Columns, average number of cells per 
well for one representative experiment; bars, SD. Reproduced from Yemelyanov et al. (2008) [5]. 
The hypothesis put forward by Yemelyanov et al. is that the remarkable 
cytostatic potential of CpdA in PCa cells is the result of the inhibition of numerous 
pro-proliferative and anti-apoptotic TFs, such as factors from the Ets family, NFκB, 
and AP-1 combined with the blocked defence response of cancer cells mediated via 
gene activation by steroid hormone receptors [5,7]. Our results indicate that the 
S.tuberculatiformis extract could function under a similar mechanism and perhaps 
more efficiently. Although caspase activity was not observed in our study apoptosis 
is not excluded. As discussed the absence of caspase activity could be due to the 
shorter exposure or the choice of cell models. Further study into different cell lines is 
needed to demonstrate this observation. 
A final consideration regarding apoptosis is that, although caspase-3 could 
not be shown to be involved, the S.tuberculatiformis extract and CpdA may also 
produce cell death effects through PCD pathways that are independent of caspases. 
In the past, PCD was considered to be the same as apoptosis, a process  of cell 
death characterized by changes  in cell morphology including cell shrinkage and 
condensation of chromatin leading to disintegration of the cell into  ‘‘apoptotic 
B A 
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bodies’’ or small fragments that are removed by phagocytosis [402]. Once the 
apoptotic pathways are triggered, the caspase cascade is activated to execute the 
cell in a controlled fashion [397]. More recently it has become evident that the 
distinction between apoptosis and necrosis is an over simplification of the complex 
processes which protect the organism against unwanted, damaged and potentially 
harmful cells. Although caspases may be necessary for the classical apoptotic 
process, caspase activation is not the only determinant of life and death in PCD [403–
407].  Xiang et al described one of the first examples of caspase-independent PCD. 
They showed that inhibition of caspase activities in the human leukemic cell line, 
Jurkat, did not inhibit Bax-induced cell death itself but only changed the morphology 
of the dying cells [408]. More evidence that PCD can occur in the absence of caspases 
is accumulating, and other, non-caspase proteases have been found to be able to 
trigger PCD [409–415]. In addition, in a study by Cauwels et al., it was shown that 
caspase inhibition did not alleviate but rather exacerbated tumour necrosis factor 
(TNFα)-induced toxicity in mice, demonstrating caspase-independent PCD in vivo 
[416,417]. Thus the various forms of caspase-independent cell death cannot easily be 
classified as ‘‘apoptosis’’ or ‘‘necrosis,’’ and alternative types of PCD are now being 
described [403,404,406,409,418–420]. They occur under physiological circumstances and 
can also be induced by TNFα or chemotherapeutic drugs [421].  Not only caspases, 
but also other proteases including calpains, cathepsins, endonucleases, can initiate 
programmed cell death, and they can be directed by various intracellular organelles, 
including mitochondria, lysosomes, and the endoplasmic reticulum, alone or in 
collaboration with each other. Several models of caspase-independent cell death 
have been described but it is clear that they may overlap and several characteristics 
may be displayed at the same time (Figure 5.8). It has therefore been postulated that 
the dominant cell death phenotype is determined by the relative speed of the 
available death programs, and only the fastest and most effective pathway is usually 
evident [422]. Thus S.tuberculatiformis extract and CpdA could be affecting cell death 
through these pathways but this would need further clarification and investigation. 
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Figure 5.7. Cross-talk between cellular organelles resulting in apoptosis or caspase-
independent cell death. Upon a lethal stimulus, a cell has access to different death programs. As 
depicted here, the signals from the different organelles are linked and may act both upstream and 
downstream of each other. Reproduced from Broker et al. (2005) [423]. 
Overall, the S.tuberculatiformis extract and CpdA both induced cell death in 
PCa cells making them possible therapeutic options for PCa. Based on our study the 
mechanism by which cell death was achieved is uncertain but these compounds 
continue to show great promise for applications in the treatment of advanced PCa.  
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5.6 CONCLUSIONS 
Africa has many health challenges with significant health, social and economic 
implications. PCa can be considered one of the pivotal diseases. It is set to become 
the leading cancer in men and there is clear evidence, supported by the studies by 
Heyns et al. and others, that people of African descent have increased risk and 
present with more aggressive and more advanced disease with reduced chance of 
recovery on the currently available therapies. As a consequence there is a significant 
need, as well as a large gap, between the current situation and the need for more 
effective interventions and therapies. This places research into novel treatment 
strategies and new chemotherapeutic agents for PCa as a medical priority and drugs 
derived from our indigenous flora are an attractive alternative with implications for 
cost effective development. 
The first aim of this study was to produce an S.tuberculatiformis extract with 
confirmed biological activity. This was achieved successfully through methanol 
extraction, with the biological activity verified using the bioassay developed by Swart 
et al [8,336]. Subsequently this extract could be used for the comparative evaluation 
against CpdA. As the selective steroid modulation is one of the characteristics of 
CpdA with the most exciting therapeutic applications, the initial aim was to prove 
steroid receptor translocation as a marker for potential modulatory bioactivity in the 
S.tuberculatiformis extract. Lastly, and with particular reference to the anticancer 
effects, the effects on cell growth and apoptosis were investigated and compared 
between the S.tuberculatiformis extract and CpdA.  
The results showed that both the extract and CpdA interacted with the GR and 
AR causing nuclear translocation of both receptors. Furthermore, the effect of the 
S.tuberculatiformis extract on GR translocation was stronger than that exhibited by 
CpdA. This is the first indication that the two compounds are not biologically identical 
and supports the conjecture that there may be alternate or differing clinical effects 
that could affect the therapeutic potential. Although it is too early to speculate that 
the advantage lies with the crude extract, it is the GR-mediated transrepression that 
controls the anti-inflammatory response and therefore a stronger effect on the GR 
would lend support for the extract’s improved potential over CpdA. Lastly, in terms of 
cell viability, both CpdA and the S.tuberculatiformis extract demonstrated 
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comparable effects on growth inhibition which is central to the expected benefit in 
PCa therapy. However, further investigation failed to demonstrate caspase cascade-
induced apoptosis. It is possible that the mechanism for cell death as the extrinsic 
pathway and the Bl-2 family may be involved.  Further clarification and exploration is 
needed to resolve this. Despite this the effect on cell growth remains supportive of 
anti-cancer potential, at least as potent as CpdA if not more.  
Thus CpdA appears to be a good biological mimic of S.tuberculatiformis extract 
activity but the crude extract has exhibited early indications of possible additional 
beneficial properties. Future studies need to revisit the isolation of active compounds 
and possible co-factors to better decide on the development of novel lead 
compounds that could be applied therapeutically especially in the areas of cancer 
chemotherapy and autoimmune conditions where selective steroid modification has 
proven therapeutic 
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5.7 FUTURE RESEARCH 
This study is only the beginning of the work needed to fully characterise the 
S.tuberculatiformis extract and many more biological characteristics need to be 
demonstrated and proven.  Mechanisms of action must be further elucidated and 
related to biological functions to direct future research. 
For the crude extract transactivation and transrepression need to be 
demonstrated to prove selective steroid modulation and anti-inflammatory effects. 
Apoptosis must be revisited using extended incubation periods and different cell 
lines to further determine the mechanisms of cell death. Active fractions from the 
crude extract must be identified and isolated with cofactors, if these are found to 
significantly affect stability or potency, and from there, more detailed studies to 
examine specific receptor properties such as virtual docking for the AR, GR and 
other steroid receptors. 
The potential therapeutic application of S.tuberculatiformis in diseases other than 
PCa, specifically other hormone dependent cancers and inflammatory diseases, 
needs to be investigated. This would also be influenced by the effects on other 
steroid receptors. Finally, in terms of clinical applications, it will become important to 
investigate S.tuberculatiformis as part of multidrug therapies focusing on enhancing 
potency of therapy through multiple simultaneous targets.  
 
 
 
  
Stellenbosch University  https://scholar.sun.ac.za
113 
 
BIBLIOGRAPHY 
1. Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and 
major patterns in GLOBOCAN 2012: Globocan 2012. Int. J. Cancer 136, E359–
E386 (2015). 
2. Torre, L. A. et al. Global cancer statistics, 2012: Global Cancer Statistics, 2012. 
CA. Cancer J. Clin. 65, 87–108 (2015). 
3. Parkin, D. M., Bray, F. I. & Devesa, S. S. Cancer burden in the year 2000: The 
Global Picture. Eur. J. Cancer 37, 4–66 (2001). 
4. WHO. Cancer. (World Health Organisation, 2016). 
5. Yemelyanov, A. et al. Novel steroid receptor phyto-modulator compound A inhibits 
growth and survival of prostate cancer cells. Cancer Res. 68, 4763–4773 (2008). 
6. Yemelyanov, A. et al. Tumor suppressor activity of glucocorticoid receptor in the 
prostate. Oncogene - Nat. 26, 1885–1896 (2007). 
7. Yemelyanov, A. et al. Differential targeting of androgen and glucocorticoid 
receptors induces ER stress and apoptosis in prostate cancer cells: A novel 
therapeutic modality. Cell Cycle 11, 395–406 (2012). 
8. Swart, P., Swart, A. C., Louw, A. & van der Merwe, K. J. Biological activities of the 
shrub Salsola tuberculatiformis Botsch.: contraceptive or stress alleviator? 
Bioessays 25, 612–619 (2003). 
9. Basson, P. et al. ‘“Grootlamsiekte”’: a specific syndrome of prolonged gestation in 
sheep caused by a shrub, Salsola tuberculata. J. Vet. Res. 36, 59–104 (1969). 
10. Breasted, J. The Edwin Smith Surgical Papyrus: Hieroglyphic transliterations, 
translations and commentary. University of Chicago Press (1930). 
Stellenbosch University  https://scholar.sun.ac.za
114 
 
11. Abate-Shen, C. & Shen, M. M. Molecular genetics of prostate cancer. Genes 
& development. Genes Dev. 14, 2410–2434 (2000). 
12. NIH. ABout Cancer. (National Insitiutes of Health, 2016). 
13. Wilt, T. J. et al. Radical Prostatectomy versus Observation for Localized 
Prostate Cancer. N. Engl. J. Med. 367, 203–213 (2012). 
14. Hoffman, R. M. Screening for prostate cancer. N. Engl. J. Med. 365, 2013–
2019 (2011). 
15. Parkin, D. M. et al. Part I: Cancer in indigenous Africans -burden, distribution 
and trends. Lancet Oncol. Med. J. 9, 683–692 (2008). 
16. Brawley, O. ., Jani, A. . & Master, V. Prostate Cancer and Race. Curr. Probl. 
Cancer 31, 211–225 (2007). 
17. Heyns, C. F., Lecuona, A. T. & Trollop, G. S. Prostate cancer: Prevalence and 
treatment in African men. J. Mens Health Gend. 2, 400–405 (2005). 
18. Gueye, S. M. et al. Clinical characteristics of prostate cancer in African 
Americans, American Whites and Senegalese men. J. Urol. 61, 987–992 (2003). 
19. Powell, I. J. Epidemiology and pathophysiology of prostate cancer in African-
American men. J. Urol. 177, 444–449 (2007). 
20. Kang, J. S., Maygarden, S. J., Mohler, J. L. & Pruthi, R. S. Comparison of 
clinical and pathological features in African-American and Caucasian patients with 
localized prostate cancer. Br. J. Urol. 93, 1207–1210 (2004). 
21. Evans, S., Metcalfe, C., Ibrahim, F., Persad, R. & Ben-Shlomo, Y. 
Investigating Black-White differences in prostate cancer prognosis: A systematic 
review and meta-analysis. Int. J. Cancer 123, 430–435 (2008). 
Stellenbosch University  https://scholar.sun.ac.za
115 
 
22. Ross, R. et al. Serum testosterone levels in healthy young black and white 
men. J. Natl. Cancer Inst. 76, 45–48 (1986). 
23. Ross, R. K. et al. 5-alpha-reductase activity and risk of prostate cancer among 
Japanese and U.S. white and black males. Lancet Oncol. Med. J. 339, 887–889 
(1992). 
24. de Jong, F. H. et al. Peripheral hormone levels in controls and patients with 
prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese 
case-control study. Cancer Res. 51, 3445–3450 (1991). 
25. Huggins, C. B. & Hodges, C. V. Studies on prostatic cancer: The effect of 
castration, of estrogen and of androgen injections on serum phosphatases in 
metastatic carcinoma of the prostate. Cancer Res. 1, 293–297 (1941). 
26. Heyns, C. F., Fisher, M., Lecuona, A. & Van der Merwe, A. Prostate cancer 
among different racial groups in the Western Cape: Presenting features and 
management. SAMJ South Afr. Med. J. 101, 267–270 (2011). 
27. Benninghoff, A. Macroscopic anatomy, embrology and histology of man. 
(Urban and Schwarzenberg, 1993). 
28. Thompson, H. The diseases of the prostate: their pathology and treatment. 
(1873). 
29. Mann, T. & Lutwak-Mann, C. in Biochemistry and investigative andrology 
(Springer-Verlag Berlin Heidelberg). 
30. Berry, P. A., Maitland, N. J. & Collins, A. T. Androgen receptor signalling in 
prostate: Effects of stromal factors on normal and cancer stem cells. Mol. Cell. 
Endocrinol. 288, 30–37 (2008). 
Stellenbosch University  https://scholar.sun.ac.za
116 
 
31. McNeal, J. E. Normal histology of the prostate. Am. J. Surg. Pathol. 12, 619–
633 (1988). 
32. Partin, A. W. & Coffey, D. S. in Campbrll’s Urology 1381–1428 (WB Saunders 
Co., 1998). 
33. Collins, A. T. & Maitland, N. J. Prostate Cancer Stem Cells. Eur. J. Cancer 42, 
1213–1218 (2006). 
34. Bonkhoff, H. & Remberger, K. D. Differentiation pathways and 
histogeneticaspects of normal and abnormal prostate growth: a stem cell model. 
The Prostate 28, 98–106 (1996). 
35. Bui, M. & Reiter, R. E. Stem cell genes in androgen-independent prostate 
cancer. Cancer Metastasis Rev. 17, 391–399 (1999). 
36. Ho, C. K. & Habib, F. K. Estrogen and androgen signaling in the pathogenesis 
of BPH. Nat. Rev. Urol. 8, 29–41 (2011). 
37. Vermeulen, A. in The endocrine function of the testis 157–170 (Academic 
Press, 1973). 
38. Isaacs, J. T. & Coffey, D. S. Changes in dihydrotestosterone metabolism 
associated with the development of canine benign prostatic hyperplasia. J. 
Endocrinol. 108, 445–453 (1981). 
39. Bruchovsky, N. & Dunstan-Adams, E. in Regulation of androgen action 31–34 
(Proceedings of an international symposium, Congressdruck, 1985). 
40. Labrie, F. et al. Structure of human type II 5α-reductase gene. J. Endocrinol. 
131, 1571–1573 (1992). 
Stellenbosch University  https://scholar.sun.ac.za
117 
 
41. Bartsch, G., Rittmaster, R. . & Klocker, H. Dihydrotestosterone and the 
concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur. 
Urol. 37, 367–380 (2000). 
42. Silver, I. R. et al. . Expression and regulation of steroid 5alpha-reductase 2 in 
prostate disease. J. Urol. 152, 433–437 (1994). 
43. Heinlein, C. A. & Chang, C. Androgen Receptor in Prostate Cancer. Endocr. 
Rev. 25, 276–308 (2004). 
44. Assimos, D., Smith, C., Lee, C. & Greyhack, J. T. Action of prolactin in 
regressing prostate: independent of action mediated by androgen receptors. The 
Prostate 5, 589–595 (1984). 
45. Aragona, C. & Friesen, H. G. Specific prolactin binding sites in the prostate 
and testis of rat. J. Endocrinol. 97, 6776–6783 (1975). 
46. McKeehan, W. L., Adams, P. S. & Rosser, M. P. Direct mitogenic effects of 
insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary 
factors and possibly prolactin, but not androgen, on normal rat prostate epithelial 
cells in serum-free primary cell culture. Cancer Res. 44, 1998–2010 (1984). 
47. Simpson, E. et al. Local estrogen biosynthesis in males and females. Endocr. 
Relat. Cancer 6, 131–137 (1999). 
48. Grayhack, J. T., Keeler, T. C. & Kozlowski, J. M. Carcinoma of the prostate: 
Hormonal therapy. J. Cancer 60, 589–601 (1987). 
49. Brolin, J., Skoog, L. & Ekman, P. Immunohistochemistry and biochemistry in 
detection of androgen, progesterone, and estrogen receptors in benign and 
malignant human prostatic tissue. The Prostate 20, 281–295 (1992). 
Stellenbosch University  https://scholar.sun.ac.za
118 
 
50. Mobbs, B. G., Johnson, L. E. & Liu, Y. The quantitation of cytosolic and 
nuclear estrogen and progesterone receptors in benign untreated and treated 
malignant human prostatic tissue by radioligand binding and enzyme 
immunoassays. The Prostate 16, 235–244 (1990). 
51. McDonald, P. C. Origin of estrogen in men. (1998). 
52. Schweikert, H. U., Milewich, L. & Wilson, J. D. Aromatization of 
androstenedione by cultured human fibroblasts. J. Endocrinol. Metab. 43, 785–
792 (1976). 
53. Walsh, P. C. & Wilson, J. D. The induction of prostatic hypertrophy in the dog 
with androstanediol. J. Clin. Invest. 57, 1093–1097 (1976). 
54. DeKlerk, D. P. et al. Comparison of spontaneously and experimentally 
induced canine prostatic hyperplasia. J. Clin. Invest. 64, 842–849 (1979). 
55. Krieg, M., Klotzl, J., Kaufman, J. & Voigt, K. D. Stroma of human benign 
prostatic hyperplasia: preferential tissues for androgen metabolism and estrogen 
binding. Acta Endocrinol. Cph. 96, 422–432 (1981). 
56. Donnelly, B. J., Lakey, W. H. & McBlain, W. B. Estrogen receptors in human 
benign prostatic hyperplasia. J. Urol. 130, 183–187 (1983). 
57. Huggins, C. Endocrine-induced regression of cancers. Cancer Res. 27, 1925–
1930 (1967). 
58. Haranda, M., Lida, M. I., Yamaguchi, M. & Shida, K. in In Prostate Cancer and 
Bone Metastasis 173–182 (Springer US, 1992). 
59. Budendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study 
of 1,589 patients. Hum. Pathol. 31, 578–583 (2000). 
Stellenbosch University  https://scholar.sun.ac.za
119 
 
60. Shah, R. B. et al. Androgen independent prostate cancer is a heterogeneous 
group of diseases: lessons from a rapid autopsy program. Cancer Res. 64, 9209–
9216 (2004). 
61. Roudier, M. P. et al. Phenotypic heterogeneity of end-stage prostate 
carcinoma metastatic to bone. Hum. Pathol. 34, 646–653 (2003). 
62. Chen, C. D. et al. Molecular determinants of resistance to antiandrogen 
therapy. Nat. Med. 10, 33–39 (2004). 
63. Gomella, L. D. Effective Testosterone Suppression for Prostate Cancer: Is 
There a Best Castration Therapy? Nat. Rev. Urol. 11, 52–60 (2009). 
64. Debes, J. D. & Tindall, D. J. Mechanisms of androgen-refractory prostate 
cancer. N Engl J Med 351, 1488–1490 (2004). 
65. Gregory, C. W., Johnson, R. T., Mohler, J. L., French, F. S. & Wilson, E. M. 
Androgen receptor stabilization in recurrent prostate cancer is associated with 
hypersensitivity to low androgen. Cancer Res. 61, 2892–2898 (2001). 
66. Weber, M. J. & Gioeli, D. Ras signaling in prostate cancer progression. J. 
Cell. Biochem. 91, 13–25 (2004). 
67. Visakorpi, T. et al. In vivo amplification of the androgen receptor gene 
andprogression of human prostate cancer. Nat. Genet. 9, 401–406 (1995). 
68. Koivisto, P. et al. Androgen receptor gene amplification: a possible molecular 
mechanism for androgen deprivation therapy failure in prostate cancer. Cancer 
Res. 57, 314–319 (1997). 
Stellenbosch University  https://scholar.sun.ac.za
120 
 
69. Linija, M. J., Savinainen, K. J. & Saramaki, O. R. Amplification and 
overexpression of androgen receptor gene in hormone-refractory prostate cancer. 
Cancer Res. 61, 3550–3555 (2001). 
70. Latil, A. et al. Evaluation of androgen, estrogen (ERα and ERβ), and 
progesterone receptor expression in human prostate cancer by real-time 
quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 
61, 1919–1926 (2001). 
71. Edwards, J., Krishna, N. S., Grigor, K. M. & Bartlett, J. M. S. Androgen 
receptor gene amplification and protein expression in hormone refractory prostate 
cancer. Britich J. Med. 89, 552–556 (2003). 
72. Holzbeierlein, L. et al. Gene expression analysis of human prostate carcinoma 
during hormonal therapy identifies androgen-responsive genes and mechanisms 
of therapy resistance. Am. J. Pathol. 164, 217–227 (2004). 
73. Labrie, F. et al. Treatment of prostate cancer with gonadotropin-releasing 
hormone agonists. Endocr. Rev. 7, 67–74 (1986). 
74. Feldman, B. J. & Feldman, D. The development of androgn-independent 
Prostate cancer.pdf. Nat. Rev. Cancers 1, 34–45 (2001). 
75. Gelmann, E. P. Molecular Biology of the Androgen Receptor. J. Clin. Oncol. 
20, 3001–3015 (2002). 
76. Taplin, M.-E. & Balk, S. P. Androgen receptor: A key molecule in the 
progression of prostate cancer to hormone independence. J. Cell. Biochem. 91, 
483–190 (2004). 
Stellenbosch University  https://scholar.sun.ac.za
121 
 
77. Wilding, G., Chen, M. & Gelmann, E. P. Aberrant response in vitro of 
hormone-responsive prostate cancer cells to antiandrogens. The Prostate 14, 
103–115 (1989). 
78. Veldscholte, J. et al. The androgen receptor in LNCaP cells contains a 
mutation in the ligand binding domain which affects steroid binding characteristics 
and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 41, 665–669 
(1992). 
79. Zhao, X. . et al. Glucocorticoids can promote androgen-independent growth of 
prostate cancer cells through a mutated androgen receptor. Nat. Med. 6, 703–706 
(2000). 
80. Buchanan, G. et al. Collocation of androgen receptor gene mutations in 
prostate cancer. Clin. Cancer Res. 7, 1273–1281 (2001). 
81. Shi, X.-B., Ma, A.-H., Xia, L., Kung, H.-J. & de Vere White, R. W. Functional 
analysis of 44 mutant androgen receptors from human prostate cancer. Cancer 
Res. 62, 1496–1502 (2002). 
82. Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate cancer. N. Engl. J. 
Med. 349, 366–381 (2003). 
83. Tindall, D. J. et al. Symposium on androgen action in prostate cancer. Cancer 
Res. 64, 7178–7180 (2004). 
84. Culig, Z. et al. Androgen receptor activation in prostatic tumor cell lines by 
insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth 
factor. Cancer Res. 54, 5474–5478 (1994). 
Stellenbosch University  https://scholar.sun.ac.za
122 
 
85. Craft, N., Shostak, Y., Carey, M. & Sawyers, C. L. A mechanism for hormone-
independent prostate cancer through modulation of androgen receptor signaling 
by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280–285 (1999). 
86. Gioeli, D. et al. Androgen receptor phosphorylation Regulation and 
identification of the phosphorylation sites. J. Biol. Chem. 277, 29304–29314 
(2002). 
87. Paget, S. The distribution of secondary growths in cancer of the breast. 
Cancer Metastasis Rev. 8, 98–101 (1989). 
88. Pienta, K. J. & Loberg, R. The‘“emigration,migration, and immigration”’of 
prostate cancer. Clin. Prostate Cancer 4, 24–30 (2005). 
89. Loberg, R. D., Logothetis, C. J., Keller, E. T. & Pienta, K. J. Pathogenesis and 
treatment of prostate cancer bone metastases: targeting the lethal phenotype. J. 
Clin. Oncol. 23, 8232–8241 (2005). 
90. Janne, O. A. et al. Androgen-receptor-interacting nuclear proteins. Biochem. 
Soc. Trans. 28, 401–405 (2000). 
91. Gregory, C. W. et al. A mechanism for androgen receptor-mediated prostate 
cancer recurrence after androgen deprivation therapy. Cancer Res. 61, 4215–
4319 (2001). 
92. Li, P. et al. Heterogeneous expression and functions of androgen receptor co-
factors in primary prostate cancer. Am. J. Pathol. 161, 1467–1474 (2002). 
93. Kang, Z., Janne, O. A. & Palvimo, J. J. Co-regulator recruitment and histone 
modifications in transcriptional regulation by the androgen receptor. Mol. 
Endocrinol. 18, 2633–2648 (2004). 
Stellenbosch University  https://scholar.sun.ac.za
123 
 
94. Wang, L., Hsu, C. L. & Chang, C. Androgen receptor co-repressors: an 
overview. The Prostate 63, 117–130 (2005). 
95. Fujimoto, N., Yeh, S. & Kang, H. Y. Cloning and characterisation of androgen 
receptor co-activator, ARA55, in human prostate. J. Biol. Chem. 274, 8316–8321 
(1999). 
96. Ngan, E. S., Hashimoto, Y., Ma, Z. Q., Tsai, M.-J. & Tsai, S. Y. Over-
expression of Cdc25B, an androgen receptor co-activator, in prostate cancer. 
Oncogene 22, 734–739 (2003). 
97. Debes, J. D. et al. p300 in prostate cancer proliferation and progression. 
Cancer Res. 63, 7638–7640 (2003). 
98. Comuzzi, B. et al. The transcriptional co-activator cAMP response element-
binding protein-binding protein is expressed in prostate cancer and enhances 
androgen-and anti-androgen-induced androgen receptor function. Am. J. Pathol. 
162, 233–241 (2003). 
99. Scher, H. I. & Sawyers, C. L. Biology of progressive, castration-resistant 
prostate cancer: directed therapies targeting the androgen-receptor signaling axis. 
J. Clin. Oncol. 23, 8253–8261 (2005). 
100. McDonnell, T. J. et al. Expression of the proto-oncogene bcl-2 in the prostate 
and its association with emergence of androgenindependent prostate cancer. 
Cancer Res. 52, 6940–6944 
101. Colombel, M. et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 
in hormone-refractory human prostate cancers. Am. J. Pathol. 143, 390 (1993). 
Stellenbosch University  https://scholar.sun.ac.za
124 
 
102. Raffo, A. J. et al. Overexpression of bcl-2 protects prostate cancer cells from 
apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer 
Res. 55, 4438–4445 (1995). 
103. Furuya, Y., Krajewski, S., Epstein, J. I., Reed, J. C. & Isaacs, J. T. Expression 
of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer 
Res. 2, 389–398 (1996). 
104. Maitland, N. J. et al. Prospective identification of tumorigenic prostate cancer 
stem cells. Cancer Res. 65, 591 (2005). 
105. Kerr, J. F., Wyllie, A. H. & Currie, A. R. Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Britich J. Cancer 
26, 239 (1972). 
106. Adams, J. M. & Cory, S. The Bcl-2 apoptotic switch in cancer development 
and therapy. Oncogene 26, 1324–1337 (2007). 
107. Johnstone, R. W., Ruefli, A. A. & Lowe, S. W. Apoptosis: a link between 
cancer genetics and chemotherapy. Cell 108, 153–164 (2002). 
108. Fulda, S. & Debatin, K. M. Modulation of apoptosis signaling for cancer 
therapy. Arch. Immunol. Ther. Exp. (Warsz.) 54, 173–175 (2006). 
109. Hengartner, M. O. The biochemistry of apoptosis. Nature 407, 770–776 
(2000). 
110. Strasser, A., O’Connor, L. & Dixit, V. M. Apoptosis signaling. Annu. Rev. 
Biochem. 69, 217–245 (2000). 
111. Fulda, S. & Debatin, K. M. Extrinsic versus intrinsic apoptosis pathways in 
anticancer chemotherapy. Oncogene 25, 4798–4811 (2006). 
Stellenbosch University  https://scholar.sun.ac.za
125 
 
112. Walensky, L. D. BCL-2 in the crosshairs: tipping the balance of life and death. 
Cell Death Differ. 13, 1339–1350 (2006). 
113. Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-
death switch. Nat. Rev. Cancers 2, 647–656 (2002). 
114. Karbowski, M., Norris, K. L., Cleland, M. M., Jeong, S. Y. & Youle, R. J. Role 
of Bax and Bak in mitochondrial morphogenesis. Nature 443, 658–662 (2006). 
115. McDonnell, T. J. et al. Expression of bcl-2 oncoprotein and p53 protein 
accumulation in bone marrow metastases of androgen independent prostate 
cancer. J. Urol. 157, 569–574 (1997). 
116. Rosser, C. J. et al. Bcl-2 is significantly overexpressed in localized radio-
recurrent prostate carcinoma, compared with localized radio-naive prostate 
carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 56, 1–6 (2003). 
117. Mackey, T. J., Borkowski, A., Amin, P., Jacobs, S. C. & Kyprianou, N. bcl-
2/bax ratio as a predictive marker for therapeutic response to radiotherapy in 
patients with prostate cancer. Urology 52, 1085–1090 (1998). 
118. Pollack, A. et al. Molecular markers of outcome after radiotherapy in patients 
with prostate carcinoma. Cancer 97, 1630–1638 (2003). 
119. An, J., Chervin, A. S., Nie, A., Ducoff, H. S. & Huang, Z. Overcoming the 
radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 26, 
652–661 (2007). 
120. Kim, R., Emi, M., Matsuura, K. & Tanabe, K. Antisense and nonantisense 
effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer 
therapy. Cancer Gene Ther. 14, 1–11 (2007). 
Stellenbosch University  https://scholar.sun.ac.za
126 
 
121. Castilla, C. et al. Bcl-xL is overexpressed in hormone-resistant prostate 
cancer and promotes survival of LNCaP cells via interaction with proapoptotic 
Bak. Endocrinology 147, 4960–4967 (2006). 
122. Lebedeva, I., Rando, R., Ojwang, J., Cossum, P. & Stein, C. A. Bcl-xL in 
prostate cancer cells: effects of overexpression and down-regulation on 
chemosensitivity. Cancer Res. 60, 6052–6060 (2000). 
123. Li, X. et al. Overexpression of Bcl-XL underlies the molecular basis for 
resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res. 61, 
1699–1706 (2001). 
124. Li, X. et al. Adenovirus-mediated Bax overexpression for the induction of 
therapeutic apoptosis in prostate cancer. Cancer Res. 61, 186–91 (2001). 
125. Lin, Y. et al. Androgen and its receptor promote Bax-mediated apoptosis. Mol. 
Cell. Biol. 26, 1908–1916 (1916). 
126. Krajewska, M. et al. Elevated expression of inhibitor of apoptosis proteins in 
prostate cancer. Clin. Cancer Res. 9, 4914–4925 (2003). 
127. Kishi, H. et al. Expression of the survivin gene in prostate cancer: correlation 
with clinicopathological characteristics, proliferative activity and apoptosis. J. Urol. 
171, 1855–1860 (2004). 
128. Shariat, S. F. et al. Survivin expression is associated with features of 
biologically aggressive prostate carcinoma. Cancer 100, 751–757 (2004). 
129. McEleny, K. R., Watson, R. W. G., Coffey, R. N., O’Neill, A. J. & Fitzpatrick, J. 
M. Inhibitors of apoptosis proteins in prostate cancer cell lines. The Prostate 51, 
133–140 (2002). 
Stellenbosch University  https://scholar.sun.ac.za
127 
 
130. McEleny, K. et al. An antisense oligonucleotide to cIAP‐1 sensitizes prostate 
cancer cells to fas and TNFα mediated apoptosis. The Prostate 59, 419–425 
131. Lorenzo, P. I., Arnoldussen, Y. J. & Saatcioglu, F. Molecular mechanisms of 
apoptosis in prostate cancer. Crit. Rev. Oncog. 13, 1–38 (2007). 
132. Fulda, S. & Debatin, K. M. Signaling through death receptors in cancer 
therapy. Curr. Opin. Pharmacol. 4, 327–332 (2004). 
133. Krueger, A., Baumann, S., Krammer, P. H. & Kirchhoff, S. FLICE-inhibitory 
proteins: regulators of death receptor-mediated apoptosis. Mol. Cell. Biol. 21, 
8247–8254 (2001). 
134. Gao, S. et al. The androgen receptor directly targets the cellular Fas/FasL-
associated death domain protein-like inhibitory protein gene to promote the 
androgen-independent growth of prostate cancer cells. Mol. Endocrinol. 19, 1792–
1802 (2005). 
135. Diaz, J. I. et al. Cytometric analysis of Fas and Bcl-2 expression in normal 
prostatic epithelium and prostate cancer. Urol. Oncol. Semin. Orig. Investig. 5, 
149–154 (2000). 
136. Jiang, J. et al. Fas and Fas ligand expression is elevated in prostatic 
intraepithelial neoplasia and prostatic adenocarcinoma. Cancer 95, 296–300 
(2002). 
137. O’Kane, H. F. et al. Targeting death receptors in bladder, prostate and renal 
cancer. J. Urol. 175, 432–438 (2006). 
Stellenbosch University  https://scholar.sun.ac.za
128 
 
138. Takayama, H. et al. Fas gene mutations in prostatic intraepithelial neoplasia 
and concurrent carcinoma: analysis of laser capture microdissected specimens. 
Lab. Investiagation 81, 283–288 (2001). 
139. Hedlund, T. E., Duke, R. C., Schleicher, M. S. & Miller, G. J. Fas‐mediated 
apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage. 
The Prostate 36, 92–101 (1998). 
140. Hedlund, T. E. et al. Adenovirus-mediated expression of Fas ligand induces 
apoptosis of human prostate cancer cells. Cell Death Differ. 6, 175–182 (1999). 
141. Chopra, D. P., Menard, R. E., Januszewski, J. & Mattingly, R. R. TNF-α-
mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. 
Cancer Lett. 203, 145–154 (2004). 
142. Taghiyev, A. F., Guseva, N. V., Sturm, M. T., Rokhlin, O. & Cohen, M. B. 
Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to 
death receptor ligands treatment. Cancer Biol. Ther. 4, 388–396 
143. Catz, S. D. & Johnson, J. L. Transcriptional regulation of bcl-2 by nuclear 
factor κB and its significance in prostate cancer. Oncogene 20, 7342–7351 (2001). 
144. Babior, B. M. & Johnson, J. L. JFC1 is transcriptionally activated by nuclear 
factor-κB and up-regulated by tumour necrosis factor α in prostate carcinoma 
cells. Biochem. J. 367, 791–799 (2002). 
145. Nakashima, J. et al. Association between tumor necrosis factor in serum and 
cachexia in patients with prostate cancer. Clin. Cancer Res. 4, 1743–1748 (1998). 
146. Chen, X. et al. Constitutively active Akt is an important regulator of TRAIL 
sensitivity in prostate cancer. Oncogene 20, 6073–3083 (2001). 
Stellenbosch University  https://scholar.sun.ac.za
129 
 
147. Seol, J. W. et al. Wortmannin elevates tumor necrosis factor-related 
apoptosis-inducing ligand sensitivity in LNCaP cells through down-regulation of 
IAP-2 protein. Exp. Oncol. 27, 120–124 
148. Nguyen, D. M. et al. The Essential Role of the Mitochondria‐Dependent 
Death‐Signaling Cascade in Chemotherapy‐Induced Potentiation of Apo2L/TRAIL 
Cytotoxicity in Cultured Thoracic Cancer Cells: Amplified Caspase 8 Is 
Indispensable for Combination‐Mediated Massive Cell Death. Cancer J. 12, 257–
273 (2006). 
149. Lu, X. p53: a heavily dictated dictator of life and death. Curr. Opin. Genet. 
Dev. 15, 27–33 (2005). 
150. Yee, K. S. & Vousden, K. H. Complicating the complexity of p53. 
Carcinogenesis 26, 1317–1322 (2005). 
151. Giono, L. E. & Manfredi, J. J. The p53 tumor suppressor participates in 
multiple cell cycle checkpoints. J. Cell. Physiol. 209, 13–20 (2006). 
152. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 
307–310 (2000). 
153. Bode, A. M. & Dong, Z. Post-translational modification of p53 in 
tumorigenesis. Nat. Rev. Cancer 4, 793–805 (2004). 
154. Jeffers, J. R. et al. Puma is an essential mediator of p53-dependent and-
independent apoptotic pathways. Cancer Cell 4, 321–328 (2003). 
155. Vilunger, A. et al. p53-and drug-induced apoptotic responses mediated by 
BH3-only proteins puma and noxa. Science 302, 1036–1038 (2003). 
Stellenbosch University  https://scholar.sun.ac.za
130 
 
156. Chipuk, J. E. & Green, D. R. Dissecting p53-dependent apoptosis. Cell Death 
Differ. 13, 994–1002 (2006). 
157. Navone, N. M. et al. p53 protein accumulation and gene mutation in the 
progression of human prostate carcinoma. J. Natl. Cancer Inst. 85, 1657–1669 
(1993). 
158. Quinn, D. I., Henshall, S. M. & Sutherland, R. L. Molecular markers of 
prostate cancer outcome. Eur. J. Cancer 41, 858–887 (2005). 
159. Dong, J. T. Prevalent mutations in prostate cancer. J. Cell. Biochem. 97, 433–
447 (2006). 
160. Ruijter, E. et al. Molecular genetics and epidemiology of prostate carcinoma. 
Endocr. Rev. 20, 22–45 (1999). 
161. Ribeiro, F. R. et al. Comparison of chromosomal and array-based 
comparative genomic hybridization for the detection of genomic imbalances in 
primary prostate carcinomas. Mol. Cancer 5, 1 (2006). 
162. Nantermet, P. V. et al. Identification of genetic pathways activated by the 
androgen receptor during the induction of proliferation in the ventral prostate 
gland. J. Biol. Chem. 279, 1310–1322 (2004). 
163. Rokhlin, O. W. et al. Androgen regulates apoptosis induced by TNFR family 
ligands via multiple signaling pathways in LNCaP. Oncogene 24, 6773–6784 
(2005). 
164. Fernandez, P. L., Hernandez, L., Farre, X., Campo, E. I. . & Cardesa, A. 
Alterations of cell cycle-regulatory genes in prostate cancer. Pathobiology 70, 1–
10 (2002). 
Stellenbosch University  https://scholar.sun.ac.za
131 
 
165. Shenk, J. L. et al. p53 represses androgen-induced transactivation of 
prostate-specific antigen by disrupting hAR amino-to carboxyl-terminal interaction. 
J. Biol. Chem. 276, 38472–38479 (2001). 
166. Cronauer, M. V., Schulz, W. A., Burchardt, T., Ackermann, R. & Burchardt, M. 
Inhibition of p53 function diminishes androgen receptor-mediated signaling in 
prostate cancer cell lines. Oncogene 23, 3541–3549 (2004). 
167. Leite, K. R. et al. Abnormal expression of MDM2 in prostate carcinoma. Mod. 
Pathol. 14, 428–436 (2001). 
168. Wang, H., Yu, D., Agrawal, S. & Zhang, R. Experimental therapy of human 
prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone 
antisense oligonucleotides: In vitro and in vivo activities and mechanisms. The 
Prostate 54, 194–205 (2003). 
169. Levav-Chen, Y., Haupt, S. & Haupt, Y. Mdm2 in growth signaling and cancer: 
Mini review. Growth Factors 23, 183–192 (2005). 
170. Lu, S., Liu, M., Epner, D. E. & Tsai, M. J. Androgen regulation of the cyclin-
dependent kinase inhibitor p21 gene through an androgen response element in 
the proximal promoter. Mol. Endocrinol. 13, 376–384 (1999). 
171. Rigaud, J. et al. Expression of p21 cell cycle protein is an independent 
predictor of response to salvage radiotherapy after radical prostatectomy. The 
Prostate 58, 269–276 (2004). 
172. Fizazi, K. et al. The association of p21 (WAF-1/CIP1) with progression to 
androgen-independent prostate cancer. Clin. Cancer Res. 8, 775–781 (2002). 
Stellenbosch University  https://scholar.sun.ac.za
132 
 
173. Franke, T. F., Hornik, C. P., Segev, L., Shostak, G. A. & Sugimoto, C. 
PI3K/Akt and apoptosis: size matters. Oncogene 22, 8983–8998 (2003). 
174. Toker, A. & Yoeli-Lerner, M. Akt signaling and cancer: surviving but not 
moving on. Cancer Res. 66, 3963–3966 (2006). 
175. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation 
and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 
(2005). 
176. Scheid, M. P. & Woodgett, J. R. Unravelling the activation mechanisms of 
protein kinase B/Akt. FEBS Lett. 546, 108–112 (2003). 
177. Graff, J. R. et al. Increased AKT activity contributes to prostate cancer 
progression by dramatically accelerating prostate tumor growth and diminishing 
p27Kip1 expression. J. Biol. Chem. 275, 24500–24505 (2000). 
178. Liao, Y. et al. Increase of AKT/PKB expression correlates with gleason pattern 
in human prostate cancer. Int. J. Cancer 107, 676–680 (2003). 
179. Ayala, G. et al. High levels of phosphorylated form of Akt-1 in prostate cancer 
and non-neoplastic prostate tissues are strong predictors of biochemical 
recurrence. Clin. Cancer Res. 10, 6572–6578 (2004). 
180. Shukla, S., MacLennan, G. T., Marengo, S. R., Resnick, M. I. & Gupta, S. 
Constitutive activation of PI3K‐Akt and NF‐κB during prostate cancer progression 
in autochthonous transgenic mouse model. The Prostate 64, 224–239 (2005). 
181. Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E. & Sawyers, C. L. The 
PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of 
Stellenbosch University  https://scholar.sun.ac.za
133 
 
the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. U. S. A. 95, 
15587–15591 (1998). 
182. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase–AKT pathway 
in human cancer. Nat. Rev. Cancer 2, 489–501 (2002). 
183. Majumder, P. K. & Sellers, W. R. Akt-regulated pathways in prostate cancer. 
Oncogene 24, 7465–7474 (2005). 
184. Ke, N. et al. A new inducible RNAi xenograft model for assessing the staged 
tumor response to mTOR silencing. Exp. Cell Res. 312, 2726–2734 (2006). 
185. Romashkova, J. A. & Makarov, S. S. NF-κB is a target of AKT in anti-
apoptotic PDGF signalling. Nature 401, 86–90 (1999). 
186. Hughes-Fulford, M., Li, C. F., Boonyaratanakornkit, J. & Sattah, S. 
Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces 
gene expression in prostate cancer. Cancer Res. 66, 1427–1433 (2006). 
187. Li, Y. & Sarkar, F. H. Inhibition of nuclear factor κB activation in PC3 cells by 
genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 8, 2369–2377 
(2002). 
188. Kumar, A. P. et al. 4-Hydroxy-3-methoxybenzoic acid methyl ester: a 
curcumin derivative targets Akt/NFκB cell survival signaling pathway: potential for 
prostate cancer management. Neoplasia 5, 255–266 (2003). 
189. Stern, D. F. More than a marker… phosphorylated Akt in prostate carcinoma. 
Clin. Cancer Res. 10, 6407–6410 (2004). 
190. Engelberg, D. Stress-activated protein kinases—tumor suppressors or tumor 
initiators? Semin. Cancer Biol. 14, 271–282 (2004). 
Stellenbosch University  https://scholar.sun.ac.za
134 
 
191. Chang, L. & Karin, M. Mammalian MAP kinase signalling cascades. Nature 
410, 37–40 (2001). 
192. Wada, T. & Penninger, J. M. Mitogen-activated protein kinases in apoptosis 
regulation. Oncogene 23, 2838–2849 (2004). 
193. Maroni, P. D., Koul, S., Meacham, R. B. & Koul, H. K. Mitogen activated 
protein kinase signal transduction pathways in the prostate. Cell Commun. Signal. 
2, 5–17 (2004). 
194. Royuela, M. et al. Regulation of proliferation/apoptosis equilibrium by 
mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous 
human prostate. Hum. Pathol. 33, 299–306 (2002). 
195. Gioeli, D., Mandell, J. W., Petroni, G. R., Frierson, H. F. & Weber, M. J. 
Activation of mitogen-activated protein kinase associated with prostate cancer 
progression. Cancer Res. 59, 279–284 (1999). 
196. Uzgare, A. R., Kaplan, P. J. & Greenberg, N. M. Differential expression and/or 
activation of P38MAPK, erk1/2, and jnk during the initiation and progression of 
prostate cancer. The Prostate 55, 128–139 (2003). 
197. Ricote, M. et al. P38 MAPK protects against TNF-α-provoked apoptosis in 
LNCaP prostatic cancer cells. Apoptosis 11, 1969–1975 (2006). 
198. Sah, N. K. et al. Translation inhibitors sensitize prostate cancer cells to 
apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) by activating c-Jun N-terminal kinase. J. Biol. Chem. 278, 20593–20602 
(2003). 
Stellenbosch University  https://scholar.sun.ac.za
135 
 
199. Shimada, K. et al. c‐Jun NH2‐terminal kinase‐dependent fas activation 
contributes to etoposide‐induced apoptosis in p53‐mutated prostate cancer cells. 
The Prostate 55, 265–280 (2003). 
200. Yang, Y. M. et al. C-Jun NH2-terminal kinase mediates proliferation and tumor 
growth of human prostate carcinoma. Clin. Cancer Res. 9, 391–401 (2003). 
201. Oh, S. J., Erb, H. H., Hobisch, A., Santer, F. R. & Culig, Z. Sorafenib 
decreases proliferation and induces apoptosis of prostate cancer cells by inhibition 
of the androgen receptor and Akt signaling pathways. Endocr. Relat. Cancer 19, 
305–319 (2012). 
202. Tang, Y. et al. Flavokawain B, a kava chalcone, induces apoptosis via up‐
regulation of death‐receptor 5 and Bim expression in androgen receptor negative, 
hormonal refractory prostate cancer cell lines and reduces tumor growth. Int. J. 
Cancer 127, 1758–1768 (2010). 
203. Chen, L. F. & Greene, W. C. Shaping the nuclear action of NF-κB. Nat. Rev. 
Molcecular Cell Biol. 5, 392–401 (2004). 
204. Suh, J. & Rabson, A. B. NF‐κB activation in human prostate cancer: Important 
mediator or epiphenomenon? J. Cell. Biochem. 91, 100–117 (2004). 
205. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 
441, 431–436 (2006). 
206. Luo, J. L., Kamata, H. & Karin, M. IKK/NF-κB signaling: balancing life and 
death–a new approach to cancer therapy. J. Clin. Invest. 115, 2625–2632 (2005). 
Stellenbosch University  https://scholar.sun.ac.za
136 
 
207. Shukla, S. et al. Nuclear factor-κB/p65 (Rel A) is constitutively activated in 
human prostate adenocarcinoma and correlates with disease progression. 
Neoplasia 6, 390–400 (2004). 
208. Lindholm, P. F., Bub, J., Kaul, S., Shidham, V. B. & Kajdacsy-Balla, A. The 
role of constitutive NF-κB activity in PC-3 human prostate cancer cell invasive 
behavior. Clin. Exp. Metastasis 18, 471–479 (2000). 
209. Hwang, Y. S., Hodge, J. C., Sivapurapu, N. & Lindholm, P. F. 
Lysophosphatidic acid stimulates PC‐3 prostate cancer cell matrigel invasion 
through activation of RhoA and NF‐κB activity. Mol. Carcinog. 45, 518–529 (2006). 
210. Huang, S., Pettaway, C. A., Uehara, H., Bucana, C. D. & Fidler, I. J. Blockade 
of NF-κB activity in human prostate cancer cells is associated with suppression of 
angiogenesis, invasion, and metastasis. Oncogene 20, 4188–4197 (2001). 
211. Shimada, K., Nakamura, M., Ishida, E., Kishi, M. & Konishi, N. Roles of p38-
and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced 
p53 induction and apoptosis. Carcinogenesis 24, 1067–1075 (2003). 
212. Dehm, S. M. & Tindall, D. J. Molecular regulation of androgen action in 
prostate cancer. J. Cell. Biochem. 99, 333–344 (2006). 
213. Beato, M. Gene regulation by steroid hormones. Cell 56, 335 (1989). 
214. Necela, B. M. Mechanisms of Glucocorticoid Receptor Action in 
Noninflammatory and Inflammatory Cells. Proc. Am. Thorac. Soc. 1, 239–246 
(2004). 
Stellenbosch University  https://scholar.sun.ac.za
137 
 
215. Brinkmann, A. O. et al. The human androgen receptor: domain structure, 
genomic organization and regulation of expression. J. Steroid Biochem. 34, 307–
310 
216. Manglesdorf, D. J. et al. The nuclear receptor superfamily: the second 
decade. Cell 83, 835–839 (1995). 
217. Li, J. & Al-Azzawi, F. Mechanism of androgen receptor action. Maturitas 63, 
142–148 (2009). 
218. Thornton, J. W. & Kelley, D. B. Evolution of the androgen receptor: structure--
function implications. Bioessays 20, 860–869 (1998). 
219. Tanner, T. M., Claessens, F. & Haelens, A. The hinge region of the androgen 
receptor plays a role in proteasome-mediated transcriptional activation. Ann. N. Y. 
Acad. Sci. 1030, 587–592 (2004). 
220. Saporita, A. J. et al. Identification and characterization of  a ligand-regulated 
nuclear export signal in androgen receptor. J. Biol. Chem. 278, 41998–42005 
(2003). 
221. Africander, D. Comparative study of the molecular mechanism of action of the 
synthetic progestins, medroxyprogesterone acetate and norethisterone acetate. 
(University of STellenbosch, 2010). 
222. Tora, L. et al. The human estrogen receptor has two independent nonacidic 
transcriptional activation functions. Cell 59, 477–487 (1989). 
223. Bevan, C. L., Hoare, S., Claessens, F., Heery, D. M. & Parker, M. G. The AF1 
and AF2 domains of the androgen receptor interact with distinct regions of SRC1. 
J. Mol. Cell Biol. 19, 8383–8392 (1999). 
Stellenbosch University  https://scholar.sun.ac.za
138 
 
224. Rochette-Egly, C. Nuclear receptors: integration of multiple signalling 
pathways through phosphorylation.Nuclear receptors: integration of multiple 
signalling pathways through phosphorylation. Cell. Signal. 15, 355–366 (2003). 
225. Glass, C. K. & Rosenfeld, M. G. The co-regulator exchange in transcriptional 
functions of nuclear receptors. Genes Dev. 14, 121–141 (2000). 
226. He, B., Minges, J. T., Lee, L. W. & Wilson, E. M. The FXXLF motif mediates 
androgen receptor-specific interactions with coregulators. J. Biol. Chem. 277, 
10226–10235 (2002). 
227. Simental, J. A., Sar, M., Lane, M. V., French, F. S. & Wilson, E. M. 
Transcriptional activation and nuclear targeting signals of the human androgen 
receptor. J. Biol. Chem. 266, 510–518 (1991). 
228. Zhou, Z. X., Kemppanien, J. A. & Wilson, E. M. Identification of three proline-
directed phosphorylation sites in the human androgen receptor. Mol. Endocrinol. 
9, 605–615 (1995). 
229. Hill, C., Langley, E., Kemppanien, J. A. & Wilson, E. M. Intermolecular NH2-
/carboxyl-terminal interactions in androgen receptor dimerization revealed by 
mutations that cause androgen insensitivity. Biol. Chem. 273, 92–101 (1998). 
230. Doesburg, P. et al. Functional in vivo interaction between the amino-terminal, 
transactivation domain and the ligand binding domain of the androgen receptor. 
Biochemistry (Mosc.) 36, 1052–1064 
231. Zhou, Z. X., Kemppanien, J. A. & Wilson, E. M. Specifcity of ligand-dependent 
androgen receptor stabilization: Receptor domain interactions inuence ligand 
dissociation and receptor stability. Mol. Endocrinol. 9, 208–218 (1995). 
Stellenbosch University  https://scholar.sun.ac.za
139 
 
232. He, B., Kemppanien, J. A., Voegel, J. J., Gronemeyer, H. & Wilson, E. M. 
Activation function 2 in the human androgen receptor ligand binding domain 
mediates interdomain communication with the NH(2)-terminal domain. Biol. Chem. 
274, 37219–37225 (1999). 
233. Claessens, F. et al. Selective DNA binding by the androgen receptor as a 
mechanism for hormone-specific gene regulation. J. Steroid Biochem. Mol. Biol. 
76, 23–30 (2001). 
234. Rosenfeld, M. G., Lunyak, V. V. & Glass, C. K. Sensors and signals: a 
coactivator/ corepressor/epigenetic code for integrating signal-dependent 
programs of transcriptional response. Genes Dev. 20, 1405–1428 (2006). 
235. Mader, S., Chambon, P. & White, J. H. Defining a minimal estrogen receptor 
DNA binding domain. Nucleic Acids Res. 21, 1125–1132 (1993). 
236. Shoenmakers, E. et al. Differential DNA binding by the androgen and 
glucocorticoid receptors involves the second Zn-finger and a C-terminal extension 
of the DNA-binding domains. Biochem. J. 341, 515–521 (1999). 
237. Hard, T. et al. Solution Structure of the Glucocorticoid Receptor DNA-Binding 
Domain. Science 249, 157–160 (1990). 
238. Gewirth, D. T. & Sigler, P. B. The basis for half-site specificity explored 
through a non-cognate steroid receptor-DNA complex. Nat. Struct. Mol. Biol. 2, 
386–394 (1995). 
239. Dahlman-Wright, K., Grandien, K., Nilsson, S., Gustafsson, J. A. & Carlstedt-
Duke, J. Protein-protein interactions between the DNA-binding domains of nuclear 
receptors: influence on DNA-binding. J. Steroid Biochem. Mol. Biol. 45, 239–250 
(1993). 
Stellenbosch University  https://scholar.sun.ac.za
140 
 
240. Mohler, J. L. et al. The androgen axis in recurrent prostate cancer. Clin. 
Cancer Res. 10, 440–448 (2004). 
241. De Winter, J. R. et al. Androgen receptor status in localized and locally 
progressive hormone refractory human prostate cancer. Am. J. Pathol. 144, 735 
(1994). 
242. Chodak, G. W. et al. Nuclear localization of androgen receptor in 
heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J. 
Urol. 147, 798–803 (1992). 
243. Sadi, M. V., Walsh, P. C. & Barrack, E. R. Immunohistochemical study of 
androgen receptors in metastatic prostate cancer. Comparison of receptor content 
and response to hormonal therapy. Cancer 67, 3057–3064 (1991). 
244. Henshall, S. M. et al. Altered expression of androgen receptor in the 
malignant epithelium and adjacent stroma is associated with early relapse in 
prostate cancer. Cancer Res. 61, 423–427 (2001). 
245. Ricciardelli, C. et al. Androgen receptor levels in prostate cancer epithelial 
and peritumoral stromal cells identify non‐organ confined disease. The Prostate 
63, 19–28 (2005). 
246. Niu, Y. et al. Differential androgen receptor signals in different cells explain 
why androgen-deprivation therapy of prostate cancer fails. Oncogene 29, 3593–
3604 (2010). 
247. Niu, Y. et al. Targeting the stromal androgen receptor in primary prostate 
tumors at earlier stages. Proc. Natl. Acad. Sci. U. S. A. 105, 12188–12193 (2008). 
Stellenbosch University  https://scholar.sun.ac.za
141 
 
248. Niu, Y. et al. Androgen receptor is a tumor suppressor and proliferator in 
prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 105, 12182–12187 (2008). 
249. Sun, Y. et al. Androgen deprivation causes epithelial–mesenchymal transition 
in the prostate: implications for androgen-deprivation therapy. Cancer Res. 72, 
527–536 (2012). 
250. van Bokhoven, A. et al. Molecular characterization of human prostate 
carcinoma cell lines. The Prostate 57, 205–225 (2003). 
251. van Leenders, G. J. & Schalken, J. A. Epithelial cell differentiation in the 
human prostate epithelium: implications for the pathogenesis and therapy of 
prostate cancer. Crit. Rev. Oncol. Hematol. 46, 3–10 (2003). 
252. Bonkhoff, H., Stein, U. & Remberger, K. The proliferative function of basal 
cells in the normal and hyperplastic human prostate. The Prostate 24, 114–118 
(1994). 
253. Eder, I. E. et al. Inhibition of LncaP prostate cancer cells by means of 
androgen receptor antisense. Cancer Gene Ther. 7, 997–1007 (2000). 
254. Haag, P., Bektic, J., Bartsch, G., Klocker, H. & Eder, I. E. Androgen receptor 
down regulation by small interference RNA induces cell growth inhibition in 
androgen sensitive as well as in androgen independent prostate cancer cells. J. 
Steroid Biochem. Mol. Biol. 96, 251–258 (20058). 
255. Liao, X., Tang, S., Thrasher, J. B., Griebling, T. L. & Li, B. Small-interfering 
RNA–induced androgen receptor silencing leads to apoptotic cell death in prostate 
cancer. Mol. Cancer Ther. 4, 505–515 (2005). 
Stellenbosch University  https://scholar.sun.ac.za
142 
 
256. Litvinov, I. V., Chang, C. & Isaacs, J. T. Molecular characterization of the 
commonly used human androgen receptor expression vector, pSG5‐AR. The 
Prostate 58, 319–324 (2004). 
257. Litvinov, I. V. et al. PC3, but not DU145, human prostate cancer cells retain 
the coregulators required for tumor suppressor ability of androgen receptor. The 
Prostate 66, 1329–1338 (2006). 
258. Lee, S. O. et al. Suppressor role of androgen receptor in proliferation of 
prostate basal epithelial and progenitor cells. J. Endocrinol. 213, 173–182 (2012). 
259. Halin, S., Hammarsten, P., Wikstrom, P. & Bergh, A. Androgen‐insensitive 
prostate cancer cells transiently respond to castration treatment when growing in 
an androgen‐dependent prostate environment. The Prostate 67, 370–377 (2007). 
260. Gleave, M., Hsieh, J. T., Gao, C., von Eschenbach, A. C. & Chung, L. W. 
Acceleration of human prostate cancer growth in vivo by factors produced by 
prostate and bone fibroblasts. Cancer Res. 51, 3753–3761 (1991). 
261. Lai, K. P. et al. Suppressed prostate epithelial development with impaired 
branching morphogenesis in mice lacking stromal fibromuscular androgen 
receptor. Mol. Endocrinol. 26, 52–66 (2011). 
262. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 
307–315 (2004). 
263. Jiang, Q. et al. Targeting androgen receptor leads to suppression of prostate 
cancer via induction of autophagy. J. Urol. 188, 1361–1368 (2012). 
Stellenbosch University  https://scholar.sun.ac.za
143 
 
264. Ma, W. L. et al. Hepatic androgen receptor suppresses hepatocellular 
carcinoma metastasis through modulation of cell migration and anoikis. 
Hepatology 56, 176–185 (2012). 
265. Bhuiyan, M. M. et al. Down-regulation of androgen receptor by 3, 3′-
diindolylmethane contributes to inhibition of cell proliferation and induction of 
apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate 
cancer cells. Cancer Res. 66, 10064–10072 (2006). 
266. Han, H. et al. Physalins A and B inhibit androgen-independent prostate 
cancer cell growth through activation of cell apoptosis and downregulation of 
androgen receptor expression. Biol. Pharm. Bull. 34, 1584–1588 (2011). 
267. Frezza, M., Yang, H. & Dou, Q. P. Modulation of the tumor cell death pathway 
by androgen receptor in response to cytotoxic stimuli. J. Cell. Physiol. 226, 2731–
2739 (2011). 
268. Godfrey, B., Lin, Y., Larson, J., Haferkamp, B. & Xiang, J. Proteasomal 
degradation unleashes the pro-death activity of androgen receptor. Cell Res. 20, 
1138–1147 (2010). 
269. Li, R. J. et al. Androgen receptor: a new player associated with apoptosis and 
proliferation of pancreatic beta-cell in type 1 diabetes mellitus. Apoptosis 13, 359–
971 (2008). 
270. Williams, G. T. & Smith, C. A. Molecular regulation of apoptosis: genetic 
controls on cell death. Cell 74, 777–779 (1993). 
271. Gorospe, M. et al. .P21(Waf1/Cip1) protects against p53-mediated apoptosis 
of human melanoma cells. Oncogene 14, 929–935 (1997). 
Stellenbosch University  https://scholar.sun.ac.za
144 
 
272. Asada, M. et al. Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in 
monocytic differentiation. EMBO J. 18, 1223–1234 (1999). 
273. Kimura, K., Markowski, M., Bowen, C. & Gelmann, E. P. Androgen blocks 
apoptosis of hormone-dependent prostate cancer cells. Cancer Res. 61, 5611–
5618 (2001). 
274. Kadowaki, Y. et al. PI3 Kinase inhibition on TRAIL-induced apoptosis 
correlates with androgen-sensitivity and p21 expression in prostate cancer cells. 
Apoptosis 16, 627–635 (2011). 
275. Sun, M. et al. Activation of phosphatidylinositol 3-kinase/Akt pathway by 
androgen through interaction of p85α, androgen receptor, and Src. J. Biol. Chem. 
278, 42992–43000 (2003). 
276. Yang, L. et al. nduction of androgen receptor expression by 
phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles 
in apoptosis of LNCaP prostate cancer cells. J. Biol. Chem. 280, 33558–33565 
(2005). 
277. Nguyen, T. V. ., Yao, M. & Pike, C. J. Androgens activate mitogen‐activated 
protein kinase signaling: Role in neuroprotection. J. Neurochem. 94, 1639–1651 
(2005). 
278. Simoes, V. L. et al. Regulation of apoptotic signaling pathways by 5α-
dihydrotestosterone and 17β-estradiol in immature rat Sertoli cells. J. Od Steroid 
Biochem. Mol. Biol. 135, 15–23 (2013). 
279. Diallo, J. S. et al. An androgen‐independent androgen receptor function 
protects from inositol hexakisphosphate toxicity in the PC3/PC3 (AR) prostate 
cancer cell lines. The Prostate 66, 1245–1256 (2006). 
Stellenbosch University  https://scholar.sun.ac.za
145 
 
280. Yang, H. et al. Calpain‐mediated androgen receptor breakdown in apoptotic 
prostate cancer cells. J. Cell. Physiol. 217, 569–576 (2008). 
281. Lin, Y., Lu, Z., Kokontis, J. & Xiang, J. Androgen receptor primes prostate 
cancer cells to apoptosis through down-regulation of basal p21 expression. 
Biochem. Biophys. Res. Commun. 430, 289–293 (2013). 
282. Hatzoglou, A. et al. Membrane androgen receptor activation induces apoptotic 
regression of human prostate cancer cells in vitro and in vivo. J. Clin. Endocrinol. 
Metab. 90, 893–903 (2005). 
283. Papadopoulou, N. et al. Membrane androgen receptor activation triggers 
down-regulation of PI-3K/Akt/NF-kappaB activity and induces apoptotic responses 
via Bad, FasL and caspase-3 in DU145 prostate cancer cells. Mol. Cancer 7, 88 
(2008). 
284. LaFevre-Bernt, M. A. & Ellerby, L. M. Kennedy’s disease: Phosphorylation of 
the polyglutamine-expanded form of androgen receptor regulates its cleavage by 
caspase-3 and enhances cell death. J. Biol. Chem. 278, 34918–34924 (2003). 
285. Young, J. E. et al. Polyglutamine-expanded androgen receptor truncation 
fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J. 
Neurosci. 29, 1987–1997 (2009). 
286. Wen, S., Niu, Y., Lee, S. O. & Chang, C. Androgen receptor (AR) positive vs 
negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, 
necrosis and autophagic cell death. Cancer Treat. Rev. 40, 31–40 (2014). 
287. Kino, T. et al. Glucocorticoid receptor (GR) β has intrinsic, GRα-independent 
transcriptional activity. Biochem. Biophys. Res. Commun. 381, 671–675 (2009). 
Stellenbosch University  https://scholar.sun.ac.za
146 
 
288. Oakley, R. H., Jewell, C. M., Yudt, M. R., Bofetiado, D. M. & Cidlowski, J. A. 
The dominant negative activity of the human glucocorticoid receptor β isoform 
specificity and mechanisms of action. J. Biol. Chem. 274, 27857–27866 (1999). 
289. Gottlicher, M., Heck, S. & Herrlich, P. Transcriptional cross-talk, the second 
mode of steroid hormone receptor action. J. Mol. Med. 76, 480–489 (1998). 
290. De Bosscher, K., Vanden Berghe, W. & Haegeman, G. The Interplay between 
the Glucocorticoid Receptor and Nuclear Factor-κB or Activator Protein-1: 
Molecular Mechanisms for Gene Repression. Endocr. Rev. 24, 488–522 (2003). 
291. Dostert, A. & Heinzel, T. Negative glucocorticoid receptor response elements 
and their role in glucocorticoid action. Curr. Pharm. Des. 10, 2807–2816 (2004). 
292. Dennis, A. P. & O’Malley, B. W. Rush hour at the promoter: how the ubiquitin-
proteasome pathway polices the traffic flow of nuclear receptor-dependent 
transcription. J. Od Steroid Biochem. Mol. Biol. 93, 139–151 (2005). 
293. Kinyamu, H. K., Chen, J. & Archer, T. K. Linking the ubiquitin–proteasome 
pathway to chromatin remodeling/modification by nuclear receptors. J. Mol. 
Endocrinol. 34, 281–297 (2005). 
294. Galliher-Beckley, A. J., Williams, J. G., Collins, J. B. & Cidlowski, J. A. 
Glycogen synthase kinase 3β-mediated serine phosphorylation of the human 
glucocorticoid receptor redirects gene expression profiles. Mol. Cell. Biol. 28, 
7309–7322 (2008). 
295. Chen, W. et al. Glucocorticoid receptor phosphorylation differentially affects 
target gene expression. Mol. Endocrinol. 22, 1754–1766 (2008). 
Stellenbosch University  https://scholar.sun.ac.za
147 
 
296. Nishimura, K. et al. Potential mechanism for the effects of dexamethasone on 
growth of androgen-independent prostate cancer. J. Natl. Cancer Inst. 93, 1739–
1746 (2001). 
297. Fixemer, T., Remberger, K. & Bonkhoff, H. Differential expression of the 
estrogen receptor beta (ERβ) in human prostate tissue, premalignant changes, 
and in primary, metastatic, and recurrent prostatic adenocarcinoma. The Prostate 
52, 79–87 (2003). 
298. Kassel, O. et al. Glucocorticoids inhibit MAP kinase via increased expression 
and decreased degradation of MKP‐1. EMBO J. 20, 7108–7116 (2001). 
299. Schacke, H., Docke, W. D. & Asadullah, K. Mechanisms involved in the side 
effects of glucocorticoids. Pharmacol. Ther. 96, 23–43 (2002). 
300. Bruna, A., Nicolas, M., Munoz, A., Kyriakis, J. M. & Caelles, C. Glucocorticoid 
receptor–JNK interaction mediates inhibition of the JNK pathway by 
glucocorticoids. EMBO J. 22, 6035–6044 (2003). 
301. Greenberg, A. K. et al. Glucocorticoids inhibit lung cancer cell growth through 
both the extracellular signal-related kinase pathway and cell cycle regulators. Am. 
J. Respir. Cell Mol. Biol. 27, 320–328 (2002). 
302. Ricote, M. et al. The p38 transduction pathway in prostatic neoplasia. J. 
Pathol. 208, 401–407 (2006). 
303. Wu, W. et al. Microarray analysis reveals glucocorticoid-regulated survival 
genes that are associated with inhibition of apoptosis in breast epithelial cells. 
Cancer Res. 64, 1757–1764 (2004). 
Stellenbosch University  https://scholar.sun.ac.za
148 
 
304. Yano, A. Glucocorticoids Suppress Tumor Angiogenesis and In vivo Growth 
of Prostate Cancer Cells. Clin. Cancer Res. 12, 3003–3009 (2006). 
305. McLeskey, S. W. et al. Tumor growth of FGF or VEGF transfected MCF-7 
breast carcinoma cells correlates with density of specific microvessels 
independent of the transfected angiogenic factor. Am. J. Pathol. 153, 1993–2006 
(1998). 
306. Claffey, K. P. et al. Expression of vascular permeability factor/vascular 
endothelial growth factor by melanoma cells increases tumor growth, 
angiogenesis, and experimental metastasis. Cancer Res. 56, 172–181 (1996). 
307. Balbay, M. D. et al. Highly metastatic human prostate cancer growing within 
the prostate of athymic mice overexpresses vascular endothelial growth factor. 
Clin. Cancer Res. 5, 783–789 (1999). 
308. Inoue, K. et al. Interleukin 8 expression regulates tumorigenicity and 
metastases in androgen-independent prostate cancer. Clin. Cancer Res. 6, 2104–
2119 (2000). 
309. Fakih, M., Johnson, C. S. & Trump, D. L. Glucocorticoids and treatment of 
prostate cancer: a preclinical and clinical review. Urology 60, 553–561 (2002). 
310. Ventitaraman, R. et al. Efficacy of low‐dose dexamethasone in castration‐
refractory prostate cancer. BJU Int. 101, 440–443 (2008). 
311. Yan, T. Z., Jin, F. S., Xie, L. P. & Li, L. C. Relationship between glucocorticoid 
receptor signal pathway and androgen-independent prostate cancer. Urol. Int. 81, 
228–233 (2008). 
Stellenbosch University  https://scholar.sun.ac.za
149 
 
312. Arora, V. K. et al. Glucocorticoid receptor confers resistance to antiandrogens 
by bypassing androgen receptor blockade. Cell 155, 1309–1322 
313. Sahu, B. et al. FoxA1 specifies unique androgen and glucocorticoid receptor 
binding events in prostate cancer cells. Cancer Res. 73, 1570–1580 (2013). 
314. Sahu, B. et al. Dual role of FoxA1 in androgen receptor binding to chromatin, 
androgen signalling and prostate cancer. EMBO J. 30, 3962–3976 (2011). 
315. Xie, N. et al. The expression of glucocorticoid receptor is negatively regulated 
by active androgen receptor signaling in prostate tumors. Int. J. Cancer 136, E27–
E38 (2015). 
316. Isikbay, M. et al. Glucocorticoid receptor activity contributes to resistance to 
androgen-targeted therapy in prostate cancer. Horm. Cancer 5, 72–89 (2014). 
317. Szmulewitz, R. Z. et al. Serum/glucocorticoid‐regulated kinase 1 expression in 
primary human prostate cancers. The Prostate 72, 157–164 (2012). 
318. Sharifi, N. Steroid receptors aplenty in prostate cancer. N. Engl. J. Med. 370, 
970–971 (2014). 
319. Pihlajamaa, P., Sahu, B. & Jänne, O. A. Determinants of Receptor- and 
Tissue-Specific Actions in Androgen Signaling. Endocr. Rev. 36, 357–384 (2015). 
320. Winkelstein, A. in Basic and Clinical Immunology (eds. Stites, D. P., Terr, A. 
T. & Parslow, T. G.) 767–780 (Appleton and Lange). 
321. Barnes, P. J. Molecular mechanisms of corticosteroids in allergic diseases. 
Allergy 56, 928–936 (2001). 
322. Cato, A. C. & Wade, E. Molecular mechanisms of anti‐inflammatory action of 
glucocorticoids. Bioessays 18, 371–378 (1996). 
Stellenbosch University  https://scholar.sun.ac.za
150 
 
323. Karin, M. New twists in gene regulation by glucocorticoid receptor: is DNA 
binding dispensable? Cell 93, 487–490 (1998). 
324. Barnes, P. J. Anti-inflammatory actions of glucocorticoids: molecular 
mechanisms. Clin. Sci. 94, 557–572 (1998). 
325. Kellendonk, C., Tronche, F., Reichardt, H. M. & Schutz, G. Mutagenesis of the 
glucocorticoid receptor in mice. J. Steroid Biochem. Mol. Biol. 69, 253–259 
326. Reichardt, H. M. & Schutz, G. Glucocorticoid signalling—multiple variations of 
a common theme. Mol. Cell. Endocrinol. 146, 1–6 (1998). 
327. Reichardt, H. M. et al. Repression of inflammatory responses in the absence 
of DNA binding by the glucocorticoid receptor. EMBO J. 20, 7168–7173 (2001). 
328. Mohler, J. L. et al. Androgen and glucocorticoid receptors in the stroma and 
epithelium of prostatic hyperplasia and carcinoma. Clin. Cancer Res. 2, 889–895 
(1996). 
329. Boschantzev, V. A synopsis of Salsola (Chenopodiaceae) from south and 
south-west Africa. Kew Bull. 597–614 (1974). 
330. Brondegaard, V. J. Contraceptive plant drugs. Planta Med. 23, 167–172 
(1973). 
331. De Lange, M. Prolonged gestation in karakul ewes in South West Africa. Proc 
4th Intemat Congr. Anim Reprod Hague 3, 590–592 (1961). 
332. Liggins, G. C., Fairclough, R. J., Grieves, S. A., Kendall, J. Z. & Knox, B. S. 
The mechanism of initiation of parturition in the ewe. Recent Prog. Horm. Res. 29, 
111–159 (1972). 
333. Botha, C. J., Venter, E. & others. Salsola tuberculatiformis. (2002). 
Stellenbosch University  https://scholar.sun.ac.za
151 
 
334. Zarrow, M. X., Yochim, J. M. & McCarthy, J. L. Experimental Endocrinology, A 
Sourcebook of Basic Techniques. (Academic Press, 1964). 
335. Williamson, D. G. & O’Donnell, V. J. Interaction of metopyrone with adrenal 
mitochondrial cytochrome P-450: Mechanism for the inhibition of adrenal steroid 
11beta-hydroxylation. Biochemistry (Mosc.) 8, 1306–1311 (1969). 
336. Swart, P., Todres, P., Swart, A. C. & Van der Merwe, K. J. Micro-assay for 
sheep 11b-hydroxylase activity using high-performance liquid chromatography for 
steroid analysis. J. Chromatogr. 442, 424–430 (1988). 
337. Swart, P., van der Merwe, K. J., Swart, A. C., Todres, P. C. & Hofmeyr, J.-H. 
Inhibition of cytochrome P-45011β by some naturally occurring acetophenones 
and plant extracts from the shrub Salsola tuberculatiformis. Planta Med. 59, 139–
143 (1993). 
338. Sato, R. & Omura, T. in Cytochrome P-450 (Academic Press Inc., 1978). 
339. Fourie, L., Van der Merwe, K. J., Swart, P. & de Kock, S. S. Application of fast 
atom bombardment mass spectrometry for the analysis of biologically active 
compounds. Anal. Chim. Acta 279, 163–166 (1993). 
340. van der Merwe, K. J., de Kock, S. S., Swart, P. & Fourie, L. The application of 
mass spectrometry in the study of labile natural products. Biochem. Soc. Trans. 
19, 612–619 (1991). 
341. Frank, R. W. The mitomycin antibiotics. Prog. Chem. Org. Nat. Prod. 38, 1–45 
(1979). 
342. Crooke, S. T. & Bradner, W. T. Mitomycin C: a review. Cancer Treat. Rev. 3, 
121–139 (1976). 
Stellenbosch University  https://scholar.sun.ac.za
152 
 
343. Andrez, J.-C. Mitomycins syntheses: a recent update. Beilstein J. Org. Chem. 
5, (2009). 
344. de Kock, S. S. A study of phenolic aziridines and their precursors. 
(Stellenbosch University, 1995). 
345. Van der Merwe, K. J., de Kock, S. S., Swart, P. & Fourie, L. The electron 
impact and fast atom bombardment mass spectrometry of aziridines and their 2-
chloroethylamine precursors. J. Mass Spectrom. 21, 672–674 (1992). 
346. Louw, A. & Swart, P. Salsola tuberculatiformis Botschantzev and an aziridine 
precursor analog mediate the in vivo increase in free corticosterone and decrease 
in corticosteroid-binding globulin in female Wistar rats. Endocrinology 140, 2044–
2053 (1999). 
347. Louw, A., Allie, F., Ac, S. & Swart, P. Inhibition of cytochrome P450c11 by 
biogenic amines and an aziridine precursor, 2-(4-acetoxyphenyl)-2-chloro-N-
methyl-ethylammonium chloride. Endocr. Res. 26, 729–736 (2000). 
348. Pont, A. et al. Ketoconazole blocks adrenal steroid synthesis. Ann. Intern. 
Med. 97, 370–372 (1982). 
349. Hays, S. J., Tobes, M. C., Gildersleeve, D. L., Wieland, D. M. & Beierwaltes, 
W. H. Structure-activity relationship study of the inhibition of adrenal cortical 
11beta-hydroxylase by new metyrapone analogs. J. Med. Chem. 27, 15–19 
(1984). 
350. Louw, A., Swart, P., de Kock, S. S. & van der Merwe, K. J. Mechanism for the 
stabilization in vivo of the aziridine precursor 2-(4-acetoxyphenyl)-2-chloro-N-
methyl-ethylammonium chloride by serum proteins. Biochem. Pharmacol. 53, 
189–197 (1997). 
Stellenbosch University  https://scholar.sun.ac.za
153 
 
351. Louw, A., Swart, P. & Allie, F. Influence of an aziridine precursor on the in 
vitro binding parameters of rat and ovine corticosteroid-binding globulin (CBG). 
Biochem. Pharmacol. 59, 167–175 (2000). 
352. Lesovaya, E. et al. Combination of a selective activator of the glucocorticoid 
receptor Compound A with a proteasome inhibitor as a novel strategy for 
chemotherapy of hematologic malignancies. Cell Cycle 12, 133–144 (2013). 
353. Lesovaya, E. et al. Discovery of Compound A--a selective activator of the 
glucocorticoid receptor with anti-inflammatory and anti-cancer activity. Oncotarget 
6, 30730–30744 (2015). 
354. Ronacher, K. et al. Ligand-selective transactivation and transrepression via 
the glucocorticoid receptor: role of cofactor interaction. Mol. Cell. Endocrinol. 299, 
219–231 (2009). 
355. Gossye, V. et al. Differential mechanism of NF‐κB inhibition by two 
glucocorticoid receptor modulators in rheumatoid arthritis synovial fibroblasts. 
Arthritis Rheum. 60, 3241–3250 (2009). 
356. Gossye, V. et al. A plant-derived glucocorticoid receptor modulator attenuates 
inflammation without provoking ligand-induced resistance. Ann. Rheum. Dis. 69, 
291–296 (2010). 
357. Omura, T. & Sato, R. The carbon monoxide-binding pigment of liver 
microsomes I: Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370–
2378 (1964). 
358. Omura, T. & Sato, R. The carbon monoxide-binding pigment of liver 
microsomes II: Solubilization, purification, and properties. J. Biol. Chem. 239, 
2379–2385 (1964). 
Stellenbosch University  https://scholar.sun.ac.za
154 
 
359. Champion, P. M., Stallard, B. R., Wagner, G. C. & Gunsalus, I. C. Resonance 
Raman detection of an iron-sulfur bond in cytochrome P 450cam. J. Am. Chem. 
Soc. 104, 5469–5472 (1982). 
360. Segall, M. D. An ab initio study of biological systems. (University of 
Cambridge, 1997). 
361. Shannon, R. T. & Prewitt, C. T. Revised values of effective ionic radii. Acta 
Crystallogr. B B26, 1046–1048 (1970). 
362. Hill, H. A. O., Roder, A. & Williams, R. J. P. The chemical nature and reactivity 
of cytochrome P-450. Struct. Bond. 8, 123–151 (1970). 
363. Shimura, Y. A quantitative scale of the spectrochemical series for the mixed 
ligand complexes of d6 metals. Bull. Chem. Soc. Jpn. 91, 693–698 (1988). 
364. Poulos, T. L., Finzel, B. C. & Howard, A. J. High-resolution crystal structure of 
cytochrome P450cam. J. Mol. Biol. 195, 687–700 (1987). 
365. Raag, R. & Poulos, T. L. The structural basis for substrate-induced changes in 
redox potential and spin equilibrium in cytochrome P-450CAM. Biochemistry 
(Mosc.) 28, 917–922 (1989). 
366. Poulos, T. L. & Raag, R. crystallography, oxygen activation, and electron 
transfer. FASEB J. 6, 674–679 (1992). 
367. Poulos, T. L. & Howard, A. J. Crystal structures of metyrapone-and 
phenylimidazole-inhibited complexes of cytochrome P-450cam. Biochemistry 
(Mosc.) 26, 8165–8174 (1987). 
368. Raag, R., Li, H., Jones, B. C. & Poulos, T. L. Inhibitor-induced conformational 
change in cytochrome P-450CAM. Biochemistry (Mosc.) 32, 4571–4578 (1993). 
Stellenbosch University  https://scholar.sun.ac.za
155 
 
369. Schenkman, J. B., Sligar, S. G. & Cinti, D. L. Substrate interaction with 
cytochrome P-450. Pharmacol. Ther. 12, 43–71 (1981). 
370. Omura, T. Cytochrome P-450. (Wiley-VCH Publishers Ltd., 1993). 
371. Raag, R. & Poulos, T. L. Crystal structures of cytochrome P-450CAM 
complexed with camphane, thiocamphor, and adamantane: factors controlling P-
450 substrate hydroxylation. Biochemistry (Mosc.) 30, 2674–2684 (1991). 
372. Raag, R., Swanson, B. A., Poulos, T. L. & Ortiz de montellano, P. R. 
Formation, crystal structure, and rearrangement of a cytochrome P-450cam iron-
phenyl complex. Biochemistry (Mosc.) 29, 8119–8126 (1990). 
373. Fisher, M. T. & Sligar, S. G. Control of heme protein redox potential and 
reduction rate: linear free energy relation between potential and ferric spin state 
equilibrium. J. Am. Chem. Soc. 107, 5018–5019 (1985). 
374. Testa, B. & Jenner, P. Inhibitors of cytochrome P-450s and their mechanism 
of action. Drug Metab. Rev. 12, 1–117 (1981). 
375. Testa, B. Mechanisms of inhibition of xenobiotic-metabolizing enzymes. 
Xenobiotica 20, 1129–1137 (1990). 
376. Gibson, G. G. & Skett, P. Introduction to drug metabolism. (Chapman and 
Hall, 1994). 
377. Schiffler, B. et al. The Interaction of Bovine Adrenodoxin with CYP11A1 
(Cytochrome P450scc) and CYP11B1 (Cytochrome P45011β) Acceleration of 
reduction and substrate conversion by site-directed mutagenesis of Adrenodoxin. 
J. Biol. Chem. 276, 36225–36232 (2001). 
Stellenbosch University  https://scholar.sun.ac.za
156 
 
378. Yoshida, Y. & Kumaoka, H. Studies on the substrate-induced spectral change 
of cytochrome P-450 in liver microsomes. J. Biochem. (Tokyo) 78, 455–468 
(1975). 
379. Saitoh, H. et al. Metastatic patterns of prostatic cancer. Correlation between 
sites and number of organs involved. J. Cancer 54, 3078–3084 (1984). 
380. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus 
prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 
(2004). 
381. De Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate 
cancer. N. Engl. J. Med. 364, 1995–2005 (2011). 
382. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after 
chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012). 
383. Liftonm, R. P., Dluhyz, R. G., Powersl, M., Richz, G. M. & Gutkin, M. 
Hereditary hypertension caused by chimaeric gene duplications. Nat. Genet. 2, 
66–74 (1993). 
384. Petrelli, M. & Stewart, P. M. Monogenic forms of mineralocorticoid 
hypertension: insights into the pathogenesis of’essential’hypertension? J. Hum. 
Hypertens. 12, 7–12 (1998). 
385. Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen 
receptor of human INCaP cells affects steroid binding characteristics and 
response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534–540 
(1990). 
Stellenbosch University  https://scholar.sun.ac.za
157 
 
386. Sun, C. et al. Androgen receptor mutation (T877A) promotes prostate cancer 
cell growth and cell survival. Oncogene 25, 3905–3913 (2006). 
387. Horoszewicz, J. S. et al. LNCaP model of human prostatic carcinoma. Cancer 
Res. 43, 1809–1818 (1983). 
388. Shi, X.-B. et al. Molecular alterations associated with LNCaP cell progression 
to androgen independence. The Prostate 60, 257–271 (2004). 
389. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F. & Jones, L. W. 
Establishment and characterization of a human prostatic carcinoma cell line (PC-
3). Invest. Urol. 17, 16–23 (1979). 
390. Tai, S. et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. 
The Prostate 71, 1668–1679 (2011). 
391. Carroll, A. G., Voeller, H. J., Sugars, L. & Gelmann, E. P. p53 oncogene 
mutations in three human prostate cancer cell lines. The Prostate 23, 123–134 
(1993). 
392. Andersen, R. J. et al. Regression of castrate-recurrent prostate cancer by a 
small-molecule inhibitor of the amino-terminus domain of the androgen receptor. 
Cancer Cell 17, 535–546 (2010). 
393. Shen, R. et al. Androgen-Induced Growth Inhibition of Androgen Receptor 
Expressing Androgen-Independent Prostate Cancer Cells Is Mediated by 
Increased Levels of Neutral Endopeptidase 1. Endocrinology 141, 1699–1704 
(2000). 
Stellenbosch University  https://scholar.sun.ac.za
158 
 
394. Yuan, S. et al. Androgen-induced inhibition of cell proliferation in an 
androgen-insensitive prostate cancer cell line (PC-3) transfected with a human 
androgen receptor complementary DNA. Cancer Res. 53, 1304–1311 (1993). 
395. Schweizer, M. T. et al. Effect of bipolar androgen therapy for asymptomatic 
men with castration-resistant prostate cancer: Results from a pilot clinical study. 
Sci. Transcr. Med. 7, 269ra2-269ra2 (2015). 
396. Hirsch, T. et al. The apoptosis-necrosis paradox. Apoptogenic proteases 
activated after mitochondrial permeability transition determine the mode of cell 
death. Oncogene 15, 1573–1581 (1997). 
397. Degterev, A., Boyce, M. & Yuan, J. A decade of caspases. Oncogene 22, 
8543–8567 (2003). 
398. Castedo, M. et al. Cell death by mitotic catastrophe: a molecular definition. 
Oncogene 23, 2825–2837 (2004). 
399. Yemelyanov, A. et al. Effects of IKK inhibitor PS1145 on NF-κB function, 
proliferation, apoptosis and invasion activity in prostate carcinoma cells. 
Oncogene 25, 387–398 (2006). 
400. Isaacs, W. B., Carter, B. S. & Ewing, C. M. Wild-type p53 suppresses growth 
of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51, 
4716–4720 (1991). 
401. Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to 
inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 98, 10314–10319 (2001). 
Stellenbosch University  https://scholar.sun.ac.za
159 
 
402. Kerr, J. F., Wyllie, A. H. & Currie, A. R. Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Britich J. Cancer 
26, 239 (1972). 
403. Blagosklonny, M. V. Cell death beyond apoptosis. Leukemia 14, 1502–1508 
(2000). 
404. Kitanaka, C. & Kuchino, Y. Caspase-independent programmed cell death with 
necrotic morphology. Cell Death Differ. 6, 508–515 (1999). 
405. Lockshin, R. A., Osborne, B. & Zakeri, Z. Cell death in the third millennium. 
Cell Death Differ. 7, 2–7 (2000). 
406. Sperandio, S., de Belle, I. & Bredesen, D. E. An alternative, nonapoptotic form 
of programmed cell death. Proc. Natl. Acad. Sci. 97, 14376–14381 (2000). 
407. Wyllie, A. H. & Golstein, P. More than one way to go. Proc. Natl. Acad. Sci. 
98, 11–13 (2001). 
408. Xiang, J., Chao, D. T. & Korsmeyer, S. J. BAX-induced cell death may not 
require interleukin 1β-converting enzyme-like proteases. Proc. Natl. Acad. Sci. 93, 
14559–14563 (1996). 
409. Borner, C. & Monney, L. Apoptosis without caspases: an inefficient molecular 
guillotine? Cell Death Differ. 6, 497–507 (1999). 
410. Boya, P. et al. Lysosomal membrane permeabilization induces cell death in a 
mitochondrion-dependent fashion. J. Exp. Med. 197, 1323–1334 (2003). 
411. Broker, L. E. et al. Cathepsin B mediates caspase-independent cell death 
induced by microtubule stabilizing agents in non-small cell lung cancer cells. 
Cancer Res. 64, 27–30 (2004). 
Stellenbosch University  https://scholar.sun.ac.za
160 
 
412. Foghsgaard, L. et al. Cathepsin B acts as a dominant execution protease in 
tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol. 153, 999–1010 
(2001). 
413. Guicciardi, M. E. et al. Cathepsin B contributes to TNF-α–mediated 
hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J. Clin. 
Invest. 106, 1127–1137 (2000). 
414. Kagedal, K., Ming, Z. H. A. O., Svensson, I. & Brunk, U. T. Sphingosine-
induced apoptosis is dependent on lysosomal proteases. Biochem. J. 359, 335–
343 (2001). 
415. Stoka, V. et al. Lysosomal protease pathways to apoptosis cleavage of Bid, 
not pro-caspases, is the most likely route. J. Biol. Chem. 276, 3149–3157 (2001). 
416. Cauwels, A., Janssen, B., Waeytens, A., Cuvelier, C. & Brouckaert, P. 
Caspase inhibition causes hyperacute tumor necrosis factor–induced shock via 
oxidative stress and phospholipase A2. Nat. Immunol. 4, 387–393 (2003). 
417. Perfettini, J. L. & Kroemer, G. Caspase activation is not death. Nat. Immunol. 
4, 308–310 (2003). 
418. Leist, M. & Jaatela, M. Four deaths and a funeral: from caspases to 
alternative mechanisms. Nat. Rev. Molcecular Cell Biol. 2, 589–598 (2001). 
419. Clarke, P. G. Developmental cell death: morphological diversity and multiple 
mechanisms. Anat. Embryol. (Berl.) 181, 195–213 (1990). 
420. King, K. L. & Cidlowski, J. A. Cell cycle and apoptosis: common pathways to 
life and death. J. Cell. Biochem. 58, 175–180 (1995). 
Stellenbosch University  https://scholar.sun.ac.za
161 
 
421. Jaatela, M. Multiple cell death pathways as regulators of tumour initiation and 
progression. Oncogene 23, 2746–2756 (2004). 
422. Bursch, W. The autophagosomal–lysosomal compartment in programmed cell 
death. Cell Death Differ. 8, 569–581 (2001). 
423. Bröker, L. E., Kruyt, F. A. & Giaccone, G. Cell death independent of 
caspases: a review. Clin. Cancer Res. 11, 3155–3162 (2005). 
 
 
Stellenbosch University  https://scholar.sun.ac.za
